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ABSTRACT 
The inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis 
(UC) are significant causes of gastrointestinal morbidity. Previous research in IBD has 
predominantly focused on large white European/American populations, which have 
defined the clinical phenotype and led to important biological insights, including its 
genetic predisposition, and immunological and metabonomic associations. Recent 
studies suggest that there may be differences in the clinical phenotype of IBD in 
different ethnic groups. There is still limited information on the phenotype of South 
Asian IBD patients originating from India, Pakistan and Bangladesh, but there have 
been suggestions that it differs from the Northern European white population. Since the 
1950s there has been substantial migration from South Asia, and currently 2.08 million 
South Asians live in the UK: studies of IBD in this population could provide valuable 
information, and may help to distinguish the degree of influence of genetic and 
environmental pathogenic factors. This thesis aimed to define the clinical phenotype of 
IBD in UK South Asians, and then to investigate the genetic, serological and 
metabonomic associations of IBD in South Asians and to compare the findings with a 
white Northern European cohort.  
The phenotypic details of 367 South Asian IBD patients (273 UC: 94 CD), undergoing 
active follow-up in five North West London hospitals, were compared to those of 403 
consecutively collected white Northern European IBD patients (188 UC: 215 CD). The 
phenotype of IBD differed significantly between the two populations with more 
extensive disease and less proctitis in the South Asian UC cohort compared to Northern 
Europeans (P<0.0001 for both). CD behaviour differed significantly between the groups 
with less penetrating disease compared to Northern Europeans (P=0.01) and a reduced 
need for surgery (P=0.003).  
Genotyping, serological testing and urinary nuclear magnetic resonance (NMR) 
spectroscopy were used to investigate cohorts of South Asian IBD patients and healthy 
South Asian controls in order to investigate the different aetiological factors in South 
Asian IBD. Results were compared with a previously collected white Northern 
European cohort. The genotype frequency of HLA-DRB1*1502 was significantly higher 
in South Asian patients with UC compared to both controls (P=0.005) and Northern 
European UC patients (P<0.0001). HLA-DRB1*0103 was not found in the South Asian 
population and CARD15/NOD2 polymorphisms were rare, significantly different to 
Northern Europeans with IBD. The sensitivity and specificity of serological tests 
(ASCA and atypical pANCA) was similar for both populations. Urinary NMR 
spectroscopy results from the South Asian IBD cohort showed significantly lower levels 
of hippurate (a co-metabolite related to gut microbial metabolism), compared to healthy 
South Asian controls (P<0.0001). Differences were also observed between the South 
Asian and Northern European UC cohorts, with lower levels of 4-cresol sulphate 
(P<0.0001) and hippurate (P=0.0006) in South Asians.  
 
Conclusion: The phenotype and genotype of IBD in South Asians living in North West 
London is significantly different from that of a white Northern European IBD cohort. 
The emerging technique of urinary NMR spectroscopy has shown specific urinary 
metabolites differ between South Asian and European IBD patients which could reflect 
underlying differences in the gut microbiota. 
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1.1 INFLAMMATORY BOWEL DISEASE 
The inflammatory bowel diseases, Crohn’s disease and ulcerative colitis are 
characterised by chronic intestinal inflammation.  Ulcerative colitis (UC) is an 
inflammatory disorder limited to the colonic mucosa. This differs from Crohn’s disease 
(CD), which can affect any part of the gastrointestinal tract and is characterised by 
chronic transmural granulomatous inflammation with a tendency to form fistulae or 
strictures.  The incidence of UC in the UK is approximately 13.9 cases/105/ year with a 
reported prevalence of 243 cases/105  (Rubin et al., 2000). Crohn’s disease affects 
144/105of the UK population with approximately 8.3 cases/105/year (Rubin et al., 
2000).  Recent studies suggest that nearly 240,000 people are affected 
 
by IBD in the UK 
(Carter et al., 2004).  The diagnosis of UC or CD is currently based on symptoms, 
endoscopic, radiological and histological findings.  However, in up to 18% of cases they 
are indistinguishable from each other (IBD unclassified) (Farmer et al., 2000;Lee et al., 
1979).  
1.2 GLOBAL VARIATION IN THE EPIDEMIOLOGY OF 
INFLAMMATORY BOWEL DISEASE 
Studies from around the world suggest a widely varying incidence of IBD, with highest 
rates of UC and CD reported in Northern Europe and North America (Loftus, Jr., 2004).  
Previously, research in IBD focused predominantly on large white European/North 
American populations, as the reporting of detailed information on the epidemiology of 
IBD in areas like Asia and South America suffered from poor reporting networks, 
limited population data and non-uniform diagnostic criteria. The first reports of 
Chapter 1: Introduction 
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differences in the prevalence and incidence of IBD between ethnic groups came from 
studies in North America which demonstrated that Ashkenazi Jews had an increased 
incidence and prevalence of IBD compared to white Americans (Acheson, 1960).  
Subsequent studies in other ethnic groups including African Americans and French 
Canadians (Veluswamy et al., 2010;Bhat et al., 2009), also noted variations in the 
epidemiology of IBD compared with Caucasian populations living in the same area.  
  
To the present day, there is still very limited information on the epidemiology of IBD in 
South Asia (India, Pakistan and Bangladesh).  It has been assumed that the incidence 
was lower than in Europe, however a population-based study of UC in North India 
showed that the incidence (6 cases/105/year) and prevalence (44.3/105
Figure 1-1
) is similar to 
those observed in some Western countries (Sood et al., 2003;Vucelic et al., 1991;Mate-
Jimenez et al., 1994) ( ).  The community-based epidemiological study by 
Sood was performed in 1999 via a house-to-house survey over a 1-year period, with 
suspected UC cases confirmed by endoscopy and biopsy, thus ensuring good case 
ascertainment.  
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Figure 1-1:  World map showing the prevalence rates (cases/105
 
) of ulcerative colitis, based on 
population studies. 
Studies from other Asian countries have reported the incidence and prevalence of IBD 
using a variety of methods ranging from nationwide and hospital-based registries, with 
the denominator for incidence calculation based on census of the population applied to a 
specific region and period (Loftus, Jr., 2004;Morita et al., 1995;Leong et al., 2004;Yang 
et al., 2008;Niriella et al., 2010;Lok et al., 2008). The incidence rates for UC range from 
0.37 – 3.08 cases/105
 
/year, much less than in India (Figure 1-2).   
The scarcity of well-designed population-based studies in Asia, to authenticate the 
reported incidence and prevalence figures is a major obstacle.  However, it is likely that 
there are racial groups among Asians that are more susceptible to IBD. 
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Figure 1-2:  Bar graph showing the incidence rates (cases/105
                    (■ Ulcerative colitis and ■ Crohn’s disease).   
/year) of IBD in Asian countries  
                    (Values adapted from;  Morita et al., (1995) [Japan],  Yang et al., (2008) [South Korea],   
                      Lok et al., (2008) [China], Leong et  al., (2004)[China],  Sood et al. (2003)[India], Niriella et al.,   
                      (2010) [Sri Lanka])  
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1.2.1 A comparison of the demographics and clinical phenotype of ulcerative 
colitis between Asians and Caucasians  
Age & Gender 
South Asian studies report a similar peak age of onset for UC as typically seen in 
Caucasian populations with the mean and median age at diagnosis in the third and 
fourth decade (Sood et al., 2003;Khosla et al., 1986;Loftus, Jr. and Sandborn, 2002).  
Studies from Asia have suggested a male predominance in the incidence of UC (Hou et 
al., 2009).  This is in contrast to developed countries that generally show an equal 
gender distribution in UC.  However, it is not clear if this is a genuine difference as 
reports are predominantly from hospital-based studies and could reflect a bias of the 
existing social structure in the region, perhaps making medical services more accessible 
to men than women.  
 
UC Phenotype 
Comparing the clinical features of UC across studies is fraught with difficulties, given 
the differences in diagnostic modalities, definitions of extent (some studies report the 
prevalence of limited proctitis, left sided colitis and extensive colitis but others only 
indicate disease extending into the sigmoid or beyond), time points of assessment, and 
statistical methods.  This may explain why the literature appears inconsistent with 
several differences reported in disease location and behaviour even within the same 
ethnic group.  For example, reports from mainland China demonstrate wide variations in 
the prevalence of extensive colitis (21.3% to 33.8%) (Jiang et al., 2006;APDW2004 
Chinese IBD Working Group, 2006a).  Studies from South Asia have described a more 
consistent phenotype between ethnic groups living in the same region:  in a Sri Lankan 
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hospital-based study of 240 UC patients, 51.1% had proctosigmoiditis, 22.6% had left-
sided colitis, and 22.3% had extensive colitis (Niriella et al., 2010).  The prevalence of 
extensive colitis in the Sri Lankan study is similar to areas of India, which report the 
prevalence of extensive colitis to range between 16% and 20.3% (Kochhar et al., 
1991;Sood et al., 2003) (Figure 1-3).  The figures are similar to studies from Europe, 
with 28% of Portuguese patients having extensive colitis, but lower than  Japan which 
reports a higher rate of extensive colitis (41%) (Fujimoto et al., 2007).    However, as 
previously stated, the comparisons should be interpreted with caution as it is not clear 
whether maximal extent of disease was based on endoscopic, radiological or 
histological results and if full colonoscopy was performed in all cases. 
 
    
       
Figure 1-3:  Stacked chart totalling 100%, depicting the distribution of UC in studies from Northern 
Europe and Asia.   
                     (■) Extensive colitis, (■) left-sided colitis and (■) proctitis or *proctosigmoiditis  
(Values adapted from Portela (2010), Sood et al., (2003); Kochhar et al., (1991), Niriella et 
al., (2010), Fujimoto et al., (2007) Jiang et al., (2006); APDW (2004) Chinese IBD Working 
Group (2006a)). 
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Extraintestinal manifestations in UC patients 
Few papers from Asia have studied extraintestinal manifestations (EIMs) in detail.  An 
early study by Kochhar et al.(1991) prospectively studied EIMs in 150 UC patients from 
the city of Chandigarh in North India.  EIMs were seen in 34.7% of patients but 
included back pain without radiological changes, conjunctivitis and oral aphthous 
ulcers.  Peripheral arthritis was the most frequently reported EIM (10.7%), most 
commonly involving the large joints. Eight percent of patients had backache with 
radiological evidence of sacroiliitis and 3.3% had anterior uveitis.  Primary sclerosing 
cholangitis and skin manifestations were uncommon (1.3% and 2.7% respectively).  A 
subsequent smaller study of 46 consecutive UC patients attending IBD clinics in the 
North West Indian state of Rajasthan showed only one person (2%) had peripheral 
arthritis and two had anterior uveitis (4%).  No other EIMs were observed (Pokharna et 
al., 2004).  The authors concluded that EIMs were rare in Indian patients in contrast to 
Kochhar’s earlier study.  A similar low frequency of EIMs has also been reported in 
China (6.1%) (Jiang and Cui, 2002).  A large study of white British UC patients, 
showed 10.5%  have arthritis and 3.1% anterior uveitis (Orchard et al., 1998).  
 
Colectomy rates 
A previous study from Japan reports that 33.9% of UC patients required surgery with 
cumulative colectomy rates of 4.1% in the first year, 6.8% in the second year and a 1–
2% annual increase thereafter until the 14th year (Hiwatashi et al., 1991).  This is 
comparable to early European studies which reported 32.4% - 37.6% of patients 
required colectomy, with cumulative rates of  20% after 5 years, 28% after 10 years, and 
45% after 15 years (Farmer et al., 1993;Leijonmarck et al., 1990).  
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There are no reports of colectomy rates from the Indian subcontinent but a recent Sri 
Lankan study of UC patients reported a low colectomy rate of only 4.6% of cases.  In 
this cohort, only 26.3% of patients had pancolitis and disease severity was mild in 
nearly 60% of cases, which may explain the lower colectomy rate.  It is also possible 
that even those patients with extensive disease may have a disease phenotype amenable 
to medical therapy, although this was not specifically studied.   
 
1.2.2 A comparison of the demographics and clinical phenotype of Crohn’s 
disease between Asians and Caucasians 
Early reports of CD in some areas of Asia were met with scepticism as major doubts 
persisted as to whether it was true CD as opposed to intestinal tuberculosis (TB) which 
is particularly common in some parts of India. However, in the past 10 years there has 
been a growing realisation that despite the high prevalence of TB, CD is becoming more 
common. This is likely to be related to increasing awareness and availability of 
diagnostic facilities. 
 
Age & Gender 
The peak age of onset of CD in Asian patients is reported as being in the second and 
third decade, similar to Caucasian studies (Yang et al., 2008;Leong et al., 2004;Yang et 
al., 2001). Interestingly, there appears to be an overwhelming male predominance in 
Asian CD patients, more than is seen in UC.  In Western studies, there is generally an 
equal gender distribution or a moderate female predominance for CD (Vind et al., 
2006;Bernstein et al., 2006).  The reason for this difference is not clear but perhaps 
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higher rates of smoking in Asian males compared to females may influence the onset of 
CD in this ethnic group. 
 
CD location and behaviour 
The phenotype of CD is widely variable between white and Asian ethnic groups (Table 
1-1).  A large European study from Portugal reported that CD patients in this cohort had 
ileocolonic disease in 45% of cases (Magro et al., 2009) which is similar to a Canadian 
study that also reported a predominant phenotype of ileocolonic disease (42.5%) 
(Freeman, 2007).  As the incidence and prevalence of CD in India is low, there are few 
reports on CD phenotype from this region.  A single centre study from South West India 
(n=25) observed ileocaecal disease in 24% of patients and 76% had large bowel 
involvement (Pai and Khandige, 2000).  A more recent multicentre study from North 
East India reported on 182 CD patients recruited over 7 years (Das et al., 2009).  The 
commonest age of onset was 17-40 years (A2, as per the Montreal classification, 
Silverberg et al., 2005) with colonic disease (L2) being the most common disease 
location (41%).  The predominant disease behaviour was nonstricturing, nonpenetrating 
(B1).  Colonic disease location was also the most common finding from a Sri Lankan 
study of 55 CD patients of which 80% had only large intestinal involvement, the CD 
behaviour was not reported in this study (Niriella et al., 2010).  In China, similar 
proportions of ileocolonic and colonic disease are observed (APDW2004 Chinese IBD 
Working Group, 2006b).  In other areas of East Asia, the most common disease location 
is ileocolonic, as shown by a recent population based study from Korea (n=138).  Sixty-
seven percent of patients had ileocolonic CD, 21% had isolated small bowel and only 
12% had colonic involvement at diagnosis (Yang et al., 2000).  The findings are 
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consistent with a Japanese hospital-based cohort, where ileocolonic involvement 
predominated (65.8%) (Oriuchi et al., 2003).  
 
Surgery for CD 
Requirements for surgery are not well reported in the literature.  The epidemiology 
study by Das et al. (2009) reports that 37% of Indian CD patients required surgical 
intervention, much higher than reported in a Sri Lankan study (18.2%) (Niriella et al., 
2010).  This may be a reflection of differences in disease location, as patients with ileal 
involvement are likely to develop more complicated disease behaviour requiring 
surgery.  Only 20% of Sri Lankan patients had ileal or ileocolonic disease compared to 
55% in the Indian cohort.   
 
Extraintestinal manifestations in CD patients 
There are few reports of EIMs in Asian CD patients.  Das et al. (2009) showed that 
13.7% of Indian CD patients had EIMs (after excluding back pain and oral ulceration).  
Peripheral arthropathy was present in 6% of Indian CD patients and 3% had sacroiliitis, 
less than a clinic-based CD population in the UK (Orchard et al., 1998).  
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Table 1-1:  Ethnic variation in Crohn’s disease phenotype  
                   (Values expressed in %) 
 
 Portugal 
(n=1413) 
Canada 
(n=1015) 
Korea 
(n=138) 
Japan 
(n=183) 
China 
 (n=515) 
India 
 (n=182) 
Sri Lanka 
(n=55) 
Location (%)        
L1: Ileal 34 26.4 66.7 20 28.4 32 12.7 
L2: Colonic 15 30.8 12.3 33 36.3 41 80 
L3: Ileocolonic 45 42.5 66.7 46 35.3 23 7.3 
L4:  Upper GI only 1 0.3 - 1 - 4 5.5 
Behaviour (%)        
B1: Nonstricturing,   
         nonpenetrating 
38 35.3 - 45 - 51 - 
B2: Stricturing 26 33.6 - 31 - 24 - 
B3: Penetrating 36 31.1 - 24 - 25 - 
Perianal (p) - 7.3 - 34 5.6 17 7.3 
EIMs (%) - - - - 22.3 13.7 - 
Surgery - - - - - 37 18.2 
 
Disease phenotype as per the Montreal Classification (Silverberg et al., 2005). 
EIMs, Extraintestinal manifestations, (-); information not available. 
Information adapted from; Magro et al., (2009) [Portugal], Freeman (2007) [Canada]), APDW2004 
Chinese IBD Working Group, (2006)b [China], Das et al., (2009) [India], Niriella et al., (2010) [Sri Lanka], 
Yang et al., (2000) [Korea], Oriuchi et al., (2003) [Japan]. 
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1.2.3 Rationale for studying migrant populations  
IBD studies among migrant populations living in developed countries, with improved 
access to healthcare facilities, may provide more reliable data than those reported from 
underdeveloped parts of the world.  These studies could also be helpful in determining 
if there are clinical differences related to ethnicity by comparing the migrant ethnic 
group with the host population.   
The study of disease development in migrant groups who move from their place of birth 
to a new country can generate data related to the evaluation of environmental influences 
on the disease. These are of greatest value in identifying possible aetiological factors 
when the migrant population under investigation adopts the social, cultural and dietary 
habits of the host country.  Provided inter-marriage with the host population is 
uncommon, the relative importance of genetic and environmental factors may become 
clearer (Probert et al., 1996b)).   This epidemiological approach has been used for 
conditions such as diabetes and myocardial disease (Tillin et al., 2007;Chaturvedi et al., 
2007;Chambers and Kooner, 2002;Chambers et al., 2001).   
 
1.2.4 Epidemiological studies of migrant IBD populations living in Asia 
Comparative prevalence data between different ethnic groups with IBD living in 
Singapore and Malaysia have previously been reported.  In Singapore, the prevalence of 
UC in Asian Indians is high (16.2/105) compared to 6/105 in Chinese and 4.8/105 in 
Malaysians (Lee et al., 2000).  A retrospective review from Malaysia, performed over a 
13 year period (from 1985 -1998), also showed a high prevalence of UC in Indians 
(17.9/105) compared to 11.2/105 in Chinese and  3.7/105 in Malaysians (Tan and Goh, 
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2005).  Phenotype studies have also been reported from these multi-racial countries and 
shown interesting differences in clinical phenotype between ethnic groups with UC.  A 
study of 118 patients in Malaysia showed that Indian patients (n=48) had considerably 
higher rates of extensive colitis (60.4%: 29/48) compared to 33.3% (12/36) in Chinese 
and 43.3% (13/30) in Malaysia (P=0.058) (Hilmi et al., 2009).  In keeping with other 
Asian countries, colectomy rates were also low in this study; Indian population 2.1% 
(1/48), Chinese 8.3% (3/36) and Malaysian 6.7% (2/30).   The observed differences in 
UC phenotype seen in the Malaysian study are further strengthened by a Singaporean 
study showing 54% (26/48) of Indian patients had extensive colitis compared to 32% 
(54/169) of Chinese patients (P=0.04) (Ling et al., 2002). 
 
 
Between 1950 and 1980 there was substantial migration of South Asians (originating 
from India, Pakistan and Bangladesh) to Europe, and currently 2.08 million South 
Asians live in the UK (Office for National Statistics 2001).  This large-scale migration 
has opened up the possibility of epidemiological studies into environmental and genetic 
risk factors affecting the South Asian population.  However, there are still only a few 
studies in the literature with reference to inflammatory bowel disease in UK South 
Asians.  
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1.2.5 Epidemiology and clinical phenotype of UC in South Asian migrants living 
in the UK 
Epidemiology 
A retrospective epidemiological study compared the incidence and prevalence of South 
Asian UC patients living in Leicestershire, UK between 1972-1989 with Europeans 
from the same area (Probert et al., 1992). One hundred and fifteen new UC cases and 29 
cases of ulcerative proctitis were identified in South Asians during the study period.  
The standardised incidence of UC in the South Asian Hindu and Sikh population was 
over twice as high as that in Europeans (10.8, 16.5, 5.3 cases/105
 
/year respectively).  
This study also showed that South Asians had fewer operations for UC compared to 
Europeans, suggesting that UC may be less severe in UK South Asians.   
Family studies show a positive history of IBD amongst Europeans more often than 
South Asians.  In a study of 1254 patients in Leicester the risk to first degree relatives of 
European patients with UC was 15 fold compared to 3.5 in South Asians (Probert et al., 
1993). This may indicate that environmental factors are more important than genetic 
factors in the South Asian IBD population.  
 
The incidence rate for UC among indigenous Punjabi Indians (6.02/cases/105) (Sood et 
al., 2003), although higher than other Asian UC incidence rates, is still lower than that 
seen in the South Asian migrant study from Leicestershire, where UC incidence rates 
ranged from 13.1 to 14.3 cases/105/year (Probert et al., 1992) . Despite differences in 
methods and time period of assessment in both studies, this disparity in incidence rates 
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suggests the importance of environmental exposure, possibly acting as a triggering 
factor among South Asians who are genetically susceptible to IBD. 
 
UC phenotype in UK South Asians 
In Probert’s original study (1992), there was no statistical difference in disease extent 
between Europeans and South Asians, however, South Asians tended to have more 
extensive disease (47%) and less proctitis (23%) compared to Europeans (39% and 36% 
respectively).   
 
Differences in IBD phenotype have been reported in a small study of 82 South Asian 
IBD patients from Manchester, with South Asians demonstrating a higher rate of 
pancolonic disease (34/82: 41%) compared to a white British IBD cohort (41/158: 26%) 
(Rashid et al., 2008), but it was not clear whether this related to a combination of UC 
and CD patients or UC alone. 
 
A later study, also from Leicestershire (Carr and Mayberry, 1999), studied the effects of 
migration on first and second-generation UC patients.  In contrast to Probert’s study 
(1992) that showed no differences between the disease phenotype in first- and second-
generation South Asians, Carr and Mayberry suggested that second-generation patients 
are at a greater risk of extensive UC compared with first-generation South Asians.  
However, because of the small sample size (South Asian patients n=33), there is 
insufficient evidence to draw any firm conclusions about the influence of genetic and 
environmental factors.   
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Previous studies of UC in South Asians living in London have concentrated on the 
Bangladeshi community in East London (Jayanthi et al., 1992b;Tsironi et al., 2004).  
Tsironi’s study in 2004 reported 16 new cases of UC in Bangladeshi migrants living in 
East London between 1997 and 2001.  This correlated to an age-standardised incidence 
of 8.2 cases/105/year, compared with an incidence of 2.3 cases/105
 
/year in the 1980s.  In 
this study, the majority of UC patients had extensive disease (9/16; 56%) and only two 
patients had proctitis (12.5%), but the population size was too small to make a 
meaningful phenotypic comparison 
1.2.6 Epidemiology and clinical phenotype of CD in South Asian migrants living 
in the UK 
Epidemiology 
There have been few studies of Crohn’s disease in migrant South Asian populations.  
One study from the UK showed that the incidence of CD in South Asians living in 
Leicestershire has increased, particularly in South Asian Muslims (5.4 cases/105/year) 
(Jayanthi et al., 1992a). Tsironi et al. conducted an epidemiological study to compare 
the incidence of IBD and abdominal tuberculosis in immigrants originating from 
Bangladesh (Tsironi et al., 2004). Nineteen new cases of CD in Bangladeshi migrants 
were reported during the study period 1997-2001.  The mean age-standardised incidence 
of CD was 7.3 cases/105/year in the period 1997-2001 compared with 2.3 cases/105/year 
between 1981 and 1989.  This indicates an increase in the incidence of CD and a fall in 
the incidence of abdominal tuberculosis (7.4 cases/105/yr [1995-1989] - 2.5 cases/105
 
/yr 
[1997-2001]).  
Chapter 1: Introduction 
38 
 
CD phenotype in UK South Asians 
In Jayanthi’s study (1992), the predominant disease location for both South Asians and 
Europeans was terminal ileal disease, and both groups had similar surgical 
requirements.  Trironi et al. (2004) reported 47.4% (9/19) of newly diagnosed CD 
patients had disease limited to the terminal ileum (L1), 21% (4/19) had colonic disease 
only and the remaining patients (31.6%: 6/19) had ileocolonic disease.  Nonpenetrating 
nonstricturing disease behaviour was the most common disease behaviour (9/16: 
56.3%).  Stricturing disease occurred in 6/19 patients (31%) and penetrating in 4 of 19 
(21%). 
 
Chapter 1: Introduction 
39 
 
1.3 INFLAMMATORY BOWEL DISEASE GENETICS 
It is well known within the Caucasian population that IBD demonstrates a familial 
pattern of disease with a much higher disease frequency in first-degree relatives of 
affected individuals (CD: 14%, UC: 8.6%) compared to the general population (1.1%) 
(Peeters et al., 1996;Yang et al., 1993). 
 
  Twin studies support the genetic basis for IBD, 
with a much higher rate of disease concordance demonstrated in monozygotic twins 
(11/63: 17%) compared with dizygotic twins (4/80: 5%), particularly in Crohn’s disease 
(Thompson et al., 1996;Halfvarson et al., 2003).  
Observations from twin studies led to significant interest in unravelling the genetic basis 
of IBD. The first major breakthrough came using linkage analysis - this technique 
involves identifying whether chromosomal segments are shared between family 
members with disease, compared to those without it. Using sibling-pair linkage, a locus 
was found on chromosome 16, labelled as IBD1, that was linked to CD (Hugot et al., 
1996). Further susceptibility loci were found on chromosomes 3, 5, 6, 12, 14 and 19  
(Hampe et al., 1999;Satsangi et al., 1996a;Rioux et al., 2001).  Fine mapping studies 
could then be used to study specific genes within the susceptibility loci. 
         
An alternative method to identify potential susceptibility genes in IBD is to use a 
candidate gene approach.  In this approach biologically plausible genes are identified 
either by their position within regions of linkage, or by their potential function and are 
then studied in an association study comparing patients with healthy controls.  
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More recently genetic research has focused on Genome Wide Association (GWA) 
studies, which provide an analysis that is hypothesis-free, and can screen the whole 
genome for associations with IBD. GWA studies look for associations that are 
significantly higher than statistically expected and compare the allele frequency of 
patients with healthy controls.  Using this technique, a number of immune-related genes 
have been identified, such as those involved in bacterial clearance via autophagy or the 
interleukin response.   
To date, over 70 IBD susceptibility loci have been identified.  Twenty-one have been 
confirmed in UC alone and 23 specifically for CD.  A further 26 loci have been 
associated with both CD and UC. (Barrett et al., 2008;Mathew, 2008;The Wellcome 
Trust Case Control Consortium, 2007;Hugot et al., 2001;McGovern et al., 
2010;Thompson and Lees, 2011).  Genes of particular interest are discussed below. 
 
1.3.1 Caspase activating recruitment domain 15 (CARD15)/Nucleotide-binding 
oligomerization domain 2 (NOD2) 
The first gene contributing to Crohn’s disease susceptibility was identified in 2001 by 
Hugot using both the candidate gene approach and fine mapping. It was located within 
the IBD1 susceptibility locus on chromosome 16.  The gene was named caspase 
activating recruitment domain 15 (CARD15) or nucleotide-binding oligomerization 
domain 2 (NOD2) (Hugot et al., 2001).  Of particular interest are three coding single 
nucleotide polymorphisms (SNPs) within the gene (SNP8 [R702W], SNP12 [G908R], 
SNP13 [1007fsinsC]) (Figure 1-4), that are strongly and independently associated with 
Crohn’s disease in many Caucasian populations and between them represent 82% of 
CARD15/NOD2 polymorphisms in this population (Hugot et al., 2007).  The CARD15 
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protein is expressed in the cytoplasm of peripheral blood monocytes, paneth cells and 
intestinal epithelial cells, and acts as an intracellular recognition protein for bacterial 
components such as peptidoglycans.  When intracellular CARD15 recognises bacterial 
muramyl dipeptide, it activates the nuclear factor kappa B pathway (NFκB) which 
regulates inflammation and therefore acts as a protective function (Ogura et al., 2001).  
The CARD15/NOD2 polymorphisms Arg702Trp, Gly908Arg, and Leu1007fsinsC are 
associated with defective NFκB activation by muramyl peptide (Hugot et al., 
2001;Maeda et al., 2005).  However, it is unclear whether the polymorphisms cause a 
loss of function (as shown by Ogura et al. (2001)) and thus are less effective at 
clearance of bacterial flora, or whether it causes an inappropriate activation of NFkB in 
monocytes.  
 
        
 
Figure 1-4: Structure of the CARD15/NOD2 gene and protein showing polymorphisms Arg702Trp, 
Gly908Arg, and Leu1007fsinsC in the Leucine-rich Repeat Region (LRR). 
                        (Adapted from Hugot et al,2007) 
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In Northern European Caucasian patients with CD, 10-30% were heterozygous and 3-
15% homozygous or compound heterozygous for the CARD15/NOD2 polymorphisms. 
The corresponding proportions from the control population were 8-15% and 0-1% 
respectively (Hugot et al., 2007).  A meta-analysis in 2004 calculated that the overall 
relative risk of developing CD in the Caucasian population was 2.4 for carriers of one 
CARD15/NOD2 SNP and 17.1 for two SNPs (Economou et al., 2004).   
 
1.3.2 Autophagy-Related-16-like 1 gene (ATG16L1) 
Autophagy is a biological process of membrane trafficking in which autophagosomes 
engulf organelles and cytosolic macromolecules, followed by fusion of the 
autophagosome with a lysosome to form an autolysosome and sequestered material is 
degraded (Shih and Targan, 2009).  Autophagy is important for cellular homeostatic 
functions including structural remodelling, nutrient and energy generation and 
degradation of damaged or long-lived cytoplasmic components.  The role of autophagy 
as a defence against invading intracellular microorganisms has also been recognised 
(Nakagawa et al., 2004).  It is proposed that any bacteria entering the cytoplasm by 
either invasion or escape from an endocytic vesicle are engulfed and compartmentalised 
within autophagosomes.  The cell can then deploy a number of mechanisms to eliminate 
the bacteria eg. fusing with lysosomes and activating respiratory burst cascades (Radtke 
and O'Riordan, 2006).  Within some cells, autophagy may also play a role in loading 
antigen into MHC binding groves for presentation at the cell surface (Munz, 2006).  
This protective role of autophagy is an important part of the innate immune response, 
but also links to adaptive immunity by delivery of foreign antigens necessary for 
immune recognition.  Defective elimination of intracellular bacteria secondary to defects 
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in autophagy provides a plausible link with the pathogenesis of CD. 
 
Recently, genome-wide association studies have identified a highly significant 
association (P=0.039) between Crohn's disease and the autophagy-related 16-like 1 gene 
(ATG16L1) on chromosome 2 at the rs2241880 loci (Hampe et al., 2007). This was 
specific for CD and had a lack of correlation with UC (P>0.04).  The loci rs2241880 is 
a coding SNP that carries virtually all the disease risk exerted by the ATG16L1 gene and 
is probably confined to individuals carrying susceptibility allele G at rs2241880.  The 
frequency of the G allele was 0.6 in affected individuals and 0.53 in controls. Two 
additional genome wide association studies and an extension study from the Wellcome 
Trust consortium have been subsequently published confirming ATG16L1 as a 
susceptibility gene in CD (The Wellcome Trust Case Control Consortium, 2007;Rioux 
et al., 2007). 
 
The ATG16L1 gene encodes a protein in the autphagosome pathway responsible for 
intracellular bacterial killing (Figure 1-5). The exact functional consequences of the 
rs2241880 remain unclear.  The human ATG16L1 protein has an N-terminal APG16 
domain consisting of coiled coils and eight C-terminal WD repeats.  The ATG16L1 
polymorphism leads to an amino acid exchange (threonine to alanine) (Hampe et al., 
2007) and is thought to lead to a defective immune responses in CD allowing 
commensal enteric bacteria to cause an overly aggressive T cell response and 
subsequent chronic inflammation (Hampe et al., 2007;Rioux et al., 2007;Sartor, 2008). 
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Figure 1-5:  Diagram showing the role of NOD2 proteins in NFκB production and the importance of 
ATG16L1 in autophagosome formation.   
                  (Note: It is unclear whether polymorphisms in CARD15/NOD2 lead to loss of function or   
                   inappropriately high levels of NFκB production). 
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1.3.3 Immunity-Related GTPase protein M (IRGM) 
In addition to ATG16L1, the Wellcome Trust Case Control Consortium (WTCCC) 
discovered SNPs near the Immunity-Related GTPase protein type M (IRGM) gene on 
chromosome 5q33.1 were associated with CD. The finding was replicated in an 
independent panel and the strongest replications were for SNPs rs13361189 and 
rs4958847 (P = 6.6 x104 and 3.1 x 104
 
, respectively) (The Wellcome Trust Case Control 
Consortium, 2007).  The IRGM gene does not seem to be involved in the predisposition 
to UC (Parkes et al., 2007).  
The association of the IRGM locus with CD appears robust, but significant questions 
remain regarding the nature of its contribution to pathogenesis. The exact function of 
IRGM in CD aetiology and pathogenesis is unknown, but animal and human studies 
implicate IRGM as having a pivotal function in the autophagy pathway. IRGM deficient 
mice have reduced defence against intracellular pathogens such as Toxoplasma gondii 
and Listeria monocytogenes  (Franke et al., 2008); similarly, human IRGM acts as its 
functional equivalent in the autophagy pathway and participates in conferring resistance 
against mycobacterial infections (Collazo et al., 2001).  Initial sequencing of the IRGM 
gene by Parkes et al. did not identify any causal amino acid changes.  However, a recent 
study by McCarroll et al. (2008) showed that a deletion polymorphism, immediately 
upstream of IRGM and in perfect linkage disequilibrium (r2
 
 =1.0) with the most strongly 
CD-associated IRGM risk allele at the SNP rs13361189, could be the potentially causal 
variant. 
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For a long time it has been postulated that commensal intestinal bacteria predispose to 
CD but without any understanding as to how they might do so.  Taken together, the 
genetics for ATG16L1 and IRGM implicate defects in autophagy as a key part in the 
pathogenic pathway predisposing to CD. 
 
1.3.4 Interleukin 23 Receptor Gene (IL23R) 
In 2006, Duerr et al. identified the IL23R gene located on chromosome 1p31 as an IBD 
susceptibility gene in a GWA study testing 308,332 SNPs in 547 non-Jewish ileal CD 
cases and 548 controls.  The IL23R SNP at rs11209026 led to an amino acid change 
(Arg391Gln) and was associated with a lower risk for developing CD (Duerr et al., 
2006). 
This proved to have significant biological plausibility as the IL23 Receptor is stimulated 
by interleukin (IL) 23 and is pivotally involved in cytokine regulation via the T helper 
cell type (Th) 17 response.  Th17 cells produce IL17 (Harrington et al., 
2005;Annunziato et al., 2007), which acts on both immune and non-immune cells 
resulting in the recruitment of neutrophils at sites of inflammation, and triggers T cell 
proliferation and upregulation of a number of pro-inflammatory molecules (Awane et 
al., 1999;Laan et al., 2001) (Figure 1-6).  IL17  plays a key role in host defence against 
bacteria, particularly at mucosal surfaces, by favouring the local recruitment of immune 
cells (Curtis and Way, 2009). 
 
 Additionally, IL17 induces pro-inflammatory cytokine 
production by macrophages, thus creating a link between innate and adaptive immune 
responses (Kolls and Linden, 2004). 
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Figure 1-6:  An illustration of the role of the Interleukin 23 receptor (IL23R) in bacterial clearance. 
                    Adapted from McGovern et al. (2010). 
 
Fuss et al. (2006) demonstrated that active inflammation in the colon of CD patients is 
associated with high levels of IL23 secretion and many chronically inflamed human 
tissues are infiltrated by highly differentiated Th17 lymphocytes (Pene et al., 2008).  
IL17 over-expression has been found in a number of inflammatory disorders, including 
IBD (Fujino et al., 2003).  In addition, animal studies have suggested that IL23 may be 
responsible for developing intestinal inflammation within the terminal ileum (Becker et 
al., 2003). Therefore, a polymorphism in the IL23 receptor may reduce the subsequent 
Th17 and IL17 response leading to less inflammation and protection against CD. 
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The same SNP associated with CD (at rs11209026) has also been shown to confer 
protection in UC. (rs11209026,  P = 1.3  10-8; OR=0.56) (Silverberg et al., 
2009;McGovern et al., 2010).  However, there is contrasting data on the molecular role 
of IL23R in UC.  Early studies by Fujino (2003) using immunohistochemistry showed 
that there was higher IL17 expression in CD mucosa than in UC.  In contrast,  
Kobayashi et al
 
 (2008) detected high levels of IL17 transcripts in both CD and UC 
mucosa compared to normal gut concluding that IL23 regulates the Th17 balance in UC 
and CD.  The demonstration by Fuss et al. (2006) that IL23 is upregulated in active CD 
but not UC further confuses the picture, and makes it difficult to understand the precise 
role of the IL23R in UC. 
1.3.5 Human Leukocyte antigen (HLA) 
The IBD3 locus on the short arm of chromosome 6p, contains the genetic region known 
as the major histocompatibility complex (MHC).  The human leukocyte antigens (HLA) 
are the products of genes mapped in the MHC region (Figure 1-7).  The HLA complex 
is divided into three regions - class I, class II and class III.  On the basis of their 
structure and function, class I antigens characterise the main products of HLA-A, -B 
and –C genes (as well as the less important (HLA-E, -F, -G) and class II antigens 
characterise the main products of HLA-DR, -DQ and –DP genes.  In contrast, the class 
III region, located between class I and II genes, contains a diverse collection of over 20 
genes that encode for complement, hormones, intracellular peptide processing, and 
other aspects of the immune response (Cassinotti et al., 2009). 
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Figure 1-7: The major histocompatibility complex genes located on chromosome 6p. 
                    (Adapted from Cassinotti et al. 2009). 
 
 
For each of the HLA loci, multiple alleles exist in the population. At a single locus, the 
allele has a ‘co-dominant expression’, meaning that each individual will have two 
alleles for any given locus and both will be expressed.   Class I antigens are expressed 
on the surface of most nucleated cells and platelets compared to Class II antigens that 
are expressed on B lymphocytes, monocytes, macrophages and dendritic cells.  The key 
role of class I and II molecules is to bind to peptides and transport them to the 
membrane of cells for recognition by the T-cell antigen receptor.  Class I molecules 
present mainly endogenously synthesised peptides (such as viral or tumour peptides) to 
CD8+ cytotoxic cells, whereas class II molecules present predominantly exogenous 
antigens (such as bacterial peptides) to CD4+ T helper cells.   
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Class I molecules are composed of a transmembrane α-chain, encoded by the HLA-A, -
B or –C gene locus non-covalently bound to β-2 microglobulin.  There are three types 
of HLA Class II molecules expressed by a single cell, namely HLA-DR, HLA-DQ and 
HLA-DP.  These are each made up of αβ heterodimers (Figure 1-8). The β chains are 
encoded by the DRB1, DQB1 and DPB1 genes respectively, which are all highly 
variable and the α-chains are coded for by the DPA and DQA genes which are also 
highly variable and the DRA gene which is invariant (Ahmad et al., 2006).  
 
                                           
 
Figure 1-8: Structure of the HLA class II molecule showing the binding of αβ heterodimers 
 
 
The HLA system is made more complex by the fact that certain alleles occur together in 
the same haplotype more often than would be expected by chance, a term referred to as 
‘linkage disequilibrium’ (LD).  This is particularly apparent with HLA class II to the 
extent that HLA-DR alleles can be used to predict the HLA-DQ allele with a high 
degree of accuracy (Piancatelli et al., 2004).  
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HLA genes are highly polymorphic at each locus (DP, DQ, DR), this means that there 
are several alleles that may only differ by a few nucleotides in the DNA sequence, 
allowing many different HLA codifying sequences to exist in the human population.  
The combination of HLA genes on each chromosome 6 represents one HLA haplotype 
that is inherited from each parent. 
 
Linkage within the HLA region has been confirmed in genome-wide scanning 
(rs9469220; P=8.7×10-7;  The Wellcome Trust Case Control Consortium, 2007) and a 
meta-analysis combining all published linkage scans confirmed the HLA region to be 
the most consistent for linkage across all IBD studies (van Heel et al., 2004).  The 
extensive linkage disequilibrium across the region has provided a great hurdle in 
defining the precise genes involved in disease susceptibility in the region, however, 
several linkage and association studies have implicated the HLA class II region in IBD 
susceptibility (Danze et al., 1996;Yang et al., 1999).    
 
As HLA class II molecules bind peptides largely resulting from endosomal degradation 
of exogenous and endogenous proteins, they play a key role in eliciting immune 
responses to bacteria.  This area is therefore of particular interest in IBD on the basis of 
its biological plausibility.  The exact mechanism by which Class II genes exert their 
influence in IBD is unclear although one hypothesis is that in IBD, cross reactivity may 
exist between the peptides derived from bacterial luminal flora and from self-antigens in 
the gut.  This may lead to the generation of auto reactive T cells, which contribute to 
disease pathogenesis through either stimulation, or inhibition of the immune system 
(Ahmad et al., 2006).  
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1.3.6 HLA class II genes and IBD 
The HLA-DRB1 gene is the most extensively studied HLA gene and has been 
implicated in determining susceptibility to both UC and CD.  Although some 
associations have not been confirmed, others have been found more consistently (Table 
1-2).  
 
Table 1-2: HLA-DRB1 associations with Crohn’s disease and ulcerative colitis 
 
 Positive associations Negative associations 
Crohn’s Disease DRB1*07 DRB1*1501 
 DRB1*0103  
   DRB1*04  
Ulcerative colitis DRB1*0103 DRB1*04 
 DRB1*1502  
Information adapted from: Ahmad et al., 2002, Hancock et al., 2008, Stokkers et al., 1999, Yoshitake et al., 
1999, Ahmad et al., 2003. 
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HLA-DRB1 associations with CD 
The HLA-DRB1*0701 is the most replicated association with CD.  The allele has a 
frequency of between 5% and 29% in European and North American populations but 
less than 1% in Japanese.  Studies, from the United Kingdom (Ahmad et al., 2002) , 
Canada (Newman et al., 2004)  and Spain (Fernandez et al., 2004) have shown that the 
HLA-DRB1*07 allele is specifically associated with ileal disease (with or without 
colonic disease). 
 
The association between HLA-DRB1*0103 and CD has been widely replicated in 
European patients and is strongly associated with colonic location, particularly isolated 
colonic disease (Newman et al., 2004;Silverberg et al., 2003;Hancock et al., 2008). 
However, it is a relatively rare allele and occurs in less than 2% of the European and 
North American Caucasian population and is absent in the Japanese population.  Studies 
have reported an association with HLA-DRB1*0103 and perianal location, but this 
probably reflects their clinical association with colonic disease rather than an 
independent genetic association.  
 
Associations with CD and the HLA-DRB1*04 allele have been demonstrated in 
Japanese cohorts, in particular DRB1*0405 and *0410 (Yoshitake et al., 1999;Matake et 
al., 1992;Nakajima et al., 1995).  These associations are not as strong in Northern 
Europeans/North American cohorts (Ahmad et al., 2003).   HLA-DRB1*1501 is a 
common allele, with a frequency of 6-25% in European and North American Caucasian 
populations and 6-10% in Japanese.  It is negatively associated with overall CD 
susceptibility (Stokkers et al., 1999) and probably confers protection against CD in all 
ethnic groups. 
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HLA-DRB1 associations with UC 
The 
 
HLA-DRB1*0103 allele is the most consistently replicated association in Caucasian 
UC patients.  The association is observed in both the DRB1*0103-DQB1*0301 and 
DRB1*0103-DQB1*0501 haplotypes, strongly implicating DRB1*0103 in the 
pathogenesis of the disease (Stokkers et al., 1999).  The association is strong in patients 
with extensive or severe disease (defined by the need for colectomy for failed medical 
management).  However its low allele frequency (7.8% in UC patients vs 3.7% in 
controls) (Ahmad et al., 2003) limits its clinical value in predicting disease course. 
HLA-DRB1*1502 is associated with UC in Europeans (Ahmad et al., 2003), North 
Americans (Trachtenberg et al., 2000), Japanese (Futami et al., 1995;Yoshitake et al., 
1999) and Korean populations (Myung et al., 2002). There is marked variation in the 
allele carriage rates between the populations with carriage of 20-25% in Japanese but 
<1% in Caucasian UC populations.  Despite this, there are similar odds ratios for the 
gene in the disease population across the ethnic groups suggesting it is a true disease 
causing-variant. A small study in Japan (Masuda et al., 1994) suggested that HLA-
DRB1*1502 is associated with extensive and intractable UC but this has not been 
replicated in other East Asian populations (Myung et al., 2002).  These results have to 
be interpreted with caution as in Japanese and British patients, UC has also been 
reportedly associated with HLA-B*52 (Seki et al., 2001;Ahmad et al., 2003a), the class I 
allele in linkage disequilibrium with DRB1*1502.  
 
The HLA-DRB1*04 allele may be a protective allele as it is negatively associated with 
UC in North European populations (Stokkers et al., 1999). This is confined to the most 
prevalent subtype in the UK HLA-DRB1*0401 but only when it is present on the 
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haplotypes DRB1*0401 – DQB1*0301.  
  
It is not known whether a gene-dose effect operates, such that the possession of two 
high-risk HLA alleles confers additional risk.  However, it is apparent from the 
literature that HLA associations vary with ethnicity, reflecting genetic heterogenecity 
and population-specific patterns of linkage disequilibrium across the HLA complex.   
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1.3.7 Correlation between genotype and IBD phenotype 
Crohn’s disease 
Rigorous stratification of IBD patients by clinical phenotype has successfully shown an 
association between genotype and phenotype.  In nearly all CD phenotype studies, 
CARD15/NOD2 polymorphisms are significantly more prevalent in patients with ileal 
disease than those with CD limited to the colon (Lesage et al., 2002).  A meta-analysis 
showed that the odds ratio for ileal compared with colon-only disease was 2.5 (95% CI 
2.0 to 3.2) (Economou et al., 2004). 
 
Parkes original association study of SNPs within the IRGM gene was performed in an 
unselected CD population which included all sub-types of CD as classified by disease 
extent and behaviour.  On sub group analysis, there was no clear association with 
disease phenotype although ‘pure ileal disease’ tends to associate more strongly with the 
SNPs than ‘pure colorectal’ (Parkes et al., 2007).  In contrast, an Italian study of 823 
CD patients, Latiano et al. (2009) showed a genotype-phenotype association of the 
IRGM rs4958847 polymorphism and fistulising CD behaviour (P=0.037).  An 
explanation for the observed differences may relate to the much larger number of 
fistulising CD patients in the Italian CD cohort (25%), higher than that reported in 
British studies.  
 
The first study noting the association of IL23R with CD was performed in patients with 
ileal CD, but as the authors chose to study only this subgroup (to minimise pathogenic 
heterogeneity) no phenotype comparisons are available.   A later German study by Glas 
et al. included 833 CD patients of all phenotypes and 456 UC patients.  In CD patients 
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with different rs1209026 genotypes, there were no differences in the frequency of 
disease characteristics such as age of onset, disease behaviour, disease location and 
EIMs (Glas et al., 2007). 
 
To date, there are no reports of association studies with ATG and a particular CD 
phenotype. 
 
Ulcerative colitis 
Phenotype studies in UC have shown the HLA-DRB1*0103 allele is associated with 
extensive or severe disease, as defined by the need for colectomy for failed medical 
management (Ahmad et al., 2003). There is also evidence to suggest that the HLA-
DRB1*0103 allele is important in determining the extraintestinal manifestations 
associated with CD and UC (Orchard et al., 2002).  In particular, there is a strong 
association between HLA-DRB1*0103 and type 1 peripheral arthropathy (Orchard et al., 
2000) with 35% of patients possessing the allele compared to 3% of controls.  The allele 
has also been associated with pyoderma gangrenosum (Williams et al., 2007). 
 
1.3.8 Variation in IBD genetics between different ethnic groups 
Ethnic variation in CD susceptibility genes 
Genetic studies in different ethnic groups have reported a widely differing carriage rates 
of IBD susceptibility genes.  The CD-associated CARD15/NOD2 polymorphisms are 
either rare or absent in Japanese, Korean and Chinese CD patients (Inoue et al., 
2002;Lee et al., 2005;Leong et al., 2003).  CARD15/NOD2 polymorphism frequencies 
among African American and Hispanic CD children are also lower compared with white 
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children (Kugathasan et al., 2005).  Two studies from India have reported the frequency 
of the three common CARD15/NOD2 mutations in this population.  The first study was 
a small case-control study from the Punjab of 25 South Asian CD patients.  Neither the 
patients or controls showed any polymorphisms for SNP 8, SNP12 or SNP13 on 
CARD15/NOD2 (Juyal et al., 2007).  Ramakrishna’s group from Vellore, Southern 
India, performed a larger study of 82 CD patients and 149 controls and also reported 
that none of the patients showed any of the three CARD15/NOD2 polymorphisms 
(Pugazhendhi et al., 2008) (Table 1-3).  Phenotypically, the patients in the study 
included 28 patients with ileocolonic disease and 26 patients with ileal disease, the 
patterns associated with the CARD15/NOD2 mutations in Western populations.  The 
absence of the common CARD15/NOD2 mutations in any of these patients indicates a 
need to undertake more detailed and possibly non-hypothesis driven studies in this 
population.  
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Table 1-3: Frequency of the three CARD15/NOD2 polymorphisms associated with Crohn’s disease 
in patients of different ethnic origin 
 
  European 
(n=468) 
African American 
(n=183) 
Chinese 
(n=65) 
North India 
(n=25) 
South India 
(n=82) 
   SNP Allele % % % %          % 
rs2066844  
Arg720Trp 
(SNP8) 
C 89 96.7 100 100  100 
T 11 3.3 0 0    0 
rs2066845  
Gly908Arg 
(SNP 12) 
G 94 98.9 100 100   100 
C 6 1.1 0 0     0 
rs2066847  
Leu107fsinsC 
(SNP13) 
WT 88 96.2 100 100   100 
Ins C 12 3.8 0 0     0 
 
Allele frequencies adapted from Hugot et al. (2001),  Leong et al., (2003), Kugathasan et al., (2005), 
Juyal et al.,(2007), Pugazhendhi et al., (2008). 
 
 
Yamazaki et al. (2009) recently published data on the frequency of CD associated 
polymorphisms in the Japanese population (Cases=484, Controls=470).  Compared to 
results reported by the Wellcome Trust Consortium (2007) they demonstrated very 
variable background gene frequencies between the two populations (Table 1-4) and 
showed no association with IL23R, ATG16L1 or IRGM in the Japanese CD patients.  
There are no data on the frequency of these polymorphisms in South Asian populations. 
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Table 1-4: Summary of the genetic differences between UK and Japanese populations in single 
nucleotide polymorphisms (SNPs) associated with Crohn’s disease susceptibility 
 
 European population Japanese population 
MAF MAF 
SNP Chr Gene Case Control Case Control 
rs11805303 1p31 IL23R 0.39 0.32 0.57 0.55 
rs10210302 2q37 ATG16L1 0.40 0.48 0.24 0.24 
rs4958847 5q33 IRGM847 0.15 0.11 0.51 0.50 
rs13361189 5q33 IRGM189 0.10 0.07 0.36 0.33 
 
Chr., chromosome; MAF, minor allele frequency as defined in the control cohorts 
 
 
As previously mentioned, the HLA-DRB1*04 allele association is stronger in Japanese 
CD patients compared with Northern Europeans/North American cohorts (Ahmad et al., 
2003a;Nakajima et al., 1995).  The only reported data on associations of HLA-DR and 
DQ antigens in Indian CD patients came from a family study of 9 CD patients, 52 first 
degree relatives and 110 ethnically matched controls. This showed no significant 
differences between the groups but in view of the small study numbers, it is not possible 
to draw any conclusions from this study (Thakur et al., 2003). 
 
Ethnic variation in UC susceptibility genes 
Juyal’s CARD15/NOD2 study, also reported the frequency of CARD15/NOD2 
polymorphisms in Indian UC patients (Juyal et al., 2007).  As with CD the frequency of 
SNPs 8,12 & 13 were low.  However, the group subsequently resequenced all the 
coding regions in the CARD15/NOD2 gene and revealed another two SNPs in this 
population.  One of the polymorphisms at rs2066842 (SNP5) was more frequent among 
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UC cases compared to controls (17% vs 12%: Bonferroni adjusted P value=0.02) but 
did not reach significance for CD.   SNP5 conferred modest risk for UC (OR=1.72, 95% 
CI: 1.17-2.52). This is interesting, as polymorphisms in CARD15/NOD2 have been 
traditionally associated with ileal CD.   Genotype-phenotype analysis revealed no 
associations between SNP5 and UC disease extent or EIMs.  Although this SNP has 
been associated with CD in a French study (P=0.0003) (Lesage et al., 2002), it is of note 
that a previous study demonstrated this variant occurs in phase with the R702W, 
G908R, and 1007fs mutations and that the association was thought to be related to 
linkage disequilibrium (Hugot et al., 2001).  
 
The HLA-DRB1*0103 subtype is extremely rare in the Japanese and Korean populations 
however, the Japanese and Korean UC population show a significantly increased 
frequency of the HLA-DRB1*1502 allele (Myung et al., 2002;Masuda et al., 
1994;Futami et al., 1995).  This allele is associated with UC in European, North 
American, Japanese and Korean populations with similar odds ratios of 2 to 4.5 despite 
variable background prevalence, suggesting it is a disease causing variant (Futami et al., 
1995;Trachtenberg et al., 2000).  The Japanese study by Masuda et al. (n=45) showed 
the gene frequency of DRB1*1502 was significantly higher in patients with total colitis 
compared to left-sided and proctitis (P<0.05) but this association with UC phenotype 
was not observed in the Korean study (Myung et al., 2002).  
 
There is no published data with respect to UC and HLA Class II associations in the 
South Asian population and there is a need for further research in this area. 
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1.4 METABOLIC PROFILING - EVIDENCE FOR THE ROLE OF THE 
MICROBIOTA IN THE PATHOGENESIS OF IBD 
The clinical features of IBD are likely to be the result of interactions between 
genetically susceptible individuals and environmental stimuli, the key environmental 
trigger being the host intestinal microbiota.  The gut microbiota was shown to be 
important in IBD after early animal models of IBD demonstrated that colitis does not 
occur when experimental animals are reared in germ-free conditions (Bhan et al., 1999), 
but the introduction of a gut bacterial load resulted in rapid mucosal inflammation (Rath 
et al., 2001).  Subsequent human studies using fluorescent in situ hybridization (FISH) 
have shown that patients with IBD have an altered gut microbiota compared to controls, 
with bacterial changes localised to the luminal communities (Kleessen et al., 2002).  
Sokol et al. used flow cytometry to analyze the bacterial composition of faecal samples 
and showed that species of Clostridia, especially those involved in short chain fatty acid 
production, are reduced in both UC and CD compared with healthy controls (Sokol et 
al., 2006).  
 
Therefore, the chronic intestinal inflammation seen in IBD is likely the result of an 
abnormal immunological response to commensal bacteria within the gut lumen in a 
genetically susceptible host (Figure 1-9). 
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Figure 1-9: Model of IBD pathogenesis.  The interaction of susceptibility genes, disease phenotype 
genes, the host immune response and environmental stimuli, contribute to the 
pathogenesis of ulcerative colitis and Crohn’s disease.  
 
 
As no particular species of bacteria has been shown to cause IBD (Lodes et al., 2004), 
this has led to the hypothesis that a dysbiosis of the microbiota may be involved either 
in initiating the disease or maintaining it, in a genetically susceptible host (Marchesi et 
al., 2007). 
                                   
There is a clear need to better understand the role of the gut flora in disease 
pathogenesis.  Nuclear Magnetic Resonance Spectroscopy (NMRS) provides a potential 
method for studying the relationship between patients and the intestinal flora.  It allows 
the generation of metabolic information based on the analysis of biofluids and provides 
an opportunity to identify specific biomarkers of disease dependent on underlying 
bacterial metabolic processes.  
IBD
Gut flora 
& environment
Genetic 
suceptibilty
Host immune 
response
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1.4.1 Principles of nuclear magnetic resonance spectroscopy (NMRS) 
NMRS is a non-invasive technique which allows the study of the molecular 
composition of biofluids.  It is the interaction between atoms, a static magnetic field and 
a radiofrequency pulse that defines NMRS.  The nucleus consists of protons and 
neutrons that determine its charge and mass. The nuclei of certain atoms, hydrogen-1 
(1H), carbon-13, (13C) phosphorous -31 (31P) and fluorine-19 (19
Figure 1-10
F) rotate around an axis 
and possess a quantum mechanical property known as ‘spin’.  The ‘spin’ provides 
angular momentum to the charged particle producing a magnetic field analogous to that 
produced by movement of electrons in a loop of wire.   The nucleus is said to behave 
like a miniature bar magnet (Cobbold J, 2005) ( ).  
 
 
                 
 
Figure 1-10:  A charged spinning nucleus creates a magnetic field causing it to behave like a dipole 
or bar magnet. 
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In NMRS the sample is subjected to a strong magnetic field to align the magnetic 
dipoles of the protons in the sample.  A radiofrequency pulse is applied at 900
Figure 1-11
 to the 
external magnetic field to stimulate the nuclei into a higher energy level.  When the 
pulse is removed, the nuclei relax to their normal energy level producing radiofrequency 
signals which contain information about each nucleus and therefore about the molecules 
in which they exist.  Therefore, a nucleus within any particular molecule has a 
characteristic chemical shift.  The signal that is detected is known as a free induction 
decay but is difficult to interpret in the time domain.  Fourier transformation (a 
mathematical operation that decomposes a signal into its constituent frequencies) 
converts the time domain into the frequency domain producing the typical NMR spectra 
( ). 
             
 
Figure 1-11: A typical NMR spectra which contains signals from hundreds of metabolites. 
 
The technique detects a wide variety of metabolites from host and gut microbial 
metabolism, thus maximising opportunity for novel biomarker discovery.  The use of 
metabolic profiling has been extensively explored because of its potential to identify 
biomarkers, enhance clinical diagnosis and expand hypothesis generation (Bjerrum et 
al., 2008). 
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1.4.2 Clinical applications of NMRS 
NMR based spectroscopy has proven particularly successful in rapid analysis of 
complex biological samples.  Each spectrum that is generated, yields a unique metabolic 
fingerprint for each biological sample and is the product of genetic and environmental 
contributions (eg. diet, lifestyle, gut microbial activity) under a particular set of 
conditions. Analyzing metabolites (molecules <1 kDa) in body fluids using 
spectroscopic methods provides knowledge of the metabolic phenotype.  The metabolic 
profile provides information that cannot be obtained directly from the genotype, gene 
expression profiles or even the proteome of an individual. 
 
Using a hypothesis-free approach, spectra can be compared between disease groups and 
controls and this has identified metabolic profiles associated with a number of diseases 
including diabetes, hypertension and osteoarthritis (Chung et al., 2005;Holmes et al., 
2008;Lamers et al., 2005).  In circumstances where previous metabolic characteristics 
have been identified, a hypothesis-driven approach can be used to study specific 
metabolites within the spectrum. 
 
1.4.3 The role of NMRS in the characterisation of IBD  
Previous experiments have demonstrated that the host microbiota significantly 
contributes to the overall metabolic profile generated from biofluids (Wikoff et al., 
2009;Li et al., 2008;Marchesi et al., 2007), therefore any changes in the gut microbiota 
will be reflected in the spectroscopic profile of the biofluid being examined.   
Chapter 1: Introduction 
67 
 
Studies using NMR spectroscopy of colonic mucosal biopsies have been able to 
distinguish healthy control tissue from that of IBD patients and to further distinguish 
ulcerative colitis from Crohn’s disease (Bezabeh et al., 2001).  The diagnostic accuracy 
was 97.9% for the differentiation of IBD tissue from healthy controls however, this 
technique is invasive and open to sampling error.   
 
Non-invasive metabonomic approaches to help in the diagnosis of IBD have acquired 
much interest.  In 2007 a group from Ireland created metabolic profiles of faecal 
extracts from IBD patients and healthy controls (Marchesi et al., 2007).  The faecal 
extracts of both CD and UC patients were characterized by reduced levels of 
microbiota-related metabolites (butyrate, acetate, methylamine, and trimethylamine) in 
comparison with a control population.  This is consistent with the theory that a 
disruption or dysbiosis of the normal gut bacterial ecology is seen in patients with IBD.  
A new and exciting approach to non-invasive NMRS is the use of urine samples to 
analyse specific metabolites dependent on either gut bacterial metabolism alone or co-
metabolism of the host and the intestinal microflora.   Urinary NMR profiling has the 
significant advantage of having easy of sample collection.  There is good evidence from 
animal studies to support differences in the urinary NMR profile of healthy animals and 
those with intestinal inflammation:  Experiments comparing mice with dextran sulphate 
sodium (DSS) induced colitis and healthy mice, showed that the urinary metabolic 
profile was clearly distinguishable between the groups (Schicho et al., 2010).  Large 
amounts of methylamines (dimethylamine [DMA], trimethylamine [TMA] and its 
oxidation product trimethyl-amine n-oxide [TMAO]) that are produced by gut bacteria 
were found to be elevated in the urine of DSS-treated mice.  Metabonomic studies in an 
IL10 deficient colitis mouse model also displayed higher urinary levels of metabolites 
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produced and or modulated by the gut microflora (TMA and TMAO) compared to a 
cohort of healthy mice (Murdoch et al., 2008).  
 
Studies using urinary NMR spectroscopy have recently been performed in Caucasians 
with IBD.  NMRS of the urine has shown distinct urinary metabolic profiles for CD and 
UC (Williams et al., 2009).  In particular, levels of hippurate (a metabolite dependent on 
the co-metabolism of host and gut flora) were significantly lower in IBD patients when 
compared to a healthy control cohort.   This novel technique has never been used to 
study other ethnic populations with IBD.   Comparing the metabolic profiles of IBD 
patients of different ethnicities could help determine if there is variation in the 
microbiota between ethnic groups.   It will also help determine if the biomarkers already 
identified in Caucasian populations, will have potential worldwide applicability in IBD 
diagnosis. 
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1.5  SEROLOGICAL MARKERS IN INFLAMMATORY BOWEL DISEASE 
PATIENTS  
The chronic intestinal inflammation seen in IBD is likely to be the result of an aberrant 
immunological response to commensal bacteria within the gut lumen.  Many patients 
with UC and CD exhibit serological responses to microbial antigens and this could 
reflect the relevant microorganisms involved in pathogenesis or may simply reflect the 
increased permeability of the gut.    In 1959, investigators first reported antibodies to 
colon extract in patients with ulcerative colitis (Broberger and Perlmann, 1959).  Since 
that time, several antibodies have been described.  The two most widely studied 
serologic markers in IBD are atypical perinuclear anti-neutrophil cytoplasmic antibody 
(pANCA) and anti-Saccharomyces cerevisiae antibody (ASCA). More recently, 
additional serum autoantibodies including anti outer membrane porin C (anti-OmpC) 
have been reported as showing an associated with IBD (Landers et al., 2002).  
 
1.5.1 Atypical perinuclear anti-neutrophil cytoplasmic antibody (atypical 
pANCA) 
Perinuclear anti-neutrophil cytoplasmic antibody (pANCA) is an autoantibody directed 
against neutrophil granules. Testing is performed on serum by indirect 
immunofluorescence of peripheral blood neutrophils.  Two pANCA patterns are 
detectable: the typical pANCA pattern of staining which results in homogeneous rim-
like staining of the perinuclear cytoplasm and the atypical pANCA reactivity that is 
recognised by a broad non-homogeneous rim-like staining of the nuclear periphery with 
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multiple intranuclear foci (Figure 1-12). 
 
The atypical pANCA staining is the most frequent ANCA pattern seen in patients with 
IBD, especially UC.  In the literature, the atypical pANCA pattern may be referred to as 
‘pANCA with diffuse cytoplasmic staining’ or ‘x-ANCA’.  The target antigen of 
atypical pANCA has not been clearly identified but it is likely that it is associated with 
the inner side of the neutrophil nuclear membrane (Terjung et al., 2000). 
 
                                  
 
Figure 1-12: Atypical pANCA staining showing a broad inhomogeneous rim-like staining of the 
nuclear periphery with multiple intranuclear foci. 
                      (Image from Ruffatti et al (2002)) 
 
Detection of atypical pANCA in the sera of UC patients remains considerably higher 
(40- 80%) than CD patients (5-25%) (Saxon et al., 1990;Rump et al., 1990;Bossuyt, 
2006). Although the test is reasonably specific (84-95%) the sensitivity is not optimal 
(48-63%) (Bossuyt, 2006). 
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1.5.2 Anti-Saccharomyces cerevisiae antibodies (ASCA) 
Anti-Saccharomyces cerevisiae antibodies (ASCA) are directed primarily against 
mannose residues (oligomannosides) expressed in the cell wall of the yeast 
Saccharomyces cerevisiae (Main et al., 1988).   Different hypotheses concerning the 
origin of ASCA in IBD have been proposed but must take into account the widespread 
distribution of oligomannosides shared by many molecules present in a wide variety of 
organisms.  ASCA-IgG reactive antigens have been reported in the granulomas of 
bowel resections and on infiltrating lymphocytes and neutrophils in inflamed tissue 
from CD patients (Oshitani et al., 2003).  However, it is not clear whether ASCA 
detected by using S. Cerevisiae are generated by this microbe or if they represent cross-
reactivity with others microorganisms carrying similar mannose structures (Sendid et 
al., 1996).  
 
As with atypical pANCA, ASCA positivity is variable but studies have shown a higher 
positivity in  CD patients (50-80%) compared with only 2-14% positivity in UC patients 
and 1-7% of healthy controls (Peeters et al., 2001;Quinton et al., 1998). Specificity for 
ASCA can be as high as 90% and sensitivity is in the range of 41-76% (Vermeire et al., 
2001). 
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1.5.3 Antibodies against Outer Membrane Porin C (anti-OmpC)  
The antibody anti-OmpC is directed against the outer membrane porin C of Escherichia 
coli.  Detection of the IgG antibody is performed using ELISA.  In CD, the reported 
seroprevalence is 55%  (Landers et al., 2002).  The prevalence in UC and healthy 
controls was low (2% and 1.3% respectively).  Anti-OmpC may be of particular value to 
aid in the diagnosis of ASCA negative CD patients. 
 
1.5.4 IBD phenotype associations with serological markers 
Atypical pANCA 
Associations between atypical pANCA and UC phenotypes have been inconsistent.  A 
pilot study from the Mayo Clinic in 1996 showed an association with atypical pANCA 
and a severe left sided ulcerative colitis which is resistant to treatment.  The disease had 
an aggressive course requiring earlier surgery (Sandborn et al., 1996).  These findings 
have not been replicated.  Interestingly, atypical pANCA has been associated with a 
subgroup of CD patients characterised by UC-like Crohn’s colitis; the inflammation 
usually involves the left side of the colon and the response to therapy is generally good 
(Vasiliauskas et al., 1996).  Complications such as stricturing or perforation were lower 
in this group (Klebl et al., 2003).  Positivity of pANCA in this group makes it often 
difficult to distinguish colonic CD from UC serologically.  
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ASCA and anti-OmpC 
The expression of antibodies to Saccharomyces cerevisiae (ASCA) has been associated 
with a CD phenotype that is remarkably similar to that of patients with the common 
CARD15/NOD2 polymorphisms associated with IBD.  ASCA seropositive patients 
present at a younger age and are more likely to have ileal disease (Dassopoulos et al., 
2007;Quinton et al., 1998;Peeters et al., 2001).  They are also at greater risk for 
complicated disease behaviour (Vasiliauskas et al., 2000) and require surgery more 
frequently (Forcione et al., 2004).  In patients with an ASCA+ (IgG and/or IgA) 
/atypical pANCA- phenotype, small bowel involvement (with or without colonic 
disease) is more typical than pure colonic disease (Peeters et al., 2001;Mow et al., 
2004).  Stratification of CD patients based on the presence of anti-OmpC showed an 
association with penetrating disease behaviour and therefore potentially leading to a 
higher rate of surgical intervention (Mow et al., 2004).  A subgroup of CD patients do 
not appear to have ASCA antibodies.  Whether these individuals form a subgroup of 
patients with specific clinical characteristics is unknown at present. 
 
1.5.5 The frequency of IBD serological markers in South Asian IBD patients 
The only available information on the frequency of serological markers in South Asian 
IBD patients comes from two small Indian studies.  The first, a study of 59 CD patients, 
25 with UC and 21 healthy controls that recorded the frequency of ASCA (IgA or IgG) 
as being 61% in CD, 40% in UC and 9.5% in controls.  For atypical pANCA, the 
prevalence was 10.1%, 32% and 0% respectively (Makharia et al., 2007).  A second 
Indian study investigated 16 CD, 36 UC and 12 controls and recorded similar 
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frequencies of ASCA positivity (62% CD, 26% UC and 8% controls) (Ghoshal et al., 
2007).  Both studies tried to use ASCA to differentiate between CD and patients with 
abdominal TB but neither showed any statistical difference.  To date, there have been no 
studies on the frequency of anti-OmpC in the South Asian population. 
 
There have also been no studies in the literature directly comparing the frequencies of 
antibodies associated with IBD between different ethnic groups.  It is difficult to draw 
any reliable comparisons between data obtained in different countries due to varying 
methodologies and inter-observer variability.    
 
As serological markers for IBD become more sensitive, they may become useful in 
clinical practice for assisting in the diagnosis of IBD and discriminating between UC 
and CD.  In view of this, it is of interest to determine if the sensitivity and specificity of 
serological markers is the same in different ethnic groups. 
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1.  The study outlined in Chapter 3 aimed to investigate the phenotype of IBD in a 
cohort of UK South Asians.  A second aim was to determine if there are phenotypic 
differences in IBD between South Asian and white Northern Europeans living in the 
UK.  
 
Hypothesis:  Inflammatory bowel disease phenotype is different between South Asian 
and white Northern European IBD patients living in the UK. 
 
 
2.  The aim of the study described in Chapter 4 was to examine the role of previously 
described genetic associations in a South Asian IBD population; specifically 
CARD15/NOD2 (rs2066844, rs2066845, rs2066847 & rs2066842), ATG16L1 
(rs2241880), IL23R (rs11209026), IRGM variants (rs1000113 & rs4958847) and HLA 
class 2 alleles (HLA-DRB1*0103 & HLA-DRB1*1502).  The study also compared the 
frequencies of IBD associated polymorphisms in South Asians with a cohort of white 
Northern European IBD patients. 
 
Hypothesis: The frequency of genetic polymorphisms associated with IBD differs 
between South Asians and white Northern Europeans. 
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3.  The aim of Chapter 5 was to use urinary metabolic profiling to determine if there are 
differences in microbiota-related metabolites between South Asian IBD patients and 
South Asian controls.  The NMR results from South Asian IBD patients were compared 
with a matched white Northern European IBD population to investigate if there are 
differences in urinary metabolites between IBD patients of different ethnicity. 
 
Hypothesis: Metabolic differences seen in the urinary nuclear magnetic resonance 
spectra of IBD patients are independent of ethnicity and characteristic of IBD. 
 
 
4.  The study reported in Chapter 6 aimed to determine the diagnostic value of 
serological markers (atypical pANCA, ASCA IgA & IgG and anti-OmpC) in a South 
Asian cohort of IBD patients and to investigate any association of these serological 
markers with clinical phenotype.  The results from the South Asian cohort were 
compared with a white Northern European IBD cohort to determine if there is ethnic 
variation in the sensitivity and specificity of these markers.   
 
Hypothesis: The sensitivity and specificity of serological markers does not differ 
between ethnic groups.  
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3.1 INTRODUCTION 
Epidemiological studies from around the world suggest a widely varying incidence of 
IBD, with highest rates of UC and CD reported in Northern Europe and North America 
(Loftus, Jr., 2004).  Previous research in IBD has predominantly focused on large white 
European/American populations, but recent studies suggest there may be phenotypic 
differences in other ethnic groups (Hou et al., 2009;Bhat et al., 2009).   
Between 1950 and 1980 there was substantial migration of South Asians (originating 
from India, Pakistan and Bangladesh) to Europe, and currently 2.08 million South 
Asians live in the UK (Office for National Statistics 2001).  Studies of IBD in this 
population could provide valuable information that may help to distinguish the degree 
of influence of genetic and environmental pathogenic factors.  However, to date studies 
have been scarce and have involved relatively small patient numbers.  
 
A retrospective epidemiological study compared the incidence and prevalence of UC 
among South Asians living in the city of Leicester between 1972-1989 with Europeans 
from the same area (Probert et al., 1992).  South Asian patients tended to have more 
extensive disease and less proctitis compared to Europeans but this did not reach 
statistical significance.  However, differences in IBD phenotype were reported in a 
small study of 82 South Asian IBD patients from Manchester, with South Asians 
demonstrating a higher rate of pancolonic disease (34/82: 41%) compared to a white 
British IBD cohort (41/158: 26%) (Rashid et al., 2008), but it was not clear whether this 
related to a combination of UC and CD patients or UC alone. 
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There have been relatively few studies of CD in the UK South Asian population 
(Tsironi et al., 2004;Jayanthi et al., 1992a;Probert et al., 1993).  Jayanthi et al. identified 
only 28 new cases of CD in the city of Leicester between 1972 and 1989 compared to 
179 new cases in Europeans (Jayanthi et al., 1992a).  In this study, disease behaviour, 
prevalence of extraintestinal manifestations and smoking history were not investigated, 
but the predominant disease location for both South Asians and Europeans was the 
terminal ileum, and both groups had similar surgical requirements.  However, recent 
genetic studies from South Asia have demonstrated significantly lower carriage of CD-
associated polymorphisms in CARD15/NOD2 (the gene predominantly associated with 
ileal Crohn’s disease) than in Northern Europeans (Economou et al., 2004;Juyal et al., 
2007;Pugazhendhi et al., 2008), and the lack of phenotypic differences in the Leicester 
study may reflect its small size.  
 
3.1.1 Study aims 
Many South Asians live in London, and approximately 220,000 have settled in the 
North West London boroughs of Brent, Ealing, Harrow and Hounslow, making up over 
22% of the population in this area (Office for National Statistics 2001, 2004).  The 
primary aim of the study was to determine the phenotype of IBD in a South Asian 
population and to compare it with a white Northern European cohort from the same 
area.  A secondary aim was to investigate the impact of environmental factors on 
disease phenotype by comparing that of first-generation and second-generation South 
Asians.  A move towards a Northern European phenotype in second-generation South 
Asians could suggest that Western environmental stimuli are important pathogenic 
factors in determining disease phenotype. 
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3.2 MATERIALS AND METHODS 
3.2.1 Ethics Approval 
All patients gave informed consent and the study was approved by the St. Mary’s 
Hospital Research and Ethics committee with site-specific approval from each 
participating hospital trust. 
 
3.2.2 Patient Recruitment 
To capture the maximum number of South Asian IBD patients in North West London, 
the IBD and gastroenterology outpatient clinics of five hospitals (St. Mary’s and 
Hammersmith Hospitals of Imperial College Healthcare NHS Trust, St. Mark’s 
Hospital, Ealing Hospital and West Middlesex University Hospital) were monitored for 
an eighteen-month period (01.08.2008 – 01.02.2010).  In North West London, current 
practice is that IBD patients are managed in secondary care by the gastroenterology 
team.  Primary care physicians may be involved in joint care for example, managing 
disease flares or blood monitoring while on immunosuppressive therapy but patients 
remain under regular review in secondary care.  Each of the five hospitals has a 
dedicated IBD outpatient clinic.  Within these hospitals, patients with IBD are referred 
to this clinic.  In addition, patients seen in the IBD clinic include:- new referrals from 
primary care with signs and symptoms of IBD, new IBD patients referred by the 
consultant physician or surgeon at the time of hospitalisation, patients referred from 
endoscopy with IBD, IBD patients with an acute relapse and patients with quiescent 
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disease under regular follow-up.  To ensure complete coverage of the population, all the 
general gastroenterology clinics were also reviewed for South Asian patients with IBD.  
A white Northern European population of comparable size was recruited from the IBD 
clinics of the same five hospitals; patients of mixed race were excluded.  White 
Northern Europeans represent the predominant ethnic group attending the IBD clinics in 
North West London.  Northern European patients were recruited from all five sites 
consecutively for a six-month period between 01.08.2009 and 01.02.2010.  
 
3.2.3 Case Definition 
The clinical notes of all patients attending the IBD/gastroenterology clinics were 
screened by the gastroenterologist at the time of the patient’s outpatient appointment.  
Only patients with a confirmed diagnosis of IBD based on clinical evaluation, 
endoscopic/radiological appearances and histology (Van et al., 2010;Stange et al., 
2008), were recruited for the study .  
 UC was defined on clinical history/examination with endoscopic and histological 
appearances of  continuous mucosal inflammation of the colon, affecting the rectum and 
a variable extent of the colon in continuity, and characterised by a relapsing and 
remitting course (Stange et al., 2008).   CD was defined on the basis of clinical 
evaluation and a combination of endoscopic findings (mucosal ulceration, skip lesions, 
cobblestone appearance and terminal ileal ulceration), histological appearance 
(discontinuous intestinal inflammation and/or non-caseating granulomas) with or 
without radiological evidence of skip lesions, stricturing disease, or fistulising disease.  
Stool culture results and mucosal histology were reviewed for all patients and those in 
whom there was any uncertainty regarding diagnosis (ie. those with IBD, type 
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unclassified (Silverberg et al., 2005) or colitis as a result of infection, radiation or 
ischemia) were excluded from the study. 
Previous studies from the UK have defined the South Asian population as patients 
whose families originated from the Indian subcontinent (India, Pakistan and 
Bangladesh) including South Asians who had migrated via East Africa (Probert et al., 
1993;Carr and Mayberry, 1999).  For comparison, this study used the same definition of 
South Asia and only included patients both of whose parents were of South Asian 
origin.  All patients were aged ≥16 years.   
 
3.2.4 Patient demographics and clinical phenotype 
A questionnaire proforma was completed prospectively by the attending doctor at the 
time of the outpatient appointment.  Data collection included; gender, ethnic origin, 
place of birth, ethnicity and place of birth of the patient’s parents, length of time in the 
UK, extraintestinal manifestations, a current drug history and a smoking history.  
Patients were classed as smokers if they had smoked more than seven cigarettes per 
week for at least 6 months immediately prior to diagnosis of IBD and/or during follow-
up.  Non-smokers were those who never smoked, smoked a little and occasionally, or 
had stopped smoking more than 6 months before IBD was diagnosed (Cosnes et al., 
1996;Cottone et al., 1994;Lakatos et al., 2009).   The patient’s clinical notes were then 
carefully reviewed to gather additional demographic and phenotypic details including 
age at IBD diagnosis, length of follow-up, disease extent, disease behaviour, surgical 
history and to confirm any extraintestinal manifestations.   
A second gastroenterologist (Dr Horace Williams, Imperial College London) randomly 
audited 200 sets of clinical notes from patients recruited to the study in order to confirm 
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the clinical details were accurately documented.  There was disagreement regarding one 
case and this was resolved after discussion. 
 
3.2.5 Defining IBD disease behaviour and extent 
In the participating hospitals, it is standard protocol for patients with suspected IBD to 
have a full colonoscopy with ileal intubation, and biopsies taken from the terminal 
ileum, right colon, transverse colon, left colon and rectum.  Only UC patients that had 
either evaluation of the entire colon by colonoscopy with biopsy or who had a 
colectomy with histology reports were included in the study.  UC disease extent was 
recorded by both endoscopic appearance and maximum histological extent.  When 
comparing the ethnic groups, maximal disease extent was determined by histology and 
defined in terms of the Montreal classification (ulcerative proctitis (E1), left-sided UC 
(E2) and extensive colitis (E3)) (Silverberg et al., 2005).  Only CD patients who had 
undergone a full colonoscopy with ileal intubation and biopsy (when not precluded by 
stenosis) were included in the study.  Disease extent and behaviour was based on a 
combination of histological extent and small bowel imaging.  Patients had an 
oesophagogastroduodenoscopy (OGD) with biopsy when clinically indicated.  Disease 
behaviour was considered cumulatively to the time of the most recent outpatient visit.  
The Montreal classification was also used to classify CD location (terminal ileal (L1), 
colonic (L2), ileocolonic (L3) and upper GI (L4)) and disease behaviour (nonstricturing, 
nonpenetrating (B1), stricturing (B2) and penetrating (B3)) (Silverberg et al., 2005).  
Subjects with both stricturing and penetrating disease were classified as penetrating 
disease (B3).  Perianal fistulating disease alone did not constitute penetrating disease 
but was recorded as a modifier of the disease behaviour (p).  Surgical history was 
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documented and included surgery performed in North West London and elsewhere 
(colectomy for UC patients, and bowel resection or treatment of related complications 
in CD patients). 
 
3.2.6 Extraintestinal manifestations 
Extraintestinal manifestations (EIMs) were determined from patient recall with 
confirmation in the clinical notes.  EIMs were defined as peripheral arthropathy (Type 1 
or 2) (Orchard et al., 1998), ankylosing spondylitis/sacroiliitis, skin complications 
(erythema nodosum or pyoderma gangrenosum), ocular complications (anterior uveitis 
or episcleritis), primary sclerosing cholangitis and venous thrombosis.   
 
3.2.7 Assessing the impact of environmental factors in the UK on disease 
development and phenotype 
To determine the potential influence of environmental factors in the UK on the 
development of IBD in South Asians, the rates of IBD diagnosed in the 1st, 2nd, 3rd and 
subsequent decades since migration were examined.  In addition, the potential impact of 
environmental factors on disease phenotype was assessed by comparing South Asians 
born in the UK with first-generation South Asians diagnosed within 10 years of arriving 
in the UK.  This cohort was specifically chosen as being representative of a group of 
patients that had less exposure to environmental stimuli in the UK compared to South 
Asians who had been born and grown up in the UK.  The phenotype of second-
generation South Asians was directly compared to the Northern European cohort to 
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determine if there was a move towards a Northern European phenotype in second-
generation South Asians.   
 
3.2.8 Statistical Analysis 
Data from the South Asian cohort were compared with the Northern European cohort 
using the Mann-Whitney U test for continuous variables, such as duration of disease and 
age at diagnosis and the chi-square test for categorical variables, such as disease extent 
and need for surgical intervention.  The disease extent in first and second-generation 
South Asians was compared using the chi-squared test.  P values <0.05 were considered 
statistically significant. 
 
To account for potential false positives resulting from multiple comparisons, a 
Bonferroni correction was applied to P values in the phenotypic data that showed 
significance (P<0.05) (by a factor of 3 in the UC cohort, to allow for comparisons 
relating to; disease location, requirements for surgery and extraintestinal manifestations 
and by a factor of 4 in the CD cohort, to allow for comparisons of disease extent, 
disease behaviour, surgical intervention and extraintestinal manifestations).  Corrected 
P values are expressed in the text as Pc.  The data were analysed using Graph Pad Prism 
Software® (Version 5, U.S.A.).   
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3.3 RESULTS 
A total of 770 well-characterised IBD patients were recruited for the study (South Asian 
367, Northern European 403). In the South Asian population UC was the predominant 
disease (UC 74.4%: CD 25.6% [273:94]) whereas in the Northern European population 
there were similar proportions of UC and CD (46.7%:53.3% [188:215]).   
 
3.3.1 UC demographics 
Of the 273 South Asian UC patients identified, there was a male predominance (1.4:1), 
in contrast to the Northern European population which had more female patients; 
however, this did not reach statistical significance (P=0.06) (Table 3-1).  The median 
age at diagnosis was 30.7 years (inter-quartile range 23.3 – 42.1 years) for the South 
Asian population.  Two hundred and thirty-one patients (84.6%) were Indian, 39 
(14.3%) Pakistani and 3 (1.1%) Bangladeshi.  All patients had a diagnosis of IBD 
confirmed in the UK.  The majority of South Asian patients (67.0%) were aged between 
17 and 40 years old at diagnosis (Montreal classification A2).  No significant 
differences were observed in smoking habits between the South Asian and European 
cohorts (Positive smoking history: 6.9% vs 7.4% [P=0.85]). 
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Table 3-1:  Demographic details of South Asian and white Northern European ulcerative colitis 
patients living in North West London, UK 
 South Asian  
   (n=273) 
Northern European  
(n=188) 
P value 
Gender  Male: Female, n (%) 159 (58.2) : 114 (41.8)        92 (48.9) : 96 (51.1)  P = 0.06  
Age at diagnosis  (Median [IQR]; yrs) 30.7 (23.3 - 42.1) 33.2 (25.1 - 43.2) †P = 0.11  
Age at diagnosis (Montreal):  n (%)    
≤16      (A1) 10    (3.7) 9  (4.8)  P = 0.54  
17-40   (A2) 183  (67.0) 125 (66.5)  P = 0.96  
>40      (A3) 80    (29.3) 54 (28.7)  P = 0.99  
Duration of follow-up (Median [IQR]; yrs) 10.5 (5.6 – 18.1) 9.3 (4.8 – 18.9) †P =  0.27  
*Smoker: n (%) 19  (6.9) 14 (7.4)  P = 0.85 
 
IQR, inter-quartile range.  Age at diagnosis expressed as per the Montreal classification (Silverberg et al., 2005) 
†P: calculated using the Mann-Whitney U test.  All other P values calculated using the χ2 
*Smoked more than 7 cigarettes per week for at least 6 months immediately prior to diagnosis of IBD and/or during 
follow-up.  
test. 
 
 
3.3.2 UC phenotype 
The clinical features of the South Asian patients were compared with the Northern 
European cohort (Table 3-2). The disease phenotype differed significantly between the 
two populations, with 63.0% of South Asian patients having extensive colitis compared 
to 42.5% of the Northern European cohort (Pc<0.0001).  The prevalence of left-sided 
disease was similar in each group (27.1% and 31.4%), but limited rectal disease was 
less common in South Asian UC patients (9.9% vs 26.1% in Northern European patients 
(Pc<0.0001)) (Figure 3-1). Twenty-four (8.8%) of the South Asian UC population had 
Chapter 3: Defining the phenotype of IBD in UK South Asians 
89 
 
at least one extraintestinal manifestation (EIM) of IBD.  This was similar to the 
Northern European population (6.9%).  The most common EIM in South Asians was 
peripheral arthropathy (10 patients).  In addition, forty-four South Asian UC patients 
(16.1%) complained of arthralgia, but with no joint swelling or radiographic changes 
 
Table 3-2:  Phenotypic details of South Asian and white Northern European ulcerative colitis patients 
living in North West London, UK 
 South Asian  
   (n=273) 
Northern European  
(n=188) 
P value Corrected  
P value (Pc) 
Disease location (Montreal): n (%)     
Ulcerative proctitis    (E1) 27 (9.9) 49 (26.1) P< 0.0001 ‡Pc< 0.0001 
Left-sided UC           (E2) 74  (27.1) 59 (31.4) P= 0.36   
Extensive UC           (E3) 172 (63.0) 80 (42.5) P< 0.0001 ‡Pc< 0.0001 
Patients requiring colectomy: n (%) 18 (6.6) 20 (10.6) P= 0.16   
Extra-intestinal manifestations: n (%)     
Peripheral arthropathy 10 (3.7) 5 (2.7) P= 0.47   
Ankylosing spondylitis / 
Sacroiliitis 
4 (1.5) 1 (0.5) P= 0.43   
# 4 (1.5) Skin complications 4 (2.1) P= 0.82   
Uveitis / Episcleritis 6 (2.2) 4 (2.1) P= 0.82   
PSC 3 (1.1) 2 (1.1) P= 0.97   
Venous Thrombosis 2 (0.7) 1 (0.5) P= 0.79   
 
#
Disease location expressed as per the Montreal classification (Silverberg et al., 2005) 
Erythema nodosum and pyoderma gangrenosum: PSC, primary sclerosing cholangitis;  
‡Pc: After Bonferroni correction the values remain significant.  All P values calculated using the χ2 
Bold values are P values that showed significance (P<0.05). 
test. 
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Figure 3-1: Bar graph comparing the ulcerative colitis phenotype of South Asian and white  
Northern Europeans patients.    
                      (■) South Asian and (■) white Northern European patients.  P values were calculated using   
                      the χ2
 
 test.  A Bonferroni correction was applied to significant P values.                                     
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Colectomy rates in South Asians were numerically lower than the Northern European 
population but this did not reach statistical significance.  Eighteen South Asian patients 
(6.6%) had undergone resections for UC (16 for failed medical management and 2 for 
dysplasia related to UC).  Three patients had an end ileostomy and 15 had restorative 
ileo-anal pouches. This compared with 20 Northern European patients (10.6%) who had 
undergone colectomies (19 for failed medical management and 1 for dysplasia).  Nearly 
all patients in both cohorts requiring colectomy had extensive colitis (17/18 in the South 
Asian cohort and 17/20 in the Northern European cohort).  When patients with 
extensive colitis that required surgery were compared, only 17/172 South Asian patients 
with extensive colitis required a colectomy compared to 17/80 in the Northern European 
cohort (9.9% vs 21.3% P=0.01).   
 
3.3.3 CD demographics 
Of the 94 South Asian CD patients, the majority were Indian (87.2%).  Median age at 
diagnosis was 30.7 years (interquartile range 21.4–42.1 years) which was similar to the 
Northern European cohort (Table 3-3).  In both cohorts, the most common age range at 
diagnosis was 17-40 years (A2) but there were significantly fewer South Asian patients 
in the ≤16 years group (A1) ( P=0.03).  Only 10 South Asian patients had a positive 
smoking history (10.6%) compared to 68 Northern Europeans (31.6%) (P<0.0001). 
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Table 3-3:  Demographic details of South Asian and white Northern European Crohn’s disease 
patients living in North West London, UK 
 
 
 
South Asian 
(n=94) 
Northern European 
(n=215) 
P value 
Gender (Male: Female: n (%)) 48 (51.1) : 46 (48.9) 94 (43.7) : 121 (56.3)  P= 0.23 
Age at diagnosis  (Median [IQR]; yrs) 30.7 (21.4 – 42.1) 25.9 (20.1 - 38.2) †P= 0.09 
Age at diagnosis (Montreal):  n (%)    
≤16      (A1) 5 (5.3) 30   (13.9) P= 0.03 
17-40   (A2) 61 (64.9) 139 (64.7) P= 0.97 
>40      (A3) 28 (29.8) 46   (21.4) P= 0.11 
Duration of follow-up (Median [IQR]; yrs) 13.2 (7.1 – 20.9) 11.6 (6.1 - 19.6) †P= 0.39 
*Smoker: n (%) 10 (10.6) 68 (31.6)  P<0.0001 
 
IQR, inter-quartile range.  Age at diagnosis expressed as per the Montreal classification (Silverberg et al., 2005) 
†P: calculated using the Mann-Whitney U test.  All other P values were calculated using the χ2
*Smoked more than 7 cigarettes per week for at least 6 months immediately prior to diagnosis of IBD and/or during 
follow-up. 
 test. 
Bold values are P values that showed significance (P<0.05). 
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3.3.4 CD phenotype 
The South Asian CD phenotype was mainly colonic (L2=46.8%) and ileocolonic 
(L3=37.2%).  Isolated ileal disease was less common (L1=16.0%).  Disease in the 
Northern European population was predominantly ileocolonic (L3=40.5%) and although 
there was less isolated colonic disease than in the South Asians (34.8% vs 46.8%) this 
was not significantly different after correcting for multiple comparisons (Pc=0.19) 
(Figure 3-2). 
 
The clinical behaviour pattern at last follow-up was nonstricturing, nonpenetrating (B1), 
in 72.3% South Asian patients, stricturing (B2) in 23.4% and penetrating (B3) in 4.3% 
of cases.  Length of follow-up for the CD cohorts did not differ significantly.  Nineteen 
patients (20.2%) had perianal CD, including perianal fistulae and fissures.  There was 
significantly less B3 behaviour compared to the Northern European cohort (Pc=0.04).  
In all, 26.6% of South Asian patients had had surgical treatment for CD (including 
bowel resection, stricturoplasty and surgical treatment of perianal disease). This was 
significantly lower than in the Northern European cohort (44.7%, Pc=0.01).   
 
In order to determine if surgical intervention was related to disease phenotype, a 
subgroup analysis was performed in all patients that required surgery.  In the South 
Asian cohort, 40% (10/25) of surgical intervention was for B1 behaviour, 44% (11/25) 
for B2+B3 behaviour and 16% (4/25) for perianal disease. This was different to the 
Northern European population were the vast majority of operations were for B2+B3 
behaviour (62.5%: 60/96) and only 16.6% (16/96) for B1 behaviour and 20.9% (20/96) 
for perianal disease.  
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Figure 3-2:  Bar graph comparing Crohn’s disease location in South Asians and white Northern 
Europeans. 
                      (■) South Asian and (■) white Northern European patients.  P values were calculated using   
                      the χ2
 
 test.  A Bonferroni correction was applied to significant P values. 
There were no significant differences in EIMs between South Asian and Northern 
European cohorts (P=0.18). Skin complications were the most common EIM in South 
Asian CD patients (Table 3-4). 
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Table 3-4: Phenotypic details of South Asian and white Northern European Crohn’s disease 
patients living in North West London, UK 
 
 
 
South Asian 
(n=94) 
Northern European 
(n=215) 
P value Corrected 
P value (Pc) 
Disease Location (Montreal): n (%)     
Terminal ileum   (L1) 15 (16.0) 53 (24.7) P= 0.09   
Colon                 (L2) 44 (46.8) 75 (34.8) P= 0.048 Pc=0.19 
Ileocolon            (L3) 35 (37.2) 87 (40.5) P= 0.59   
Upper GI            (L4) 0 0 -  
Upper GI modifier 10 (10.6) 16 (7.4) P= 0.35   
Disease Behaviour (Montreal): n (%)     
Nonstricturing, nonpenetrating  (B1) 68 (72.3) 125 (58.1) P= 0.02 Pc=0.08 
Stricturing         (B2) 22 (23.4) 60 (27.9) P= 0.41   
Penetrating        (B3) 4 (4.3) 30 (14.0) P= 0.01 ‡Pc=0.04 
Perianal disease modifier (p) 19 (20.2) 46 (21.4) P= 0.81   
Surgery for Crohn’s disease n (%)  25 (26.6) 96 (44.7) P= 0.003 ‡Pc=0.01 
Extraintestinal manifestations n (%)     
Peripheral arthropathy 6 (6.4) 27 (12.6) P= 0.11   
Ankylosing spondylitis / Sacroiliitis 1 (1.1) 5 (2.8) P= 0.46   
*Skin complications 7 (7.4) 18 (8.4) P= 0.78   
Uveitis / episcleritis 3 (3.2) 7 (3.3) P= 0.98   
PSC 1 (1.1) 1 (0.5) P= 0.55   
Venous Thrombosis 0 5 (2.3) P= 0.14   
 
GI, gastrointestinal; PSC, primary sclerosing cholangitis, *Erythema nodosum and pyoderma gangrenosum 
Disease location expressed as per the Montreal classification (Silverberg et al., 2005) 
‡Pc: After Bonferroni correction the values remain significant.  All P values calculated using the χ2 
Bold values are P values that showed significance (P<0.05). 
test. 
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3.3.5 Demographics of first-generation South Asian IBD patients 
The exact place of birth was not available for 17 South Asian patients (10 UC patients 
and 7 CD patients), the analysis was performed on the remaining 350 patients (263 UC 
and 87 CD). The majority of South Asian patients studied were first-generation (born 
outside the UK) (64.6%:  226 /350) and the remainder were second-generation (born in 
the UK). Eighty-three percent of first-generation patients came directly from the Indian 
subcontinent (187/226) and the remaining 17% immigrated from East Africa (39/226).  
The median year that first-generation South Asian patients arrived in the UK was 1975 
(IQR; 1968-1988).   
 
To assess the effect of changing environment on the development of IBD in first-
generation patients, the rates of diagnosis in the 1st, 2nd, 3rd and subsequent decades 
since migration were examined.  Of the 226 first-generation South Asian patients (171 
UC and 55 CD), three patients had a provisional diagnosis of IBD before arriving in the 
UK (1 UC and 2 CD).  For UC, of the remaining 170 patients, more were diagnosed in 
the first decade (34.7%: 59/170), compared to 19.5% (33/170) in the second decade, 
22.9% (39/170) in the third decade and 22.9% (39/170) in subsequent decades. Thus for 
UC there was no substantial increase in disease diagnosis with time spent in the UK.  In 
contrast in the CD cohort (although small), very few of the first-generation patients 
were diagnosed within 10 years of arrival in the UK (7.6%: 4/53).  The majority of 
patients were diagnosed in the 2nd (37.7%: 20/53) and 3rd
 
 decades (41.5% 22/53).  The 
remaining 13.2% (7/53) were diagnosed after being in the UK >30 years. 
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3.3.6 Phenotypic comparison of first and second-generation South Asian IBD 
patients 
To assess the potential impact of environmental factors in the UK on disease phenotype, 
first generation South Asians diagnosed within the first 10 years of arriving in the UK 
were compared to South Asians born in the UK.  There was no significant difference in 
phenotype between the UC groups, and the predominant UC phenotype was still 
extensive colitis (first-generation UC diagnosed within 10 years: 34/59: [57.6%] vs 
second-generation 63/92 [68.5%] P=0.17).  The numbers for CD were too small to be 
able to make any meaningful comparisons. 
 
When South Asian UC patients born in the UK  were compared to the Northern 
European UC population, there were again significantly higher rates of extensive UC in 
the South Asian cohort (63/92: [68.5%] vs 80/188 [42.5%]: Pc<0.0001) despite a 
shorter follow-up period (median duration of follow-up: 8.5 years vs 9.3 years 
respectively). 
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3.4 DISCUSSION 
This is the largest phenotypic study of IBD in the UK South Asian population, 
examining the clinical characteristics of 367 patients.  The study shows that UC is more 
common than CD in the North West London South Asian IBD population (UC 74.4%: 
CD 25.6%), and that the disease extent in South Asian UC patients is significantly 
different from that of a white Northern European cohort.  Disease behaviour and need 
for surgery differed significantly between the South Asian and white Northern European 
CD cohorts. 
Studies such as this may be prone to ascertainment bias, and hence great care was taken 
to collect a complete population of South Asian IBD patients attending IBD and 
gastroenterology outpatient clinics in a defined geographical area and to compare them 
with a comparable population of white Northern European IBD patients also from the 
same area.   Potential limitations of this study are: (i) that patients with IBD-related 
symptoms may not have been referred to the clinic and therefore not included in the 
study, however this is likely to be a very small number of patients and will be the same 
for both ethnic groups and (ii) only patients attending hospital IBD/gastroenterology 
outpatient clinics were included; IBD patients under the sole care of primary care 
physicians or surgical outpatients would not have been included. However, in North 
West London, it is current practice that IBD patients are managed in secondary care by 
the gastroenterology team.  After surgery, patients remain under joint care with the 
gastroenterologists.  Primary care physicians may be involved in joint care of patients, 
but are not responsible for the sole care of IBD patients.  This practice was confirmed in 
a survey that I conducted of 10 local primary care practices. 
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3.4.1 UC phenotype in UK South Asians 
The frequency of extensive colitis in South Asians is significantly higher (63.0%) than 
in the Northern European population (42.5%) (Pc<0.0001).  These findings support the 
suggestion from a previous smaller study that extensive colitis is more common in 
South Asian patients than in Northern European patients (Rashid et al., 2008).  A study 
by Carr and Mayberry of 33 newly diagnosed South Asian patients in Leicester City 
reported that UC disease extent is more extensive in second-generation UC patients 
(6/9; 66.6%) than first-generation (6/24; 25%). They proposed that an environmental 
risk factor may explain the difference.  In this current study, the possibility of 
environmental factors in the UK influencing disease phenotype was investigated by 
comparing South Asians born in the UK with South Asians born in the Indian 
subcontinent and diagnosed within 10 years of arriving in the UK.  Extensive colitis 
remained the predominant phenotype for each group with no significant differences 
between the groups.  Although it is not clear how long a patient needs to be exposed to 
relevant environmental factors for them to be significant, the high rates of extensive 
colitis among South Asians, together with the absence of differences between first and 
second-generation UC patients, would support the idea that genetic factors may play a 
role in the susceptibility to extensive colitis in South Asians. 
 
It is well recognised that patients with more extensive disease are at higher risk of 
colectomy (Ritchie et al., 1978;Lennard-Jones, 1983) and nearly all patients in the study 
population that required colectomy had extensive colitis (17/18 in the South Asian 
cohort and 17/20 in the Northern European cohort).  It is therefore surprising that only 
17 out of 172 South Asian patients with extensive colitis required a colectomy 
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compared to 17/80 in the Northern European cohort.  This may suggest a less severe 
phenotype of IBD in the South Asian population and the finding is consistent with the 
study by Probert et al., which also suggested that South Asians with UC are at lower 
risk of colectomy than Europeans (Probert et al., 1992).  
 
South Asian UC patients reported similar EIMs to the Northern European population 
(8.8% vs 6.9% (P=0.49)), with peripheral arthropathy being the most common EIM in 
both cohorts.  The frequency of EIMs was lower than previously described in South 
Asians (Kochhar et al., 1991).  This may reflect a more rigorous stratification in this 
study - patients with arthropathy were only included if they had objective evidence of an 
inflammatory arthropathy and patients with arthralgia or any other cause of arthritis 
were excluded. Patients with back pain but without radiological evidence of sacroiliitis 
were also excluded.  Uveitis and episcleritis were the only ocular complications 
recorded and not conjunctivitis, which had been included as a EIM in a previous study 
of Indian UC patients (Kochhar et al., 1991).  
 
3.4.2 CD phenotype in UK South Asians 
Colonic disease was the most common disease location in the CD South Asian 
population.  In both Northern European and South Asian cohorts, the predominant 
disease behaviour was nonstricturing nonpenetrating.  Despite this, a significantly lower 
prevalence of penetrating behaviour was observed in the South Asian population 
compared to Northern Europeans (Pc=0.04); this may in part explain why the 
requirements for surgery are significantly lower in South Asians (Pc=0.01).  The 
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population of South Asians with CD is smaller than the UC cohort and so further large 
studies would be required to confirm the differences reported.   
 
3.4.3 Potential explanations for differences in clinical phenotype 
Differences in clinical phenotype between ethnic groups are likely to be due to a 
combination of genetic susceptibility, environmental and immune factors. Over 70 
susceptibility genes associated with IBD have been identified in the white European 
population over the past decade (Barrett et al., 2008;Hampe et al., 2007;The Wellcome 
Trust Case Control Consortium, 2007;Thompson and Lees, 2011).  The CARD15/NOD2 
gene on chromosome 16q (IBD1) has been associated with isolated ileal disease in 
white European CD patients (Cuthbert et al., 2002;Ahmad et al., 2002;Vermeire et al., 
2002). It is of note that the three disease susceptibility variants in the CARD15/NOD2 
gene associated with CD are rare or absent in South Asian IBD populations (Juyal et al., 
2007;Pugazhendhi et al., 2008).  Therefore, other genes or polymorphisms not yet 
identified may influence susceptibility to certain clinical phenotypes in this ethnic 
group.  
 
Differences between ethnic groups do not necessarily imply a genetic cause but may 
reflect variations in environmental factors related to lifestyle in different groups. An 
environmental factor which may be of importance in determining CD phenotype is 
smoking. This study reported a significantly lower number of smokers in the South 
Asian CD cohort compared to the Northern European cohort (10.6% vs 31.6%: 
P<0.0001).  This is consistent with previous reports that have shown significantly fewer 
smokers in South Asian migrants compared to Europeans (Banerjee et al., 2010;Carr 
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and Mayberry, 1999).  Smoking has been reported to be associated with disease 
location, with a higher prevalence of ileal disease and a lower prevalence of colonic 
involvement in smokers (Lakatos et al., 2009;Lindberg et al., 1992;Mahid et al., 2007).  
Previous studies have also demonstrated that smoking is more frequently associated 
with the development of strictures or fistulae with an increased risk of surgery (Picco 
and Bayless, 2003;Reese et al., 2008).    
 
Although this study did not show any differences in IBD phenotype between first- and 
second-generation South Asians, it has been proposed that environmental stimuli may 
act as a trigger for IBD in genetically susceptible individuals when moving from one 
part of the world to another.  The ‘IBD hygiene hypothesis’ suggests that hygienic 
environments negatively affect immune development, predisposing to immune-
mediated diseases like IBD (Elliott et al., 2000;de Silva et al., 2008). Reduced exposure 
to intestinal helminths may be a factor contributing to IBD as they are involved in  host 
immune regulation, preventing excessive immune activation (Weinstock and Elliott, 
2009), and perhaps better hygiene in the UK may be responsible for reduced exposure 
to enteric infections.  This may result in immune dysregulation and subsequent 
excessive inflammation in predisposed individuals.  Ethnic variation in the gut 
microbiota, and differences between developing and developed countries may also be 
involved in the dysregulation of mucosal immunity. 
 
Previous reports have suggested that dietary constituents in the Western diet, such as 
refined sugars and saturated fats are linked with the development of IBD (Bernstein and 
Shanahan, 2008).   More recently, high levels of arachidonic acid, an essential n-6 
polyunsaturated fatty acid (n-6 PUFA), which is present in red meat, certain cooking 
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oils, and polyunsaturated margarines has also been associated with a significantly higher 
risk of developing UC (de Silva et al., 2010).  Investigators from Leicester showed that 
South Asian Hindu IBD patients have significantly altered their traditional diet (Probert 
et al., 1996a).  Dietary changes adopted by South Asians may therefore act as a potential 
environmental stimulus in disease development. 
 
The lack of large population based studies of IBD in South Asia makes attempts to 
compare epidemiological data difficult. However, the nonstricturing, nonpenetrating 
colonic pattern of disease was the dominant phenotype in a recent multi-centre Indian 
study of 182 CD patients which may suggest that the phenotype of CD remains constant 
despite migration (Das et al., 2009).  Two smaller epidemiological studies from India 
report between 16 and 20% of UC patients have extensive colitis (Kochhar et al., 
1991;Sood et al., 2003).  In contrast, the majority of South Asian patients living in 
North West London with UC had extensive disease (63.0%).  The difference could 
relate to alterations in underlying environmental factors or to a variation in diagnostic 
assessment. This study based UC disease extent on a confirmed histological diagnosis 
rather than simply endoscopic or radiological appearances (used in the study by 
Kochhar et al.), but for comparison, the current data were reassessed using endoscopic 
extent only and extensive colitis was still the predominant phenotype (59%).   
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3.4.4 Conclusion 
This study has shown that UC is more prevalent than CD in a UK South Asian 
population, and that the predominant phenotype of UC in this ethnic group is extensive 
colitis. This appears to be associated with a low risk of colectomy for active disease, 
and long-term follow-up of this group will be important, to establish whether the higher 
proportion of extensive colitis translates into an increased risk of dysplasia/cancer.  The 
most prevalent CD phenotype in UK South Asians is nonstricturing, nonpenetrating 
colonic CD.  Disease behaviour and need for surgery was significantly lower in UK 
South Asians compared with Northern Europeans.  The phenotypic variations observed 
in South Asian IBD patients are likely to reflect different hereditary, environmental and 
behavioural factors, which may be elucidated through genetic, microbiological and 
immunological studies.  
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4.1 INTRODUCTION 
In view of the high incidence and prevalence of IBD in parts of  South Asia (Sood et al., 
2003), it is of great importance to study social, environmental and host genetic factors 
that may underlie these findings.  Both CD and UC have been shown to have a strong 
genetic component in Caucasian populations (Hugot et al., 2001;Duerr et al., 2006).  
The studies described in this chapter investigate the relevance of genetic associations 
previously described in other populations, in the South Asian population. 
  
In CD, the most consistently replicated polymorphisms have been found in the 
CARD15/NOD2 gene on chromosome 16 (Hugot et al., 2001).  In Caucasian 
populations, the overall risk of developing CD was 2.4 times higher for carriers of any 
one of three polymorphisms in this gene (rs2066844, rs2066845 and rs2066847) (Hugot 
et al., 2001).  These particular SNPs are most commonly associated with ileal CD 
(Lesage et al., 2002).  The frequency of having one of the CARD15/NOD2 SNPs in 
Caucasian controls is 8-15% compared to 10-30% in CD patients (Hugot et al., 2007).  
Recent studies of Indian IBD patients has suggested that the 3 SNPs in CARD15/NOD2 
associated with Caucasian CD patents are rare in Indian CD populations (Juyal et al., 
2007;Pugazhendhi et al., 2008).  However, an additional SNP in CARD15/NOD2 
(rs2066842) was associated with susceptibility to UC in this population (Juyal et al., 
2007).  The first part of this study was undertaken to confirm the frequency of 
CARD15/NOD2 CD associated SNPs in a South Asian IBD population. 
 
In 2006 a genome wide association (GWA) study showed an association between CD 
and variants in the IL23R gene (Duerr et al., 2006).  A coding variant at rs11209026 
Chapter 4: Phenotype genotype associations of IBD in a South Asian population 
107 
 
(Arg381Gln) was reported to exert a significant protective effect in both Jewish and 
non-Jewish populations.  The protective allele was less common in CD populations 
(1.9%) compared to matched controls (7%).  Subsequent replication studies in a UK 
population confirmed the association and also reported an association with UC where 
the allele was again less common compared to controls (Tremelling et al., 2007).  
Hampe J et al.(2007) discovered an association with the autophagy 16-like 1 
(ATG16L1) gene in a GWA study of 735 CD patients and 368 controls.  This gene 
codes for a protein that has a crucial role in the degradation of cytoplasmic proteins and 
organelles.  ATG16L1 is expressed in many tissues including the colon and small bowel 
(Hampe et al., 2007).  A single allele, the 300Ala allele of SNP rs2241880 was 
associated with disease susceptibility in Caucasian CD patients. There has been no 
confirmed association with this SNP in UC populations.  Another gene associated with 
CD and linked to the autophagy pathway, is the IRGM gene on chromosome 5.  This 
gene encodes a GTP-binding protein and is particularly involved in the elimination of 
intracellular bacteria, including Mycobacterium tuberculosis (Feng et al., 2004).  SNPs 
in the IRGM gene (rs13361189 and rs4958847) are thought to result in reduced function 
and/or activity of this gene leading to a persistence of intracellular bacteria, consistent 
with existing models of CD pathogenesis (Palomino-Morales et al., 2009). 
 
4.1.1 Study Aims 
Studies from Japan suggest that SNPs in IL23R, ATG16L1 and IRGM may not be 
associated with IBD in East Asian populations (Yamazaki et al., 2007;Yamazaki et al., 
2009) however, there have been no previous studies of these SNPs in South Asian IBD 
populations.  This study aimed to determine the prevalence of SNPs in CARD15/NOD2, 
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IL23R, ATG16L1 and IRGM in a cohort of South Asian patients and controls and to 
compare the results with a white Northern European IBD cohort. 
 
The Human Leukocyte Antigen (HLA) region on chromosome 6 contains the most 
consistently replicated gene loci associated with IBD.  The HLA-DRB1*0103 allele has 
been associated with both Caucasian CD and UC cohorts (Satsangi et al., 
1996b;Trachtenberg et al., 2000).  The allele has also been positively associated with 
disease phenotype, conferring susceptibility to extensive and severe UC (Ahmad et al., 
2003a) and colonic CD (Hancock et al., 2008).  In contrast to Caucasians, the HLA-
DRB1*0103 allele is not associated with IBD in East Asian populations (Yoshitake et 
al., 1999).  However, the HLA-DRB1*1502 allele has been associated with UC in East 
Asians (59.3% in UC cases vs 24.4% in healthy controls) (Yoshitake et al., 1999) .  This 
genetic association is also seen in Caucasians but the allele is rare (1.9% in cases vs 
0.3% in controls) as the major allele of the serotype DR2 is DRB1*1501 (Ahmad et al., 
2003a).  In a small Japanese study, the allele was associated with disease extent and 
severity (Masuda et al., 1994). There have been no previous reports on HLA class II 
associations in South Asian IBD populations.  This part of the study was undertaken to 
determine the carriage frequency of the known IBD HLA associated alleles 
(DRB1*0103 and DRB1*1502) in South Asian IBD patients and controls and to 
evaluate the influence of these alleles on disease phenotype.   
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4.2 METHODS  
4.2.1 Ethics approval 
The St. Mary’s Hospital Research Ethics Committee approved this study and site-
specific approval was obtained from each of the participating trusts. The South Asian 
control cohort was collected by Dr John Chambers and Professor Jaspal Kooner with 
approval from Ealing Research Ethics Committee.  All participants gave written 
informed consent. 
 
4.2.2 Sample Collection 
South Asian patients were recruited from the inflammatory bowel disease clinics of five 
North West London hospitals (St. Mary’s and Hammersmith Hospital of Imperial 
College Healthcare NHS Trust, St. Marks, West Middlesex and Ealing Hospital).  Only 
patients with a confirmed diagnosis of Crohn’s disease or ulcerative colitis were 
included in the study.  South Asian patients were only recruited if all four grandparents 
were born in the Indian subcontinent.  
 
For each participant, 10mls of peripheral blood was collected in an anticoagulant 
vacutainer containing di-sodium EDTA.  This was immediately frozen at -80o
 
C and 
used for DNA extraction and subsequent genotyping at a later date. 
Dr John Chambers and Professor Jaspal Kooner supplied blood (2mls EDTA sample per 
patient) from a control cohort of healthy South Asian participants who each had four 
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grandparents born in the Indian subcontinent (n=204).  These patients were recruited 
though the London Life Sciences Prospective Population (LOLIPOP) Study. LOLIPOP 
is an ongoing population-based cohort study of Indian Asian men and women aged 35–
75 years in West London, U.K.   
 
A well phenotyped and genotyped white Northern European population of 149 IBD 
patients (CD:99 and UC:50) previously collected by Dr. Horace Williams (Imperial 
College London), was used for comparison.   
 
4.2.3 DNA isolation 
DNA was extracted from peripheral blood using a two-stage procedure based upon 
Miller’s salting out technique (Miller et al., 1988).  Appendix 1 outlines the reagents 
that were prepared prior to DNA extraction. 
 
Miller’s salting out technique – stage 1 
For DNA extraction, the blood sample was thawed at room temperature and transferred 
to a 15ml polypropylene tube. 7mls of red cell lysis buffer was added and the 
suspension inverted several times before leaving it for 20 minutes at room temperature.  
Each sample was centrifuged at 2500 rpm for 20 minutes to pellet the white cell.  The 
supernatant was discarded into Hycolin.  Additional red cell lysis buffer was added to 
the polypropylene tube to make a total of 13mls.  The tube was left to stand again for 20 
minutes before centrifuging at 2500 rpm for a further 20 minutes.  The supernatant was 
discarded and the resulting white cell pellet was either stored at -20oC for DNA 
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extraction at a later date or the DNA was extracted immediately by proceeding to stage 
2 as outlined below.  
 
Miller’s salting out technique – stage 2 
The second stage of DNA extraction involved re-suspension of the white cell pellet in 
3mls of nuclear lysis buffer.  Proteins were precipitated by the addition of 1ml of 6M 
NaCl and separated from the DNA by the addition of 2mls of 24:1 Chloroform Isoamyl 
alcohol.  The samples were shaken to form a milky solution and then centrifuged at 
3000 rpm for 30 minutes.  Three distinct layers were then visible.  The upper layer was 
aspirated and transferred into a new 15ml polypropylene tube.  10mls of 98% ethanol 
were added and the tube inverted several times resulting in the precipitation of DNA.  
The precipitated DNA was transferred into a sterile 1.5 ml eppendorf and left to dry for 
30 minutes.  400µl of sterile water (Baxters®) was added to re-suspend the DNA.  The 
sample was stored at 35oC for 12 hours to aid suspension before storing at -20o
 
C.   
Millers salting out technique requires greater than 4mls of blood to yield a significant 
concentration of DNA (>100ng/µl).  For blood sample volumes <4mls, DNA was 
extracted using the QIAamp® DNA blood mini kit (Qiagen®). 
 
QIAamp® blood mini kit technique 
To extract DNA using the blood mini kit, 40μl of proteinase K and 400μl of the 
participant’s blood was added to a 1.5 ml microcentrifuge tube.  The sample was 
stabilised by adding 400μl of Buffer AL (all buffers supplied by Qiagen®) and 
incubating at 56°C for 10 min.  400μl of ethanol (96–100%) was added to the sample 
making a total of 1.2mls of solution, and then mixed by pulse-vortexing for 15 s.   600µl 
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of the final solution was transferred to a QIAamp Mini spin column in a 2ml collection 
tube. The tube was centrifuged at 8000rpm for 1 min. The spin column was then placed 
in a clean 2 ml collection tube, and the tube containing the filtrate discarded.  The 
remaining 600µl of solution was added to the spin column and the above process 
repeated.  500μl Buffer AW1 was added to the spin column and the tube centrifuged at 
8000rpm for 1 min.  The spin column was again placed in a clean 2 ml collection tube.   
Buffer AW2 (500 μl) was added to the spin column and the tube centrifuged at 13,000 
rpm for 3 min.  The spin column was placed in a clean 1.5 ml microcentrifuge tube, and 
the collection tube containing the filtrate discarded.  
100μl of distilled water was added to the spin column and incubated at room 
temperature (15–25°C) for 1 min, before finally centrifuging at 8000 rpm for 1 min.  
The filtrate yields approximately 6.25µg of DNA at a concentration of 60ng/µl.  This is 
frozen at -200
 
C for future use. 
4.2.4 Determining DNA concentration 
DNA concentration was measured using a Nanodrop reader (Thermo Scientific®).  A 
1µl sample of DNA was pipetted onto the end of a fibre optic cable (the receiving fibre). 
A second fibre optic cable (the source fibre) was brought into contact with the liquid 
sample causing the liquid to bridge the gap between the fibre optic ends. A pulsed 
xenon flash lamp provides the light source and a spectrometer is used to analyze the 
light after passing through the sample. The instrument is controlled by PC based 
software, and the data was logged on a PC attached to the Nanodrop. 
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4.2.5 Single Nucleotide Polymorphism Analysis 
The term single nucleotide polymorphism (SNP) denotes the natural nucleotide 
variation that exists throughout the human genome.  SNPs can be single nucleotide 
substitutions, or single base deletions or insertions.  Such changes are classified as SNPs 
rather than mutations when the minor variant is present in at least 1% of the population 
otherwise these base changes are classified as mutations.  SNPs most likely to affect the 
gene expression or protein function are the commonest targets for study, as they may 
give rise to functional changes in the gene product, which may be of relevance to a 
disease. 
 
SNPs are highly informative tools when used in association studies in order to elucidate 
the link between variants and disease phenotypes.  The location of SNPs throughout the 
human genome is freely available from web-based databases.  In this study, the NCBI 
SNP database (http://snpper.chip.org/bio/snpper-enter) was used in conjunction with 
SNPs reported in published materials.  
 
Genotyping for SNPs in the CARD15/NOD2 gene and medium resolution HLA class II 
typing was performed in the department of human genomics at the National Heart and 
Lung Institute, Imperial College London using sequence-specific primer polymerase 
chain reaction (SSP-PCR).  Genotyping for SNPs in the ATG16L1, IL23R and IRGM 
gene were carried out using pyrosequencing at the Hammersmith Hospital, London. 
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4.2.6 Sequence Specific Primer - Polymerase Chain Reaction (SSP-PCR) 
A sequence specific primer (SSP) is designed to have its 3’ end complementary to a 
particular SNP variant and identifies the presence of this variant by polymerase chain 
reaction (PCR) amplification (Bunce et al., 1995).   At a single locus, two different 
reactions are used.  These reactions involve a shared consensus primer and an allele-
specific primer, either sense or antisense, that differs at the 3’ end.  Each reaction also 
contains primers to amplify a non-polymorphic segment of DNA, which acts as a 
positive control to confirm amplification was successful. These primers are multiplexed 
(mixed in the same reaction well and amplified simultaneously).  The presence of a 
PCR product of the expected size indicates the presence of the allele in the specimen. 
 
           
 
 
Figure 4-1: Schematic diagram showing the process of Sequence Specific Primer Polymerase 
Chain Reaction (SSP-PCR) 
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SSP-PCR is a robust and reliable method for SNP identification.  As only a small 
number of SNPs are being examined, it has the advantage of being cost affective 
compared to a chip based approach.  Two or more SNPs within the same gene, proven 
to be in tight linkage disequilibrium with each other, can be detected using allele-
specific primers in the forward and reverse directions making this technique ideal for 
HLA genotyping.   
 
SSP-PCR primers  
Established primers were used for the 3 polymorphisms associated with CD in 
Caucasians and the additional polymorphism (SNP5) previously associated with IBD in 
South Asians (with permission from Dr. Tariq Ahmad [outlined in Ahmad et al., 2002]).  
SNP id numbers and associated peptide changes are shown in Table 4-1.  Primer 
sequences are displayed in Appendix 2. 
 
Table 4-1: Single Nucleotide Polymorphism (SNP) id numbers for the 4 
polymorphisms investigated in CARD15/NOD2 
   
rs number SNPid Location Peptide change 
rs2066844 SNP8 Exon4: 2104 (C>T) R702W 
rs2066845 SNP12 Exon8: 2722 (G>C) G908R 
 rs2066847 SNP13 Exon11: 3020 (insC) 1007fs 
rs2066842 SNP5 Exon4: 802 (C>T) P268S 
 
A 48-reaction primer set was used for medium-resolution HLA class II typing courtesy 
of Dr. Hiroe Sato (derived from Bunce et al., 1995) (see Appendix 3 and Appendix 4) 
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for primer sequences). For the HLA class II genotyping, haplotypes were deduced from 
the gel photograph by reference to known haplotypes in Indian Asian and Caucasian 
populations respectively using www.allelefrequencies.net (with permission from 
Professor Derek Middleton, Queen’s University, Northern Ireland). 
 
Control primers 
The choice of the control primer is dependent on the size of the specific product. 
Products of 600 to 900bp were multiplexed with control primers 210/211 to produce a 
product size of 249bp from the Adenomatosis Polyposis Coli gene (APC).  If the 
specific product was 250- 450bp then primers 63/64 were used. These primers amplify a 
constant region of HLA-DRB1 and produce a control product of 798bp (primer 
sequences shown in Appendix: 5).   
 
SSP-PCR technique 
Primers were prepared by the manufacturers (Sigma Genosys, UK) and suspended in 
sterile water (Baxters, UK) to a concentration of 2μg/μl.  Specific and consensus 
primers were titrated to obtain optimal working concentrations depending on the 
specificity and sensitivity of each reaction. Multiplexed primer mixes were prepared 
with sterile distilled water, 40μl/ml cresol red indicator (600 mg cresol red dissolved in 
100mL dH20), which undergoes a pH related colour change from orange to purple on 
addition of DNA, and the appropriate amount of primer. For each DNA sample, 5μL 
aliquots of each multiplex primer mix are dispensed into wells of a 96 well plate and 
covered with 10μL mineral oil.  The four CARD15/NOD2 polymorphisms required 8 
reactions and medium resolution HLA class II typing required 48 reactions. 
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The DNA/PCR reaction mix (8μL) is added to the primer mix and consisted of PCR 
buffer [(NH4)2SO4], MgCl2
 
 (2mM), dNTP mix (300μM of each dNTP), Taq 
polymerase (0.32 units) and genomic DNA (dependent on DNA concentration, approx. 
0.08 μg/reaction). 
PCR amplification was carried out using thermal cyclers: initial denaturing temperature 
of 1 minute at 96oC; followed by 5 cycles of 20 seconds at 96 oC, 45 seconds at 70 oC, 
25 seconds at 72 oC; 21 cycles of 25 seconds at 96 oC, 50 seconds at 65 oC, 30 seconds at 
72 oC; and 4 cycles of 30 seconds at 96 oC, 60 seconds at 55 oC, 120 seconds at 72 o
 
C. 
Gel electrophoresis after SSP-PCR 
Amplicons were separated on 1.5% agarose gels with 0.5 X Tris Borate EDTA buffer, 
stained with Sybr safe (Invitrogen, USA). 10μls of orange G loading buffer was added 
to each well prior to this.  Electrophoresis was carried out at 200V for 20 minutes and 
gels were photographed over ultraviolet light (UV) using an AlphaDigiDoc digital 
camera (Alpha Innotech®, USA).  The presence of a specific allele was determined by 
observing an amplicon of the expected size in association with a control PCR product. 
The absence of a specific allele was determined by observing only a control PCR 
product (Figure 4-2).  
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Figure 4-2:  Photographs of agarose gels under ultraviolet light after electrophoresis following SSP-
PCR.   
(a) Products and control bands for three CARD15/NOD2 polymorphisms (using control primers 210/211 
producing a product of 249 bp).  The presence of a PCR product (labelled as specific product) indicates the 
presence of the allele.  In all three cases, the participant was homozygous for the wild type allele. (b) 
Products and controls bands for the 48 reactions making up the HLA class II plate (using controls 63/64 
producing a product of 798 bp). 
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4.2.7 Pyrosequencing 
Pyrosequencing has risen to prominence since being first described in 1996 (Ronaghi et 
al.).  Instead of using the chain termination method, pyrosequencing uses a procedure 
known as ‘sequencing by synthesis’.   The process is based on the detection of released 
pyrophosphate (PPi) during DNA synthesis and in a cascade of enzymatic reactions, 
visible light is generated that is proportional to the number of incorporated nucleotides.  
 
Principles of pyrosequencing 
After PCR amplification, double stranded DNA is first hybridised to a single stranded 
DNA amplicon that serves as a template.  This is incubated with DNA polymerase and 
other enzymes required for the reaction.  A deoxyribonucleotide triphosphate (dNTP) is 
added to the reaction.  If it is complimentary to the base in the template strand, DNA 
polymerase incorporates the dNTP into the complimentary DNA strand.  Each 
incorporation is accompanied by the release of pyrophosphate (PPi).  The released PPi 
is subsequently converted to ATP by ATP-sulfurylase, which provides the energy for 
luciferase to oxidize luciferin and generate light.  Addition of dNTPs is performed 
sequentially.  As the process continues, the complimentary DNA strand is built up and 
the nucleotide sequence is determined from the signal peaks in the Pyrogram trace 
(Figure 4-3).  The overall reaction from polymerization to light detection takes place 
within 3–4 seconds at room temperature.  
 
Pyrosequencing has the potential advantages of speed and accuracy.  Furthermore, the 
technique dispenses with the need for labelled primers, labelled nucleotides, and gel-
electrophoresis (Ronaghi, 2001). 
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Figure 4-3:  A pyrogram showing the signal peaks that determine the nucleotide sequence  
(adapted from http://www.pyrosequencing.com/DynPage.aspx?id=7454&mn1=1366&mn2=1367). 
 
 
Primer design for Pyrosequencing SNPs in ATG16L1, IL23R & IRGM 
The sequence flanking the SNPs were ascertained by performing an Ensembl search 
(http://www.ensembl.org Table 4-2) using the SNP id (rs number) ( ). 
 
Table 4-2: Single Nucleotide Polymorphism (SNP) id numbers used for primer design 
 
Gene SNP id (rs number) Chromosome Peptide change 
ATG16L1 rs2241880 2q37 T300A 
IL23R rs11209026 1p31 R381Q 
IRGM (SNP189) rs13361189 5q33 - 
IRGM (SNP847) rs4958847 5q33 - 
 
PCR primers were designed for each SNP. A primer set consisted of a Forward (F) 
(200-250bp upstream of the SNP), a Sequencing (S) (final base at the SNP) and a 
Reverse Primer (R) (200-250bp downstream of the SNP and complimentary to the 
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selected sequence, read 3’-5’) (Appendix 6). Primers were optimally designed with a 
length of 19 to 21 bases, a salt adjusted melting temperature of 58 to 61oC, a GC content 
of 45 to 55% and with no secondary structures (e.g. Hairpin loops).  The online program 
oligonucleotide properties calculator http://www.basic.nwu.edu/biotools/oligocalc.html 
was used to determine these conditions.  Once designed, primers were checked for 
specificity using the basic local alignment search tool (BLAST) 
http://www.ncbi.nlm.nih.gov/BLAST/ from the national centre for biotechnology 
information (NCBI).  BLAST looks for matches between the sequence you submit and a 
comprehensive database of all known DNA sequences.  This avoids non-specific 
priming ensuring as far as possible that primers will only anneal to an exact site match. 
 
PCR amplification prior to pyrosequencing 
A PCR mix containing 20µl of solution was added to each well of a 96 well plate (2µl 
of genomic DNA (at a concentration of >100ng/µl), 2µl of 1.5 mM MgCl2, 2µl 10x 
reaction Buffer, 1µl of each primer (F &R at 10 mM concentration), 1µl 2mM of each 
dATP, dCTP, dGTP and dTTP, 0.1µl of Biotaq polymerase (Bioline Ltd) and 10.9µl 
ddH20).  Amplifications were performed in the G-Storm thermal cycler (Alpha Metrix 
Biotech, GmbH). The cycle consisted of 5min at 95oC, followed by 30 cycles of 30sec 
at 95oC, 30sec at 50-60oC and 60sec at 72oC with an additional 10min extension at 
72o
A random selection of PCR products were analysed by standard gel electrophoresis on a 
1.5% agarose gel with Sybersafe
C.  
TM
 
 prior to pyrosequencing, to confirm PCR 
amplification. 
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Pyrosequencing technique 
The first stage of pyrosequencing involved a binding reaction to hybridise the double 
stranded DNA to single stranded DNA.  This required a plate containing 20µl PCR 
product, 38 µl of Binding Buffer (Biotage), 2 µl of Streptavidin Sepharose beads (GE 
Healthcare) and 20µl of dH2
 
0.  The plate was shaken for 15 min in a plate shaker (Web 
Scientific) at 1300g. The Streptavidin-coated magnetic beads enabled the PCR product 
to be captured onto magnetic beads.  After sedimentation, the remaining components of 
the PCR reaction were removed by washing in 70% ethanol to obtain pure double-
stranded DNA followed by alkali denaturation with 0.2M NaOH to yield ssDNA.  
Following this, the ssDNA was washed in 10X Washing Buffer (Biotage) according to 
the manufactures’ guidelines.  
The final step before analysis is the Annealing reaction; 11.5µl Annealing Buffer 
(Biotage) and 0.5µl of sequence primer (S1) are aliquoted in to PyroMark™Q24 Plates 
(Biotage) and the bound Streptavidin Sepharose-PCR product is placed in the wells and 
allowed several minutes to bind.  The plate is heated at 80o
 
C for 3 min and then placed 
in the PyroMark Q24 (Biotage) for SNP analysis as per the manufactures’ guidelines.  
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4.2.8 Statistical analysis 
Within the South Asian CD population, the analysis was designed to examine 4 SNP’s 
in the CARD15/NOD2 gene, 2 SNPs in the IRGM gene and the single IBD associated 
SNP in ATG16L1 and IL23R.  The carriage frequency of HLA-DRB1*0103 and HLA-
DRB1*1502 will also be determined.  For the UC population the single SNP at IL23R, 
the single CARD15/NOD2 SNP (SNP5) and the carriage frequency of HLA-DRB1*0103 
and HLA-DRB1*1502 will be examined.  
  
Statistical advice regarding a power calculation was discussed with the Imperial College 
London statistical advice service. As no data exist for the high risk allele frequencies of 
the SNPs in ATG16L1, IL23R and IRGM in the South Asian population and previous 
studies have shown that the 3 common NOD2 polymorphisms are monomorphic, an 
accurate power calculation could not be generated for this population.    If the sample 
size was estimated using the Western data on SNP frequencies (Balding, 2006;Sasieni, 
1997) (Shaun Purcell genetic power calculator http://pngu.mgh.harvard.edu/~purcell/gpc/), 
a comparison between the CD population and normal controls requires 85 in each group 
to detect association (i.e. difference in allele frequencies) at 99% power with an α=0.05.  
However, to allow for multiple comparisons by Bonferroni adjustment, 126 patients 
would be required in each group.  For the UC population, using western data,  163 cases 
and controls are required to give a power of 87% with α=0.05.  To allow for multiple 
comparisons 242 participants would be required in each group. 
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The HLA exhibits strong linkage disequilibrium and it is generally accepted in the 
literature that a power calculation is not necessary for this analysis.  A Bonferonni 
correction will be applied to the results to allow for multiple comparisons. 
 
Genotype and allele frequencies for each SNP were calculated from the observed 
genotype counts.  Case-control comparisons were made using the Chi-squared test.  The 
allelic frequency of SNPs in the South Asian IBD population were compared to a white 
Northern European IBD cohort also using the chi-squared test.  P values <0.05 were 
considered statistically significant.  The data was analysed using Graph Pad Prism 
Software® (Version 5, U.S.A.).   
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4.3 RESULTS 
217 IBD patients (61 CD, 156 UC) and 204 healthy controls were recruited during the 
study period.  Table 4-3 outlines the demographic details and disease characteristics of 
the recruited participants. 
 
Table 4-3: South Asian participant’s demographic details and disease characteristics 
 
 Crohn’s disease Ulcerative colitis Healthy controls 
Number (Male/Female) 61 (29/32) 156 (92/64) 204 (114/90) 
Median [range] age (years) 44 [20-83] 46 [21-82] 61 [55-75] 
Ethnicity    
Indian 54 137 204 
Pakistani 5 18 - 
Bangladeshi 2 1 - 
Disease location 
L1: 6 E1: 17 - 
L2: 26 E2: 40 - 
L3: 29  E3: 99 - 
Disease behaviour 
B1:41 -  
B2:17 -  
B3:3 -  
Previous surgery 17 8 - 
 
L1=ileal disease, L2=colonic disease, L3=ileocolonic disease.  
E1=proctitis, E2=disease limit distal to splenic flexure, E3=disease proximal to the splenic flexure. 
B1=nonstricturing, nonpenetrating; B2=stricturing; B3=perforating. (Silverberg et al., 2005) 
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Dr Horace Williams (Imperial College London) supplied DNA from a cohort of 149 
consecutively collected white Northern European IBD patients (99 CD, 50 UC).  The 
clinical details for this cohort are described in Table 4-4.  These patients had already 
been HLA typed and genotyped for the four CARD15/NOD2 polymorphisms as part of 
a previous study.  DW performed additional genotyping for IL23R, ATG16L1 and 
IRGM for this current study. 
 
 
Table 4-4:  White Northern European participant’s demographic details and disease 
characteristics 
 
 Crohn’s disease Ulcerative colitis 
Number (Male/Female) 99 (48/51) 50 (26/24) 
Median [range] age (years) 41 [19-81] 41 [19-63] 
Disease location 
L1: 20 E1: 11 
L2: 35 E2: 18 
L3: 44 E3: 21 
Disease behaviour 
B1: 62 - 
B2: 14 - 
B3: 23 - 
Previous surgery 30 1 
 
E1=proctitis, E2=disease limit distal to splenic flexure, E3=extensive colitis (disease proximal 
to the splenic flexure).  L1=ileal disease, L2=colonic disease, L3=ileocolonic disease. 
B1=nonstricturing, nonpenetrating; B2=stricturing; B3=perforating (Silverberg et al., 2005). 
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4.3.1 Frequency of Crohn’s disease associated CARD15/NOD2 polymorphisms in 
the South Asian IBD population  
All South Asian CD patients and healthy control participants were genotyped for four 
CARD15/NOD2 variants. The results were compared with a cohort of previously 
genotyped white Northern European CD patients (n=99).  Genotyping was successful in 
98.4% of the South Asian cases (60/61), 99% of South Asian controls (202/204) and 
99% of white Northern Europeans (98/99).  In the South Asian population, analysis of 
the three CARD15/NOD2 polymorphisms associated with CD in Europeans (SNP8, 
SNP12 & SNP13) showed that only 3.3% (2/60) of CD patients carried one of the three 
SNPs and 3.5% (7/202) of healthy controls.  SNP13 was monomorphic in the South 
Asian population and no South Asian CD patients carried the SNP8 allele and only 1 
South Asian control.  SNP12 was also rare with 2 heterozygotes in the CD population 
and 6 heterozygotes among the healthy controls. There were no South Asian patients or 
controls with a double mutation. The difference in the minor allele frequencies between 
South Asian CD patients and controls was not statistically significant.   
 
The frequencies of the SNPs 8, 12 &13 in the South Asian population were compared 
with a white Northern European CD cohort. The polymorphisms were more common in 
the European population, 14.3% were heterozygote for SNP8 and 7.1% for SNP12. For 
SNP13, 6.1% were heterozygotes and 3.1% homozygotes.  The minor allele frequencies 
for the white Northern European population were significantly higher for SNPs 8 & 13 
(SNP8 P=0.003; SNP13 P=0.006). Genotypes and minor allele frequencies are shown 
in Table 4-5. 
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Table 4-5: Comparison of the allele frequencies of CARD15/NOD2 risk alleles (SNP8, 12 & 13) in 
South Asian and white Northern European CD patients and South Asian healthy 
controls 
 
SNP id Allele frequency 1P value 
South Asian Northern European 
 CD 
(n=60) 
n (%) 
    Controls  
(n=202) 
n (%) 
CD 
(n=98) 
n (%) 
 
rs2066844 (SNP8)     
CC 60 (100) 201 (99.5) 84 (85.7)  
CT 0   (0) 1    (0.5) 14 (14.3)  
TT 0   (0) 0    (0) 0  (0)  
Minor allele frequency (T) 0   (0) 1   (0.2) 14  (7.1) P=0.003 
rs2066845 (SNP12)     
GG 58 (96.7) 196 (97) 91 (92.9)  
GC 2 (1.3) 6     (3) 7   (7.1)  
CC 0  (0) 0     (0) 0  (0)  
Minor allele frequency (C) 2 (1.7) 6     (1.5)  7 (3.6) P=0.32 
rs2066847 (SNP13)     
-/- 60 (100) 202 (100) 89 (90.8)  
-/insC 0   (0) 0   (0) 6 (6.1)  
insC/insC 0   (0) 0   (0) 3 (3.1)  
Minor allele frequency (insC) 0   (0) 0   (0) 12  (6.1) P=0.006 
 
CD: Crohn’s Disease, UC: Ulcerative colitis, SNP: Single Nucleotide Polymorphisms, ins: insertion.  
The minor allele is defined in the controls and its frequency in that group as well as the case sample is 
reported.  For all 3 SNPs, the minor allele is the risk allele. 
1: Using the χ2 test to compare minor allele frequencies of South Asian CD patients and white Northern 
European CD patients. 
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South Asian IBD patients (60 CD, 156 UC) and controls (n=202) were genotyped for 
CARD15/NOD2 SNP5 and compared with a white Northern European IBD cohort (98 
CD and 50 UC) (Table 4-6).   There was no significant difference in the minor allele 
frequency between South Asian patients and controls (CD, P=0.3: UC, P=0.3).  The T 
allele was significantly more frequent among the European CD cases compared to the 
South Asian CD cohort but not in the UC cohorts (CD; P<0.0001, UC; P=0.08).  
 
Table 4-6: Results of the CARD15/NOD2 genotyping for SNP5 in South Asian and white Northern 
European IBD patients and South Asian controls 
 
SNP id Allele frequency P value 
South Asian Northern European 
 CD 
(n=60) 
n (%) 
UC 
(n=156) 
n (%) 
    Controls  
(n=202) 
n (%) 
CD 
(n=98) 
n (%) 
UC 
(n=50) 
 
 
rs2066842 (SNP5)       
CC 48 (80) 121 (77.6) 145 (71.8) 47 (48) 32 (64)  
CT 10 (16.7) 32 (20.5) 53 (26.2) 39 (39.8) 17 (34)  
TT 2 (3.3) 3 (1.9) 4 (2.0) 12 (12.2) 1 (2)  
 MAF (T) 14 (11.7) 38 (12.1) 61 (15.1) 63 (32.1) 19 (19) 1P<0.0001 
2P=0.08 
 
CD: Crohn’s Disease, UC: Ulcerative colitis, SNP: Single Nucleotide Polymorphisms 
MAF: Minor allele frequency; The minor allele is defined in the controls and its frequency in that group as 
well as the case sample is reported.  The minor allele (T) is also the risk allele. 
1P: Using the χ2 test to compare minor allele frequencies of South Asian CD patients and white Northern 
European CD patients. 
2P: Using the χ2 test to compare minor allele frequencies of South Asian UC patients and white Northern 
European UC patients. 
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4.3.2 Associations of polymorphisms in ATG16L1, IRGM and IL23R in the South 
Asian CD population 
South Asian CD patients, South Asian controls and white Northern European CD 
patients were genotyped for SNPs in ATG16L1, IRGM and IL23R using 
pyrosequencing.  An example of a pyrogram that was generated for SNP IRGM189 is 
displayed in Figure 4-4.  
 
    
Figure 4-4:  A pyrogram showing the IRGM189 genotype for a participant.  The area of the gene 
representing the peptide sequence at IRGM189 is highlighted in yellow, showing a peak 
for T and no peak for C, therefore classed at genotype TT.  
 
Genotyping was successful in 98.4% (60/61) of South Asian CD patients, 99.5% 
(203/204) of controls and 99% of disease controls (98/99).  There was no significant 
difference in the frequency of any of the 4 SNPs between South Asian patients and 
controls. The minor allele frequency was significantly different between the ethnic 
groups for SNPs in IRGM and IL23R (IRGMSNP189 P=0.004; IRGMSNP847 P=0.005; 
IL23R P=0.02) (Table 4-7). 
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Table 4-7: The frequency of CD associated SNPs in ATG16L1, IRGM and IL23R in South Asian CD 
patients and controls compared to a Northern European CD cohort 
 
Gene (SNPid) Allele frequency: n (%) 1P value 
South Asian Northern 
European 
 CD 
(n=60) 
Controls  
(n=203) 
CD 
(n=98) 
 
ATG16L1  (rs2241880)     
GG 20 (33.3) 65 (32.0) 45 (45.9)  
AG 29 (48.3) 100 (49.3) 40 (40.8)  
AA 11 (18.4) 38 (18.7) 13 (13.3)  
*Minor allele frequency (A) 51 (42.5) 176 (43.3) 66 (33.7) P=0.11 
IRGM 189 ( rs13361189)     
TT 38 (63.3) 131 (64.5) 76 (77.6)  
CT 16 (26.7) 60 (29.6) 22 (22.4)  
CC 6 (10) 12 (5.9) 0 (0)  
Minor allele frequency (C) 28 (23.3) 84 (20.7) 22 (11.2) P=0.004 
IRGM 847( rs4958847)      
GG 33 (55) 118 (58.1) 72 (73.4)  
AG 21 (35) 68 (33.5) 23 (23.5)  
AA 6 (10) 17 (8.4) 3 (3.1)  
Minor allele frequency (A) 33 (27.5) 102 (25.1) 29 (14.8) P=0.005 
IL23R  (rs11209026)     
GG 59 (98.3) 195 (96.1) 86 (87.8)  
AG 1 (1.7) 8 (3.9) 12 (12.2)  
AA 0 (0) 0 (0) 0 (0)  
Minor allele frequency (A) 1 (0.8) 8 (2.0) 12 (6.1) P=0.02 
 
The minor allele is defined in the controls and its frequency in that group as well as the case sample is 
reported. 
*For ATG16L1 the risk allele is G.  For IRGM189, IRGM847 and IL23R the minor allele is the risk allele. 
1: Using the χ2
SNP: Single Nucleotide Polymorphisms, ins: insertion. 
 test to compare minor allele frequencies of South Asian CD patients and white Northern 
European CD patients. 
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The single SNP in the IL23R gene was also analysed in a UC cohort of 156 South Asian 
patients, 203 controls and 48 disease controls and showed no statistical difference 
between any of the groups (Table 4-8).  
 
Table 4-8 : The frequency of IL23R in South Asian UC patients, controls and a white Northern 
European UC cohort 
 
Gene (SNPid) Allele frequency: n (%) 1P value 
South Asian Northern 
European 
 UC 
(n=156) 
Controls  
(n=203) 
UC 
(n=48) 
 
IL23R  (rs11209026)     
GG 152 (97.4) 195 (96.1) 45 (93.8)  
AG 4 (2.6) 8 (3.9) 3 (6.2)  
AA 0 (0) 0 (0) 0  
Minor allele frequency (A) 4 (1.3) 8 (2.0) 3 (3.1) P=0.2 
 
SNP: Single Nucleotide Polymorphisms 
1: Using the χ2 test to compare minor allele frequencies of South Asian UC patients and white Northern 
European UC patients. 
 
 
 
 
 
 
Chapter 4: Phenotype genotype associations of IBD in a South Asian population 
133 
 
4.3.3 Comparison of the carriage frequency of HLA-DRB1*0103 and HLA-
DRB1*1502 in South Asian IBD cases and controls 
South Asian IBD patients and controls were genotyped for medium resolution HLA 
class II.  Genotyping was successful in all South Asian IBD patients and controls.   The 
results were compared with a white Northern European cohort of 50 UC patients and 76 
CD patients (demographic details are shown in Table 4-9).   
 
Table 4-9:  Demographic details and disease characteristics for South Asian and White 
Northern European ulcerative colitis patients  
 
 Ulcerative colitis Crohn’s Disease 
 South Asian European South Asian European 
Number (Male/Female) 156 (92/64) 50 (26/24) 61 (29/32) 76 (39/33) 
Median age (yrs) [range] 46 [21-82] 41 [19-63] 44 [20-83] 37 [19-78] 
Disease location 
E1: 17  E1: 11 L1: 6 L1: 17 
E2: 40 E2: 18 L2: 26 L2: 25 
 E3: 99  E3: 21 L3: 29 L3: 34 
Disease behaviour 
- - B1:41 B1: 48 
- - B2:17 B2: 10 
- - B3:3 B3: 18 
Previous bowel resection 8 1 17 26 
E1=proctitis, E2=disease limit distal to splenic flexure, E3=extensive colitis (disease proximal to the 
splenic flexure). L1=ileal disease, L2=colonic disease, L3=ileocolonic disease.   B1=nonstricturing, 
nonpenetrating; B2=stricturing; B3=perforating. (Silverberg et al., 2005). 
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The carriage frequency of the HLA-DRB1*1502 allele was significantly higher in the 
South Asian UC population compared to matched ethnic controls (P=0.005).  This 
remained significant after Bonferroni adjustment for multiple comparisons (P=0.01). 
There was no association with HLA-DRB1*1502 in South Asian CD patients compared 
to controls (P=0.35). None of the South Asian IBD patients or controls carried the HLA-
DRB1*0103 allele.  Table 4-10 summarise the associations between the two HLA 
alleles in South Asians.   
 
Table 4-10: The associations between IBD and HLA-DRB1*0103 and DRB1*1502 in the South 
Asian population 
 
 Allele frequency (%)  
P value Allele UC  
(n=156) 
CD  
(n=61) 
Controls  
(n=204) 
DRB1*0103 0 0 0 - 
DRB1*1502 47 (30.1) 14 (22.9) 36 (17.6) 1P=0.005 
2P=0.35 
 
The P values in this table are uncorrected. 
1P:  Using the χ2 test to compare South Asian UC patients with South Asian controls 
2P:  Using the χ2 test to compare South Asian CD patients with South Asian controls 
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HLA-DRB1*1502 association with clinical phenotype in South Asian IBD patients  
The gene frequency of HLA-DRB1*1502 in 31/99 patients with extensive colitis (31%) 
was not significantly higher than the group with left sided colitis and proctitis (16/57: 
28%; P=0.67).  Of the 8 patients requiring colectomy 3 had the DRB1*1502 allele 
(37%) compared to 30% in the rest of the UC cohort (P=0.6).  There was no association 
with the HLA-DRB1*1502 allele and disease location in CD patients (P=0.96). 
 
HLA class II haplotype associations with IBD in South Asians  
In order to determine if a specific HLA haplotype was associated with IBD in South 
Asians, the carriage frequencies of all medium resolution DRB1 and DQB1 alleles were 
compared.  The DRB1*1502/DQB1*0601 haplotype was positively associated with UC 
when compared to controls (P=0.009).   
During the analysis, it was noted that the DRB1*1001 allele was negatively associated 
with UC (P=0.001) and this remained significant after correcting for multiple 
comparisons (28 variables).  The only association that was found for CD was a negative 
association with HLA-DRB1*1001 but this association was less robust than UC 
(P=0.01). 
 
Differences in HLA frequencies between South Asian and Europeans IBD patients 
The carriage frequency of HLA-DRB1*0103 and DRB1*1502 was significantly different 
between the ethnic groups. 18% of European UC patients and 10.5% of European CD 
patients carried the DRB1*0103 allele which was not present in any of the South Asian 
IBD patients (UC, P<0.0001 and CD, P=0.004).  The DRB1*1502 allele was not found 
in any of the European UC patients compared to 30% of South Asian UC patients 
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(P<0.0001).  Only 3% of European CD patients carried the allele which was 
significantly lower than the South Asian population (23%) (P<0.0001) (Table 4-11). 
 
 
 
 
Table 4-11:  A comparison of the frequencies of HLA-DRB1*0103 and HLA-DRB1*1502 in 
South Asian and European IBD populations.  
 
 
HLA allele 
UC  CD  
P value 
 
S. Asian 
(n=156) 
European 
(n=50) 
   P value S. Asian 
(n=61) 
European 
(n=76) 
DRB1*0103 0 9 (18.0) P<0.0001 0 8 (10.5) P=0.004 
DRB1*1502 47 (30.1) 0 P<0.0001 14 (22.9) 2 (2.6) P<0.0001 
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4.4 DISCUSSION 
A vast amount of evidence is accumulating to suggest that host genetics determines 
susceptibility to IBD. Genetic studies are supplementing the knowledge gained from 
epidemiological studies, which suggest a difference in the genetic determinants of IBD 
within different ethnicities.  This study aimed to investigate the contribution of HLA 
class II alleles and SNPs in CARD15/NOD2, ATG16L1, IRGM and IL23R to IBD 
susceptibility in a South Asian IBD population.  Although these SNPs have been widely 
replicated in North American and European IBD patients there are no previous studies 
with regard to HLA class II, ATG16L1, IRGM or IL23R in the South Asian population.  
 
4.4.1 IBD associated genetic polymorphisms 
The absence of the three common CARD15/NOD2 polymorphisms (SNP8, SNP12 and 
SNP13) in the South Asian population suggests that these particular CARD15/NOD2 
polymorphisms are not important in the genetic susceptibility of CD in South Asians.  
Although the population of CD patients was small, and this may reflect a power issue, 
the findings are consistent with a previous study from India that also showed these 
SNPs were rare in this population (Pugazhendhi et al., 2008).   
 
SNPs in ATG16L1 and IRGM (SNP189 & SNP847) have been positively associated 
with CD in Caucasian populations. These SNPs were analysed in a South Asian CD 
population and although the risk allele frequency was higher for the three SNPs 
compared to controls, there was no statistical differences in the SNP frequencies. A 
single SNP in IL23R (rs11209026) has been shown to be negatively associated with 
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both CD and UC in Western populations but there was no significant difference seen 
when South Asian IBD patients were compared to ethnically matched controls.  
 
Juyal et al (2007) showed an association with SNP5 in CARD15/NOD2 and ulcerative 
colitis in North Indians.  This polymorphism at position 268 leads to an amino acid 
change Pro/Ser (C/T).  In Juyal’s study the T allele was significantly more frequent 
among UC cases compared to controls (17% vs 12%: P=0.008), whereas in this study 
there was no difference between South Asian UC patients and controls (12% vs 15%: 
P=0.3).  To exclude any differences in ethnicity across the Indian subcontinent that 
could have affected the result, the analysis was also performed comparing only Indian 
UC patients with controls and this also showed no significance (11% vs 15%: P=0.13).  
The numbers in this current study (UC=156) were less that the Juyal study (UC=298) 
and the absence of an association could be as a result of a smaller sample size, however, 
the fact that the SNP frequency in this study was higher in controls than UC patients 
would make any potential association less likely. 
 
An acknowledged limitation of the study is the small study number and lack of ileal CD 
patients within the South Asian CD population.  Previous studies have shown that SNPs 
associated with CARD15/NOD2, IRGM and IL23R may be more prevalent in patients 
with ileal CD.  As the number of patients with pure ileal disease was very small in the 
South Asian population (n=6) subgroup analysis by ileal phenotype would not produce 
any meaningful result.  A larger study with more ileal CD patients would be required to 
confirm the study’s findings.  However, the reported results would be consistent with an 
East Asian study from Japan which genotyped 484 CD patients and 439 controls and 
showed these SNPs were not associated with CD in this ethnic group (Yamazaki et al., 
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2007).  For CARD15/NOD2, IRGM and IL23R, the SNP frequencies in the South Asian 
IBD cohorts were significantly different to the European disease controls showing that 
there are interethnic variations in IBD risk allele frequencies. 
 
4.4.2 HLA associations in South Asian IBD patients 
The study has shown an association with HLA-DRB1*1502 and UC in a cohort of South 
Asian UC patients.  This finding is similar to HLA studies in Japan and South Korea 
that have also reported an association between UC and the same DRB1 allele (Masuda 
et al., 1994;Myung et al., 2002;Futami et al., 1995).  In contrast to the Japanese study, 
there was no association of HLA-DRB1*1502 with disease phenotype in South Asians.  
Previous studies of this allele in a UK population have also shown that DRB1*1502 has 
been associated with susceptibility to UC in Caucasian populations although with 
relatively low frequency (1.9% in cases vs 0.3% in controls) (Ahmad et al., 2003a).  The 
allele was not present in any of the European UC cohort, the discrepancy in this finding 
is likely to relate to the small patient numbers.   
 
Genetic associations within the MHC region are complicated by the extensive linkage 
disequilibrium in this region (Ahmad et al., 2003b). This is especially strong between 
DRB1 and DQB1 alleles, with the result that alleles are often inherited together as 
haplotypes. Association of an allele with a disease can occur if that allele is functionally 
implicated or if it is on the same haplotype as the functional gene (i.e. the allele is just a 
marker).  This is illustrated by the positive association of the DRB1*1502/DQ*0601 
haplotype with UC in the South Asian cohort.  However, it is still likely that the primary 
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association is with DRB1*1502, as DQ*0601 can also occur with DRB1*1501 and it is 
the DRB1*1502/DQ*0601 haplotype that appears to be a risk factor in this population. 
 
In this study the HLA-DRB1*1001 allele was shown to be protective for development of 
both UC and CD.  This has not been previously described in any other ethnic group and 
appears unique to the South Asian population and therefore this allele may have a role 
in IBD susceptibility in South Asian populations.  Further studies are required to 
replicate this finding. 
 
HLA associations are now recognised in a large number of chronic diseases.  In certain 
pathologies eg. coeliac disease, the HLA association directly impacts the disease; more 
than 90% of patients express the HLA-DQ2 molecule, and the majority of the remaining 
patients carry DQ8.  The DQ2 and DQ8 mediated presentation of gluten peptides to 
CD4+ T cells is a key event in the pathogenesis of the disease (Tighe et al., 1992;Sollid 
et al., 1989).  In IBD, HLA allele associations have become clear but whether it is the 
actual presentation of antigenic peptides by the associated alleles that is critical in 
disease pathogenesis remains unclear.  Molecular studies of the HLA are beginning to 
focus on the peptide binding site of HLA-DRB1 which consists of a series of peptide 
pockets.  The specific sequence of these pockets will correspond to the antigenic peptide 
that predispose to disease risk and protection and may unlock the key to the role of the 
HLA in IBD. 
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4.4.3 Genetic associations in South Asian IBD patients compared to other 
countries 
The association of DRB1*1502 in the South Asian UC cohort and the lack of 
association with SNPs in CARD15/NOD2, ATG16L1, IL23R and IRGM  in South Asian 
CD patients may suggest that this ethnic group shares a  common ancestry with  East 
Asian countries like Japan and South Korea rather than European populations.  The 
Indian subcontinent has experienced a massive gene flow from at least two large 
migrations. Firstly, 15,000 years ago as part of an eastward wave of human migration 
that entered India and secondly, 4000 years ago, the arrival of Pastoral nomads from the 
central Asian steppes and Iranian plateau (Agrawal et al., 2007) . Thus a considerable 
amount of intermingling between races has occurred, creating variation in HLA 
haplotypes (Mehra et al., 1994).  It was generally accepted that South Asians were more 
Caucasoid because of the nature of the majority of South Asian languages (Indo-
European) and it was thought that they may have once shared a common language 
superfamily, known as Dene-Caucasian (Ayub and Tyler-Smith, 2009) which led to the 
belief that there may be a genetic relatedness between Caucasians and South Asians.  
However, the results from this study suggest more of a similarity with East Asian 
genetics.   
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4.4.4 Conclusion 
The data from these results suggests four important points about the genetics of IBD in 
South Asians. Firstly, that the HLA-DRB1*1502 is significantly associated with UC in 
the South Asian IBD population. Secondly, that the allele HLA-DRB1*1001 may have 
an important protective role in the development of IBD.  Thirdly the DRB1*0103 allele 
is rare amongst the South Asian population and is not responsible for the higher 
frequency of extensive UC in the South Asian population.  Finally, the polymorphisms 
of CARD15/NOD2, ATG16L1, IRGM and IL23R that are associated with IBD in 
Western populations show no association with IBD in South Asians; however, one 
cannot exclude the possibility that an analysis of larger sample sizes or using 
sequencing to detect novel polymorphisms might unveil such an association.  
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CHAPTER 5  
URINARY METABOLIC PROFILING IN A SOUTH ASIAN 
INFLAMMATORY BOWEL DISEASE POPULATION 
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5.1 INTRODUCTION 
Although the exact pathogenesis of IBD is not clearly understood, it is widely thought 
to involve an abnormal genetically determined host immune response to an 
environmental stimulus that is likely to be bacterial (Figure: 5-1).  Animal models have 
demonstrated that the induction of IBD requires the presence of bacteria (Sydora et al., 
2006). No specific pathogen has been defined as a causative agent, but the gut 
microbiota have been shown to differ between CD and UC, and healthy control subjects 
(Sartor, 2008). IBD patients show an imbalance or ‘dysbiosis’ of their intestinal 
microbiota (Willing et al., 2009;Sartor, 2006), and this is thought in turn to lead to a 
breakdown in the relationship between the intestinal microbiota and the host immune 
system. 
    
   
 
 
Figure 5-1: Genetic predisposition and environmental triggers contributing to the pathogenesis of 
inflammatory bowel disease 
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5.1.1 Investigating changes in the gut flora using metabolic profiling 
Metabolic profiling (the study of large numbers of small molecule metabolites) using 
nuclear magnetic resonance spectroscopy (NMRS) has the potential to provide data 
regarding all metabolic processes of an organism.  NMRS detects hydrogen atoms in 
metabolites.  In a typical biological fluid, all hydrogen-containing molecules (which 
includes nearly all metabolites) will contribute to the 1
 
H NMR spectrum. The resulting 
spectrum is therefore an overview of all metabolites in a fluid. 
Previous experiments have demonstrated that the host microbiota significantly 
contributes to the overall metabolic profile generated from biofluids (Wikoff et al., 
2009;Li et al., 2008;Marchesi et al., 2007), therefore any changes in the gut microbiota 
will be reflected in the spectroscopic profile of the biofluid being examined.  The 
measurement of metabolites in urine, serum and stool has enabled researchers to 
determine metabolic differences between patients in various disease states compared to 
healthy controls. This includes studies in pneumococcal pneumonia, multiple sclerosis 
hypertension and coronary artery disease ('t Hart et al., 2003;Brindle et al., 2003;Brindle 
et al., 2002;Slupsky et al., 2009). 
 
In IBD, NMRS has revealed gut microbial contributions to metabolite compositions in 
different body fluids, including serum (Schicho et al., 2010) , urine (Williams et al., 
2009), faecal extracts (Bezabeh et al., 2009;Marchesi et al., 2007) and colonic biopsies 
(Bjerrum et al., 2010).   Significant differences have been observed between healthy 
individuals and Caucasian patients with CD and UC. 
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Studies using urinary NMRS in humans with IBD showed significant differences 
between white Northern European UC patients, CD patients and healthy controls with 
respect to the metabolites, hippurate (reduced in both UC and CD compared to 
controls), 4-cresol sulphate (reduced in CD) and formate (reduced in CD) (Williams et 
al., 2009). The groups were also distinguished using multivariate modelling, with a 
particularly important contribution from hippurate.  The urinary concentration of 
hippurate has been shown to be modulated by gut microbes (Nicholls et al., 
2003;Williams et al., 2002) and the reported differences between Northern European 
IBD patients and controls are likely to reflect differences in the intestinal microflora.  
However, it is not clear whether these differences are seen in other ethnic populations. 
 
5.1.2 Study aims 
The aims of this study were firstly to use NMR-based urinary metabolic profiling to 
determine if there are differences in microbiota-related metabolites between South 
Asian IBD patients and South Asian controls and secondly to ascertain if the urinary 
NMR profile observed in white Northern European IBD cohorts is similar to a cohort of 
South Asian IBD patients.  It was hoped that the results would provide further 
molecular insight into disease pathogenesis and help determine which metabolic 
markers are determinants of disease across different ethnic populations. 
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5.2 METHODS 
5.2.1 Ethics Approval 
The St. Mary’s Hospital Research Ethics Committee approved this study and site-
specific approval was obtained from each of the participating trusts. All participants 
gave written informed consent. 
 
5.2.2 Patient recruitment 
South Asian IBD patients 
South Asian patients were recruited from the inflammatory bowel disease clinics of five 
North West London hospitals (St. Mary’s, Hammersmith, St. Marks, West Middlesex 
and Ealing Hospital).  Only patients with a confirmed diagnosis of Crohn’s disease or 
ulcerative colitis based on clinical evaluation, endoscopic/radiological appearances and 
histology (Stange et al., 2008;Van et al., 2010), were recruited for the study.  Stool 
culture results and mucosal histology were reviewed for all patients and those in whom 
there was any uncertainty regarding diagnosis (ie. those with IBD, type unclassified or 
colitis as a result of infection, radiation or ischaemia) were excluded from the study. 
 
Healthy South Asian Controls 
A cohort of healthy South Asian controls were recruited from staff and medical students 
at the five participating hospitals and patient spouses who attended at the time of the 
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outpatient appointment.  Only volunteers with no history of chronic disease were 
included in the study.   
 
White Northern European IBD patients and controls 
Dr Horace Williams (Imperial College London) provided the Northern European data 
from previously analysed urinary spectra on a cohort of 146 IBD patients (86 CD: 60 
UC) and healthy controls (n=60).  The spectra of 50 Northern European samples were 
audited (by DW) to determine if there was inter-observer variability and no significant 
differences were found.   
 
5.2.3 Experimental design 
Urine collection 
Previous studies have demonstrated that when the diet is not standardised, the greatest 
variability in the metabolic profile is seen on the first-void urine sample (Lenz et al., 
2003;Walsh et al., 2006).  For this reason, a 10ml random mid-stream urine sample was 
collected from each participant at the time of their clinic appointment.  The sample was 
immediately stored in the fridge and within 90 minutes was centrifuged at 2500g for 20 
minutes and any sediment removed before storing at -80ºC pending analysis. 
 
Addressing potential confounders 
Significant differences in the metabolic profile have been noted between health and 
disease states, but the NMR profile of biofluids also contains information on recently 
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consumed drugs (Sun et al., 2009), the participant’s diet (Walsh et al., 2006) and 
physiological variation such as hormonal state and gender differences (Bollard et al., 
2001).  Some authors believe that when the metabolic response to disease is the primary 
focus of interest, it is often not necessary to consider the subtle dietary and 
physiological variation, as the metabolic response to disease will eclipse minor 
metabolic variations (Wang et al., 2005).  However, dietary influences have been well 
documented as causing variation in the NMR profile of healthy controls (Lenz et al., 
2004;Stella et al., 2006) and in order to exclude any potential confounding variables, a 
detailed dietary and lifestyle history was completed prospectively (by DW) (Appendix 
7) and results compared between the groups.  Data collected included: gender, ethnic 
origin, place of birth, disease extent, current drug history, smoking history and a 24-
hour recall nutrition history.    
 
Certain foods have been shown to particularly influence the NMR spectra (Walsh et al., 
2006) and for this reason patients were asked specifically about their intake of: 
1.  Tea, berries and carbonated drinks, as these foods contain benzoate and may 
influence the  urinary excretion of hippurate (Wang et al., 2005). 
2. Fish ,which markedly influences the metabolism of TMAO (Zuppi et al., 1998). 
3. Meat and vegetables, as lactovegetarians have been shown to have higher levels 
of TMAO, taurine, glycine and hippurate compared to individuals on an 
omnivorous diet (Xu et al., 2010).    
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In order to replicate normal circumstances, no dietary exclusions were imposed for this 
study but the dietary and lifestyle data from the CD, UC and control cohorts were 
analysed using the following methods to determine if there were any significant 
differences between the groups: 
i. Mann-Whitney U tests for continuous variables such as the number of cups of tea 
drunk in the preceding 24 hours and the number of hours since the last meal.   
ii. Fisher’s exact test or Chi-square test (as appropriate) for categorical variables, such 
as whether or not the subject, had eaten meat (and whether red, white or both) or fish in 
the preceding 24 hours and usually. 
 
Patients with diabetes and individuals with an intercurrent illness, who were pregnant, 
who were taking antibiotics or who were taking pre- or probiotics were excluded from 
the study.  Williams et al. (2009) has previously shown that gut dependent metabolites 
remained significantly different between IBD cases and controls in both patients taking 
IBD medications (5-ASAs/azathioprine/methotrexate) and patients off medications. 
Therefore, in this study, both patients on and off IBD medications were included. 
 
5.2.4 Urine sample preparation for NMR spectroscopy 
When required, the urine sample was thawed and 400µl of each urine sample was mixed 
with 200µl of 0.2M phosphate buffer (pH 7.35) (for preparation, see Appendix 8), to 
stabilise the pH.  The sample was vortexed for 15 seconds and then centrifuged for 10 
minutes at 13000g. 500µl of supernatant was then transferred into a 5mm NMR tube 
(Wilmad-Labglass, USA) and mixed with 50µl of 3-trimethylsilylsilyl (2,2,3,3 – 2H4)-
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1-propionate (TSP)/D2
 
0 solution (for preparation see Appendix 8).  The TSP served as 
an internal chemical shift reference (δ 0.00).  
5.2.5 In vitro NMR spectroscopy  
NMR spectroscopy was performed at the Hammersmith Hospital campus of Imperial 
College London using a JEOL 500MHz Eclipse+ NMR spectrometer and an 11.7 Tesla 
superconducting magnet.  Samples from South Asian CD, UC and healthy control 
cohorts were analysed blinded, in a random order. A standardised protocol with water 
presaturation was applied. The spectral width was 15 ppm and the number of data points 
acquired was 64K.  A pulse-collect sequence was used with a 90o
 
 pulse angle. The 
acquisition time was 8.74 s. A relaxation delay of 10 s (total repetition time 18.74 s) 
ensured full relaxation between data collects.  The 16 data collects were summated.  
5.2.6 Data analysis 
Spectra were imported to KnowItAll Informatics System v7.9 Metabonomics Edition 
(Bio-Rad, USA). Free induction decays were zero-filled by a factor of two and 
multiplied by an exponential window function with a 0.3 Hz line-broadening factor. 
They were then Fourier transformed from the free induction decay (FID) (Figure 5-2) 
into a frequency spectrum (Figure 5-3).   
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Figure 5-2:  Free induction decay (FID) of the NMR Spectra. 
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Figure 5-3:  Fourier Transformation of the FID to give the NMR spectra in the time domain 
displaying metabolite peaks. 
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The reference peak for TSP was positioned at 0ppm and the spectrum was manually 
phased and baseline corrected.  Spectral analysis included the range δ 0.2 -10.00 ppm, 
excluding the region δ 4.50-6.40 ppm to remove the effects of variable water 
suppression and variation in urea signal due to exchange of protons with the solvent 
(Figure: 5-4). 
 
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2 -3
 
 
Figure 5-4: NMR spectra after excluding the water and urea peaks in the region 6.4 to 4.5. 
 
 
 
5.2.6.1 Spectral analysis 
The NMR resonances were analysed and spectral peaks assigned according to the 
literature (http://www.hmdb.ca/) (Table 5-1).  Metabolites dependent on gut microbial 
metabolism were identified and quantified (formate, hippurate, 4-cresol sulphate, 
trimethylamine-N-oxide (TMAO) and dimethylamine (DMA)) (Figure 5-5).   
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Table 5-1: Peak assignments for urinary metabolites dependant on gut microbial metabolism. 
 
  
 Peak Chemical Shift Ppm (δ) 
Formate 8.46 
Hippurate 7.83, 3.97, 7.55, 7.64 
4-cresol sulphate 2.35, 7.21, 7.28 
Trimethylamine-N-oxide (TMAO) 3.27 
Dimethylamine (DMA) 2.73 
 
*When a metabolite is represented at more than one point of the spectra, the spectral peak that was 
easiest to quantify was used (ppm marked in bold). 
 
 
 
                      
 
Figure 5-5: Schematic diagram of assignment of spectral peaks.( a) A typical spectra  starts 
with the NMR spectrum of a biological fluid, which contains signals from 
hundreds of metabolites. (b) The individual spectra for each metabolite are 
identified according to the literature. (reproduced from Nicholson (2008)). 
 
 
The resonances were integrated and normalised to the sum of the total spectral integral.  
Values were expressed as a percentage relative to the total spectral integral. 
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5.2.7 Statistical methods and power calculation 
Previous urinary metabonomic studies have predominantly been pilot studies and not 
used a traditional power calculation (Bala et al., 2004;Chung et al., 2003).  After 
discussion with Dr Bernard North at Imperial College Statistical Advisory Service, we 
generated the following power calculation, which allows for multiple comparisons on 
univariate analysis. The calculation is based on the results of a urinary metabonomic 
study of IBD patients that was published in the American Journal of Gastroenterology 
(Williams et al., 2009).  
o An unpaired 2 sample t-test (equal variance) with 80% power and significance 
2.5% ( to adjust for multiple tests by Bonferroni) and then corrected to obtain a 
worst-case sample size requirement for the Mann-Whitney test by dividing by 
the worst case asymptotic efficiency of 0.864. 
o Controls vs CD: Mean difference (based on hippurate levels) = 1.37, SD=1.08, 
sample size = 13 per group for t-test: Sample size required for Mann-Whitney = 
13/0.855 = 15 per group. 
o Controls vs UC: Mean difference (based on hippurate levels) = 0.8, SD=1.17  
sample size = 42 per group for  t-test: Sample size required for Mann-Whitney = 
42/0.855 =  49 per group. 
Therefore, 15 CD patients, 49 controls, 49 UC patients and are required to adequately 
power the study. 
 
Differences in metabolite values between South Asian CD, UC and healthy control 
cohorts were assessed using the Mann-Whitney U test (GraphPad Prism v5.0, GraphPad 
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Software Inc., USA).  To allow for multiple comparisons (5 metabolites) a Bonferroni 
correction was applied and the level of significance set at P<0.01.  
 
The South Asian CD and UC cohorts were also compared with the Northern European 
IBD cohorts using the Mann-Whitney U test.   The dietary and lifestyle data from the 
CD, UC and control cohorts were analysed using the Kruskal-Wallis and Mann-
Whitney U tests for continuous variables and Fisher’s exact test or Chi-square test for 
categorical variables. 
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5.3 RESULTS 
Urine samples were collected from a total of 34 South Asian CD patients, 121 South 
Asian UC patients and 52 healthy South Asian controls. The spectra were acquired for 
the first 22 CD samples, 53 UC samples and 36 controls.  Further samples were due to 
be processed at the NMR spectroscopy laboratory at the Hammersmith Hospital campus 
of Imperial College London (Table 5-2).  Unfortunately, the NMR facility at 
Hammersmith Hospital was closed down in March 2009.  However, as the number of 
samples processed was close to the number required by the power calculation, data 
analysis was performed on the NMR spectra already acquired.  The patient demographic 
details of the analysed urine samples are described in Table 5-3. 
 
Table 5-2:  Total number of South Asian urine samples collected and processed 
 
 
 Proposed 
number 
Total number of samples 
collected 
Samples processed 
Crohn’s disease 15 34 22 
Ulcerative colitis 49 121 53 
 Controls 49 52 36 
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Table 5-3: South Asian participants demographic and phenotypic details 
 
 
 
Crohn’s 
disease 
Ulcerative 
colitis 
Healthy controls 
Number (Male/Female) 22 (14/8) 53 (39/14) 36 (20/16) 
Median [range] age (years) 38 [18-82] 44 [19-75] 37 [21-70] 
Disease location 
L1: 3 E1: 8 - 
L2: 8 E2: 10 - 
L3: 11 E3: 35 - 
 
L1, ileal disease; L2, colonic disease; L3, ileocolonic disease; E1, proctitis; E2, disease limited to the 
splenic flexure; E3, disease proximal to the splenic flexure (Silverberg et al., 2005) 
 
 
 
5.3.1 NMR data analysis 
The spectral peaks of metabolites dependent on gut microbial metabolism (hippurate, 
formate, 4-cresol sulphate, TMAO and DMA) were identified and quantified, relative to 
the TSP peak at 0ppm.  A representative proton NMR spectrum of urine from a South 
Asian control patient and a South Asian CD patient is shown in Figure 5-6 with the 
spectral peaks that were measured marked accordingly.   
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Figure 5-6: The NMR spectra of urine from a South Asian control patient (Figure 5-6i) and a 
South Asian Crohn’s disease patient (Figure 5-ii).  The spectra in the aromatic 
region (δ6.0-9.0) were magnified x4 compared to the aliphatic region (δ 0.5-4.5). 
 
  
Key: 
1. 4-cresol sulphate 
2. DMA 
3. TMAO    
4. Hippurate  
5. Formate 
Figure: 5-6i 
Figure: 5-6ii 
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5.3.2 A comparison of the urinary NMR profile of South Asian IBD patients with 
healthy South Asian controls 
The urinary spectra of the South Asian IBD patients was compared to a healthy South 
Asian control population to determine if there were differences in any of the five 
microbial dependent metabolites.   
 
Hippurate levels were significantly lower in the South Asian UC and CD cohorts 
compared with South Asian controls (UC: P<0.0001, CD: P<0.0001).  Formate levels 
were also significantly lower in the UC and CD cohorts compared to healthy controls 
levels (UC: P=0.01, CD: P=0.004).  There was no significant difference in hippurate or 
formate levels between the South Asian CD and UC populations Figure 5-7. 
 
  
Chapter 5: Urinary Metabolic profiling in a South Asian IBD population 
161 
 
 
            
 
 
 
 
Figure 5-7: Urinary concentrations of (a) hippurate and (b) formate (expressed as % normalised 
total spectral integral) for South Asian IBD patients and South Asian controls.   
                   (Median and interquartile ranges shown) 
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TMAO was significantly lower in the UC cohort compared to controls (UC: P=0.005).  
Allowing for multiple comparisons, there was no significant difference between TMAO 
levels in CD patients and controls (P=0.02) or between the UC and CD cohorts.  No 
significant differences were observed between the cohorts with regard to 4-cresol 
sulphate or DMA (Figure 5-8). 
 
             
 
 
 
 
Figure 5-8:  Urinary concentrations of (a) TMAO, (b) 4-cresol sulphate and (c) DMA (expressed as % 
normalised total spectral integral) for South Asian IBD patients and South Asian 
controls. 
                 (Median and interquartile ranges shown) 
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5.3.3 South Asian lifestyle & dietary comparisons 
Analysis of the lifestyle histories of the South Asian participants showed no significant 
differences between the control and disease cohorts.  When the detailed dietary histories 
were compared, there were a significantly higher number of controls (P=0.01) who had 
consumed fish in the preceding 24 hours before urine collection, compared to the 
disease cohorts.  There were no dietary differences in benzoate containing foods 
between the South Asian groups.   
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5.3.4 A comparison of the urinary NMR profile of South Asian and white 
Northern European IBD patients 
The metabolites that were quantified in the South Asian cohort (hippurate, formate, 
TMAO, 4-Cresol Sulphate & DMA) were compared to a white Northern European IBD 
cohort.  The demographic details of the cohorts are described in Table 5-4. 
 
Table 5-4: Demographic details of the white Northern European and South Asian IBD cohorts 
including sex, age and disease location 
 
 
 
 N. European UC South Asian UC N. European CD South Asian CD 
Number (Male/Female) 60 (30/30) 53 (39/14) 86 (47/39) 22 (14/8) 
Median [range] age 
(years) 
40 (17-66) 44 [19-75] 33 (16-66) 38 [18-82] 
Disease location: n (%) 
E1: 14 (23) E1: 8 (15) L1: 18 (21) L1: 3 (14) 
E2: 18 (30) E2: 10 (19) L2: 25 (29) L2: 8 (36) 
E3: 28 (47) E3: 35 (66) L3: 43 (50)  L3: 11 (50) 
 
 
L1, ileal disease; L2, colonic disease; L3, ileocolonic disease; E1, proctitis; E2, disease limited to the 
splenic flexure; E3, disease proximal to the splenic flexure (Silverberg et al., 2005). 
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When the NMR spectra of Northern European and South Asian IBD patients were 
compared, hippurate and 4-cresol sulphate levels were significantly lower in South 
Asian UC patients compared to Northern European UC patients (Figure 5-9). There 
was no significant different between the CD cohorts.   
 
 
 
 
Figure 5-9: Urinary concentrations of (a) hippurate and (b) 4-cresol sulphate (expressed as % 
normalised total spectral integral) for white Northern European and South Asian 
IBD patients. 
                    (Median and interquartile ranges shown) 
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No differences were observed for formate, TMAO or DMA levels between the UC or 
CD cohorts (Figure 5-10).  
 
 
 
Figure 5-10: Urinary concentrations of (a) formate and (b) TMAO (expressed as % normalised 
total spectral integral) for white Northern European and South Asian IBD patients. 
                 (Median and interquartile ranges shown) 
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5.3.5 Potential confounders between ethnic groups 
The lifestyle and dietary intake of the two cohorts was carefully examined to determine 
if there were any significant confounders between the groups.  The South Asian UC 
cohort consisted of significantly more males than the Northern European UC cohort 
(P=0.01) and there were more South Asian UC patients that were vegetarians compared 
to Northern European (P=0.02).  However, when comparing dietary intake of meat in 
the 24 hours prior to the urine collection, the values were not significantly different.  
There were no other differences between the cohorts with regard to lifestyle or dietary 
consumption. 
 
When disease extent was compared between the two cohorts, there was significantly 
more extensive colitis in the South Asian UC cohort compared to the Northern 
European UC cohort (P=0.04).  In order to identify if differences in disease phenotype 
was the reason for the observed variation in hippurate and 4-cresol-sulphate, the results 
were stratified by phenotype (E1, E2, E3) and levels of hippurate and 4-cresol sulphate 
compared for each of the UC phenotypes.  The metabolites remained significantly 
different between the ethnic groups (E1: Hippurate P=0.005, 4-cresol sulphate 
P<0.0001:  E2:  Hippurate P=0.006, 4-cresol sulphate P<0.0001: E3: Hippurate 
P=0.004, 4-cresol sulphate P<0.0001). 
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5.4 DISCUSSION 
It is now well established that gut bacteria play an integral part in the development of 
IBD and specific differences in the gut microflora between CD, UC, and healthy control 
subjects have been reported (Sartor, 2008).  Urinary metabolic profiling is a non-
invasive technique that can provide valuable insights into disease pathogenesis.  It 
allows an integrated view of the biochemistry in complex organisms and is strongly 
influenced by the gut microbiota.  Differences in the urinary NMR profile have been 
previously observed in Northern European IBD cohorts and controls (Williams et al., 
2009), however this is the first study to apply urinary metabolic profiling to a different 
ethnic group with IBD.   
 
5.4.1 Differences between South Asian IBD patients and controls 
The first part of the study aimed to investigate if there were differences in the urinary 
levels of gut dependent metabolites (hippurate, TMAO, formate, DMA and 4-cresol 
sulphate) between South Asian UC, CD and healthy participants. Significantly lower 
levels of urinary hippurate and formate were observed in the South Asian UC and CD 
cohorts, compared to healthy South Asian controls. Lower levels of TMAO were also 
seen in South Asian UC patients compared to controls.  No significant differences were 
seen between the UC and CD cohorts.  The finding of a reduced level of hippurate in the 
UC and CD cohorts compared to controls is consistent with what was observed in 
Caucasian studies.  However, the reduced levels of TMAO and formate seen in the 
South Asian IBD populations have not been described previously.   
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Urinary Hippurate 
Urinary hippurate is the product of the conjugation of benzoate and glycine.  
Conjugation occurs via the formation of an intermediate, benzoyl CoA, and takes place 
in the mitochondria of the liver and the kidney (Schachter D and Taggart JV, 1953) 
(Figure 5-11).  Benzoate is formed by the microbial degradation of dietary aromatic 
compounds in the intestine, such as polyphenols, purines, aromatic organic acids and 
amino acids (Gibson, 1967).  However, it is also present in a variety of foodstuffs 
including most berries, fruits and fermented dairy products (Sieber R et al., 1995).  
 
 
 
 
Figure 5-11: The synthesis of hippurate (reproduced from Williams et al. (2010)). 
 
A previous human study has shown that urinary levels of hippurate are significantly 
lower in IBD patients when compared to healthy control individuals (Williams et al. 
2009).  Williams et al. (2010) conducted a subsequent study confirming that the reduced 
urinary hippurate levels were not simply due to differences in dietary benzoate 
ingestion, and that patients with CD do not have an intrinsic defect in the conjugation of 
benzoate with glycine.  This implicates alterations in the gut microbiota in the observed 
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differences in hippurate excretion between IBD cases and controls and would be 
consistent with animal studies which have shown that urinary hippurate excretion is 
modulated according to the composition of the gut microbiota (Nicholls et al., 
2003;Williams et al., 2002).      
 
Recent experiments have adopted a strategy using a ‘transgenomic approach’ to link the 
gut microbiota with metabolic variation (Li et al., 2008).  This uses a multivariate 
strategy to model the co-variation between the gut microbiota (using DNA 
fingerprinting) and the host metabolism (defined by urinary NMRS) in an attempt to 
functionally characterise the gut microbiota.  The authors were able to correlate specific 
metabolites with a specific species or group of gut bacteria (Figure 5-12), interestingly 
hippurate correlated with certain species of Clostridia.  Experiments using fluorescent in 
situ hybridization (FISH) of faecal samples have identified a reduction in Clostridia 
species for both UC (Clostridium Coccoides) and CD (Clostridium Leptum) (Sokol et 
al., 2006) which could potentially explain the reduced levels of hippurate in the IBD 
population.   
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Figure 5-12: Phylogenetic associations with specific urine metabolites (reproduced from Li et al., 
2008). 
 
Urinary Formate 
The finding of significantly lower levels of urinary formate in South Asian IBD patients 
compared to controls is in contrast to a previous study of Northern European IBD 
patients that reported no differences in formate levels between UC patients and controls, 
and significantly higher levels in Northern European CD patients compared to controls 
(Williams et al., 2009).  Intestinal microbes have a major influence on formate 
metabolism as it is a characteristic product in the mixed acid fermentation of the 
Enterobacteriaceae and has been linked to Escherichia coli (Sartor, 2008).  Further 
studies would be required to confirm that there are true differences in formate between 
the groups, but the reduced levels of this metabolite may suggest underlying differences 
in the gut microbiota between South Asian IBD patients and controls. 
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Urinary Trimethylamine-N-oxide (TMAO) 
TMAO is an aliphatic amine and the oxidation product of trimethylamine (TMA), 
derived mainly from dietary sources, through the action of gut microbes (Al-Waiz et al., 
1992).  The consumption of fish products have been directly correlated with high levels 
of TMAO in the urinary NMR profile of humans (Bollard et al., 2005;Lenz et al., 2004).   
The South Asian control cohort had consumed significantly more fish in the 24 hours 
prior to the urine collection and this is likely to account for the observed differences 
rather than this being a true microbial difference between the groups. 
 
Although the numbers in the control group were less than suggested by the power 
calculation, significant differences were demonstrated.  However, one cannot exclude 
the fact that with higher participant numbers other metabolite differences between the 
cohorts may have been revealed.   
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5.4.2 Comparing the metabolic profiles of IBD patients of different ethnicities 
Both Northern European and South Asian IBD populations have demonstrated lower 
levels of urinary hippurate when compared to controls.  This would suggest that there 
are changes in the gut microbiota that are disease dependent and independent of 
ethnicity.  However, when the IBD cohorts were directly compared, hippurate and 4-
cresol sulphate levels were significantly lower in the South Asian UC group compared 
to Northern European UC patients.   No metabolite differences were seen between the 
CD cohorts.   
 
Similar to urinary hippurate, 4-cresol sulphate metabolism has also been linked with 
certain Clostridia species (Li et al., 2008).  It is the product of the bacterial metabolism 
of the amino acid tyrosine and to a lesser extent phenylalanine.  It is only synthesised by 
a few bacteria including Clostridia spp. and Bacteroidetes. (Bone et al., 1976) and a 
reduction in this metabolite would be consistent with already published studies showing 
a reduction in Clostridia species with UC (Sokol et al., 2006).  It is of note that there 
was no significant difference in the level of this metabolite between South Asian UC 
patients and controls.  However, there was a trend towards lower 4-cresol sulphate 
levels in South Asian UC patients (P=0.04) and a significant difference may be revealed 
in a larger study. 
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5.4.3 Potential explanations for metabolite differences between ethnic groups 
The metabolite differences between the UC cohorts could suggest subtle variations in 
the gut microbiota between patients of different ethnic origin with UC.  As both 
hippurate and 4-cresol sulphate have been associated with Clostridia spp, a reduction in 
this bacterial species may be responsible for the lower urinary metabolite levels in 
South Asian UC patients.   Further molecular and microbiological experiments would 
be required to confirm this hypothesis. 
 
NMRS studies such as this one could potentially be prone to bias from confounders like 
demographic, lifestyle and dietary differences between the South Asian and Caucasian 
populations.  When the UC cohorts were compared, there was a higher male to female 
ratio in the South Asian cohort but no significant differences in lifestyle were noted.  
Gender-related differences in metabolites are debatable.  One study (Li et al., 2008) 
described higher levels of 3-aminoisobutyrate in males, and creatine was higher in 
females.  However, another study by Lenz (2004) showed no differences in metabolites 
between genders. 
 
Dietary differences were observed between the groups with a significantly higher 
number of vegetarians in the South Asian cohort.  However, there was no difference in 
the number of participants consuming meat products in the 24 hours prior to the urine 
collection.  Long-term vegetarian status is less likely to be as important, as recently 
consumed foods because the metabolism and elimination of metabolites occurs quickly 
eg. low doses of benzoate are metabolised and eliminated rapidly, with the peak 
response of urinary hippurate excretion within 1-2 hrs of benzoate ingestion (Cathcart-
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Rake et al., 1975). Further support for the differences in the group being real is that 
lacto-vegetarians have been reported as having a higher amount of urinary hippurate 
excretion which is the reverse of what was observed in this study (Stella et al., 2006). 
 
Another potential confounding variable is the difference in disease extent observed 
between the UC cohorts, as there were a significantly higher number of patients with 
extensive colitis in the South Asian UC cohort.  This distinction reflects the disease 
distribution demonstrated in Chapter 3.  The influence of disease extent on the 
metabonomic profile has been previously addressed by Williams et al. (2009) and 
revealed no significant variation by disease location; this was confirmed by the sub-
group analysis by disease phenotype in this study, suggesting that metabolic differences 
are a generic phenomenon for each disease.  Studies of the bacterial flora in IBD have 
also found little evidence of microbial heterogenecity in different disease locations 
(Sokol et al., 2008).   
 
5.4.4 Conclusion 
This study has demonstrated significant differences in the levels of gut dependent 
metabolites in a cohort of South Asian IBD patients compared to controls.  It is difficult 
to make definitive claims regarding the exact significance of urine metabolite changes. 
Epithelial injury has been well documented in IBD (McKenzie et al., 1996) and may 
contribute to the metabolic profile as will changes in intestinal permeability (Kennedy et 
al., 2000). However, if intestinal permeability was thought to have a significant 
contribution in IBD patients, one would have expected patients with IBD to have a 
higher level of metabolites excreted in the urine rather than the lower levels of hippurate 
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and formate that were observed.  While the study shows the potential for urinary 
metabolic profiling to demonstrate differences between IBD patients and healthy 
controls, translation to clinical medicine is in part limited by the fact that there were no 
significant metabolite differences between the South Asian UC and CD cohorts. 
However, there was a trend towards lower levels of hippurate and formate in South 
Asian CD patients compared to UC patients and it is possible that a larger study may 
confirm this.  What is clear is that significantly lower levels of hippurate have now been 
reported in both Northern European and South Asian UC and CD populations and the 
metabolite appears to be specific for IBD.   The association of hippurate with Clostridia 
spp makes the findings biologically plausible.  The search is on to better link urinary 
metabolites with specific microbial strains and this could provide an essential insight 
into the pathogenesis of IBD.   
 
Diagnostic tools for IBD are currently limited to endoscopy with histology and 
radiological imaging. Numerous serological biomarkers have been proposed for the 
diagnosis of IBD, however, for clinical applications, none of the current markers stand-
alone.  More accurate tools are needed for early diagnosis of IBD in particular non-
invasive approaches that can be used in place of endoscopy.  In the future, urinary 
metabolic profiling could provide a faster, less-invasive, and cost-effective technique 
for diagnosis of IBD. 
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CHAPTER 6  
THE PREVALENCE AND DIAGNOSTIC VALUE OF 
SEROLOGICAL MARKERS IN SOUTH ASIAN IBD PATIENTS  
 
 
Chapter 6: The prevalence and diagnostic value of serological markers in South Asian IBD patients 
178 
 
6.1 INTRODUCTION 
The chronic intestinal inflammation seen in IBD is likely to be the result of an abnormal 
immunological response to commensal bacteria within the gut lumen in a genetically 
susceptible host.  The detection of antibodies directed at microbial antigens may directly 
reflect the relevant microorganisms involved or may simply be related to increased gut 
permeability in IBD patients.  The most thoroughly studied serological markers are 
auto-antibodies against an unidentified nuclear lamina protein present in neutrophils 
(atypical perinuclear anti-neutrophil cytoplasmic antibody) and antibodies against 
mannose epitopes from the yeast Saccharomyces cerevisiae (anti-Saccharomyces 
cerevisiae antibodies) (Main et al., 1988).  More recently, antibodies to the outer-
membrane porin C of Escherchia coli (anti-OmpC) has been reported in CD patients 
(Landers et al., 2002). 
 
As the exact target antigen of atypical perinuclear anti-neutrophil cytoplasmic antibody 
(atypical pANCA) has not been identified, there are currently no sensitive or specific 
assays available to screen for the antibodies.  Indirect immunofluorescence (IIF) of sera 
incubated with human peripheral blood neutrophil substrate is the only widespread 
method to detect the antibodies.  A sample is deemed positive for atypical pANCA 
staining when it exhibits a broad inhomogeneous rim-like staining of the nuclear 
periphery with multiple intranuclear foci.  However, detection rates can be highly 
variable due to differences in available substrate and the technique requires experienced 
observers for reliable interpretation (Joossens et al., 2004).   
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Anti-Saccharomyces cerevisiae antibodies (ASCA) (IgA and IgG) can be detected using 
ELISA.  Approximately two-thirds of CD patients with ASCA-IgG are also positive for 
ASCA-IgA, but 0-19% of patients have only ASCA-IgA antibodies, suggesting that it is 
important to measure both type of antibody.  Approximately 50-80% of CD patients are 
reported to be ASCA positive but only 2-14% of UC patients and 1-7% of healthy 
controls (Peeters et al., 2001;Quinton et al., 1998). Specificity can be as high as 90% 
when both ASCA IgA and IgG are positive.  Sensitivity is in the range of 41-76% 
(Vermeire et al., 2001). 
 
Detection of the IgG anti-OmpC antibody is also performed using ELISA.  In CD, the 
reported seroprevalence is 55% (Landers et al., 2002).  The prevalence in UC and 
healthy controls was low (2% and 1.3% respectively) (Table 6-1).  
 
 
Table 6-1: Prevalence of atypical pANCA, ASCA and anti-OmpC in Caucasian IBD patients and 
controls 
 Crohn’s disease Ulcerative colitis Healthy controls 
Atypical pANCA (%) 5-25 ● 40-80 2.5 
ASCA (IgA or IgG) (%)* 50-80 2-14 1.7 
Anti-OmpC (%)♦ 55 2 1.3 
 
Data adapted from:  *Quinton et al., 1998; Peeters et al., 2001, ♦Landers et al., 2002, ●Saxon et al., 1990; 
Rump et al., 1990; Bossuyt, 2006. 
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6.1.1 IBD phenotype associations with serological markers 
There have been few studies linking atypical pANCA with a particular UC phenotype.  
A small American study has reported an association with atypical pANCA and severe 
left sided ulcerative colitis, which is resistant to treatment (Sandborn et al., 1996) but 
these findings have not been repeated.  Atypical pANCA has been associated with a 
subgroup of CD patients characterised by UC-like colitis (Vasiliauskas et al., 1996).  
High prevalence of pANCA positivity in this group often makes it difficult to 
distinguish colonic CD from UC serologically. 
 
The expression of antibodies to Saccharomyces cerevisiae (ASCA) has been associated 
with a CD phenotype that is remarkably similar to that of patients with the common 
CARD15/NOD2 polymorphisms associated with IBD (Dassopoulos et al., 2007;Quinton 
et al., 1998;Peeters et al., 2001).  They are also at greater risk for complicated disease 
behaviour (Vasiliauskas et al., 2000) and require surgery more frequently (Forcione et 
al., 2004).  Stratification of CD patients based on the presence of anti-OmpC showed an 
association with penetrating disease behaviour and therefore potentially leading to a 
higher rate of surgical intervention (Mow et al., 2004).   
 
There is limited data on the prevalence, sensitivity and specificity of serological 
markers in the South Asian population.  Studies have been scarce and involved small 
numbers (Makharia et al., 2007; Ghoshal et al., 2007).   
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6.1.2 Study aims 
This study aimed to determine the prevalence of IBD associated serological markers in 
a cohort of South Asian IBD patients. A secondary aim was to calculate the accuracy of 
the serological markers in differentiating UC from CD in South Asians and to determine 
if there was any association with disease phenotype.  The final study aim was to 
investigate if the sensitivities and specificities of the serological markers varied between 
ethnic groups. As it is difficult to draw reliable comparisons between serological data 
obtained in different laboratories due to varying methodologies and inter-observer 
variability, the South Asian data was compared to a white Northern European IBD 
cohort using the same experimental techniques.  To date, there have been no studies 
directly comparing the frequencies of antibodies associated with IBD in different ethnic 
groups.   
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6.2 METHODS 
6.2.1 Ethics Approval 
The St. Mary’s Hospital Research Ethics Committee approved this study and site-
specific approval was obtained from each of the participating trusts. All participants 
gave written informed consent. 
 
6.2.2 Patient recruitment 
The same process as described in paragraph 5.2.2 was used to recruit South Asian 
patients and healthy South Asian controls.  Dr Horace Williams (Imperial College 
London) provided the sera for 196 white Northern European IBD patients (114 CD: 82 
UC).  
 
6.2.3 Sample collection 
A 3ml venous blood sample was collected into a plain tube for each subject (191 South 
Asian IBD patients [52 CD: 139 UC] and 36 healthy South Asian controls.  Samples 
were centrifuged at 2500 rpm for 15 minutes and 500μL of serum (the supernatant) 
were aliquoted into microvials and stored at -80ºC prior to use.  The demographic and 
clinical characteristics of the South Asian patients and controls are displayed in Table 
6-2. 
 
Chapter 6: The prevalence and diagnostic value of serological markers in South Asian IBD patients 
183 
 
Table 6-2: South Asian participant characteristics for serological typing 
 
 Crohn’s disease Ulcerative colitis Controls 
Number (Male/Female) 52 (26/26) 139 (83/56) 36 (20/16) 
Disease location L1: 5 E1: 16 - 
 L2: 22 E2: 34 - 
 L3: 25 E3: 89 - 
Disease Behaviour B1: 32 - - 
 B2: 16 - - 
 B3: 4 - - 
Patients that required surgery 19 7 - 
 
L1=ileal disease, L2=colonic disease, L3=ileocolonic disease; B1- nonstricturing nonpenetrating; 
B2= stricturing; B3= penetrating; E1=proctitis, E2=disease limit distal to splenic flexure, 
E3=extensive colitis (Silverberg et al., 2005).  
 
 
6.2.4 Atypical pANCA indirect immunofluorescence assay 
Determination of atypical pANCA was performed by Dr. Chris Bunn at the Department 
of Immunology, the Royal Free Hospital, London.  This laboratory has expertise in 
using serological markers associated with IBD.  All samples were anonymised and 
personally analysed by Dr Bunn, this avoided any inter-observer variability.  The 
indirect immunofluorescence technique was employed, using ethanol-fixed human 
peripheral blood neutrophil substrate (Nova Lite, INOVA Diagnostics, USA). 
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Sera were diluted 1:10 and incubated for 30 minutes at room temperature, washed using 
phosphate buffered saline (10 mM phosphate, 150 mM NaCl, pH7.30), and incubated 
with fluorescein isothiocyanate conjugated rabbit anti-human IgG (DAKO, Ely, UK). 
Following further incubation, the wash step was repeated and the slides were examined 
by ultraviolet light microscopy at x400 magnification. Samples were considered to 
possess atypical pANCA if they produced a broad, inhomogeneous rim-like staining of 
the nuclear periphery without nuclear extension (Figure 6-1). 
 
 
       
 
Figure 6-1: Ultraviolet light microscopy images taken by Dr Chris Bunn, Royal Free Hospital, 
London.  The images demonstrate (a) Atypical pANCA staining, showing a broad 
inhomogeneous rim-like staining of the nuclear periphery without nuclear extension;  
For comparison, image (b) shows typical pANCA staining with a homogeneous rim-like 
staining of the perinuclear cytoplasm with nuclear extension. 
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6.2.5 ASCA IgG and IgA Assays 
Principles of the technique 
Quanta Lite® (INOVA Diagnostics, USA) enzyme-linked immunosorbent assays 
(ELISA) for ASCA-IgG, ASCA-IgA, and anti-OmpC IgA were used according to the 
manufacturer’s instructions.  Partially purified and disrupted S. cerevisiae antigen is 
bound to the wells of a polystyrene microwell plate.  Pre-diluted controls and diluted 
patient sera are added to separate wells, allowing any ASCA antibodies to bind to the 
immobilised antigen.  Unbound sample is washed away and an enzyme labelled with 
either anti human IgA or IgG conjugate is added to each well.   A second incubation 
allows the enzyme labelled conjugate to bind to any patient’s antibodies that have 
become attached to the microwells. A further washing step is performed and the 
remaining enzyme activity is measured by adding a chromogenic substrate and 
measuring the intensity of the colour that develops.  The assay is then evaluated 
spectrophotometrically by measuring and comparing the colour intensity that develops 
in the patients’ wells with the colour in the control wells. 
 
Experimental technique: ASCA IgA assay 
Experiments were performed by the author at the National Heart and Lung Institute, 
Imperial College London under the supervision of Dr. H. Williams and Dr. H. Sato. 96-
well plates, with antigen pre-attached under conditions that preserve it in its native state, 
were supplied by the manufacturer.  Pre-diluted controls were also supplied and 
included; 
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• ELISA negative controls, containing preservative and human serum without S. 
cerevisiae antibodies.  
• ELISA ASCA IgA ‘low positive’, containing preservative and human serum 
antibodies to S. cerevisiae. 
• ELISA ASCA IgA ‘high positive’, containing preservative and human serum 
antibodies to S. cerevisiae. 
 
Preparation 
Samples and reagents were brought to room temperature and thoroughly mixed.  A 
horseradish peroxidise (HRP) wash concentrate (supplied by INOVA diagnostics) was 
diluted 1:40 with deionised water.  A 1:101 dilution of each patient sample was 
prepared by adding 5μL serum to 500μL HRP sample diluent. Each sample was assayed 
in duplicate. 
 
Procedure 
• 100μL of the prediluted controls and patient samples were added to each well.  
• The plate was covered, and incubated for 30 minutes at room temperature.  
• All wells were then washed thoroughly, five times, using the diluted wash 
buffer. 
• 100μL enzyme-labelled HRP IgA conjugate (goat anti-human IgA) was added to 
each well, with subsequent incubation at room temperature for 30 minutes.  
• The wash step was then repeated. 
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• 100μL 3-3’,5,5’-tetramethylbenzidine chromogen was added to each well and 
incubated in the dark for 30 minutes, prior to the addition of ‘stop’ solution 
(0.344 M sulphuric acid) to terminate enzymatic activity. 
• The absorbance (optical density, OD) of each well was read at 450 nm within 
thirty minutes of stopping the reaction, using a 96-well plate reader (Dynatech 
MR 5000, Guernsey, Channel Islands). 
 
As per the manufacturer’s instructions, quality control checks were implemented.  It 
was ensured that; (i) The absorbance of the ‘high positive’ control > ‘low positive’ 
control > negative control. (ii) The absorbance of the ‘high positive’ control was > 1.0, 
while that of the negative control < 0.2. (iii) The ‘low positive’ control absorbance was 
> twice that of the negative control, or > 0.25.    
 
The test result was calculated by multiplying the ratio of sample to low positive control 
optical density with the number of units assigned to the control by the manufacturer (x 
20 units). Reactivity is related to the quantity of antibody present in a nonlinear manner. 
Results are classified as negative (0.0– 20.0 Units), equivocal (20.1– 24.9 Units), and 
positive ( ≥ 25 U).  Equivocal samples were retested prior to the allocation of a result. 
 
 
Experimental technique: ASCA IgG assay 
The technique for the assay of ASCA IgG was the same as that for the IgA assay, but 
the controls were human serum IgG antibodies, and the enzyme-labelled goat anti-
human antibody was anti-IgG. Figure 6-2 shows an overview of the methods used. 
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Figure 6-2:  An outline of the experimental technique used to determine ASCA IgG positivity.  (a) 96 
well plates containing pre-attached antigens were supplied by the manufactures. (b)  
After adding the diluted patient sera and IgG conjugate, chromogen was added to 
each plate. (c)  A stop solution was then added to terminate enzymatic activity and 
the optical density calculated. 
 
6.2.6 Anti-OmpC Assay 
To determine the presence of anti-OmpC antibodies, the same principles as above was 
applied but the microwell plate is bound with a proprietary lysate consisting of partially 
purified outer membrane and associated proteins (Omp) derived from E.coli and 
Pseudomonas fluorescens.  An anti-human IgA conjugate is used for the enzyme label. 
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Experimental technique: Anti-OmpC assay 
Human serum anti-OmpC antibodies are IgA, and so the controls were IgA and the 
enzyme-labelled goat anti-human antibody was anti-IgA.  The technique for the assay 
was the same as for the ASCA IgA assay. 
 
6.2.7 Interpretation of ELISA results 
A cut-off for positivity was set at 25Uml, in accordance with the manufacturer’s 
instructions and other published articles (Papp et al., 2008;Ferrante et al., 2007).  The 
results were documented for frequency of positivity. 
 
6.2.8 Statistical analysis 
Statistical analysis was performed using GraphPad Prism Software (Version 5).  The 
differences in prevalence of positive antibodies between groups and the relationship 
among antibodies and clinical parameters were studied using the Chi-square test.  The 
sensitivity and specificity of ASCA, anti-OmpC and atypical pANCA was estimated to 
assess the validity of each antibody in distinguishing UC from CD. The results were 
compared with a white Northern European cohort also using the Chi-square test. As 
three variables were being compared (ASCA [IgG+IgA], anti-OmpC and atypical 
pANCA), a Bonferroni correction was applied and the level of significance set at 
P<0.02.   
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6.3 RESULTS 
6.3.1 The prevalence of ASCA, anti-OmpC and atypical pANCA in South Asian 
IBD patients and healthy controls 
Fifty-two patients with CD were investigated; 50% (26/52) were positive for ASCA IgA 
or IgG (40% [21/52] for ASCA IgA and 38% [20/52] for ASCA IgG), 54% (28/52) 
showed anti-OmpC positivity and 15% (8/52) were positive for atypical pANCA. 
In the UC cohort, 159 patients had serology performed. In all, 48% (67/139) were 
positive for atypical pANCA and 27% (38/139) positive for ASCA antibodies (22% 
[31/139] for ASCA IgA and 14% [19/139] for ASCA IgG).  35% (49/139) were positive 
for anti-OmpC.  Figure 6-3 outlines the number of positive results for ASCA (IgA & 
IgG), anti-OmpC and pANCA antibodies in CD patients, UC patients and healthy South 
Asian control subjects. The control cohort of 36 patients had 25% (9/36) positive for 
ASCA, 22% (8/36) for anti-OmpC and 3% (1/36) were positive for atypical pANCA.  
               
Figure 6-3: Positivity of ASCA (IgA & IgG), anti-OmpC and atypical pANCA in South Asian IBD 
patients and healthy controls. 
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The prevalence of ASCA and anti-OmpC was significantly higher in the CD cohorts 
compared to controls (P=0.019 and P=0.003) and significantly higher numbers of the 
UC cohort were positive for atypical pANCA compared to controls (P<0.0001). 
 
6.3.2 Sensitivity and specificity of serological markers for differentiating South 
Asian IBD patients from healthy South Asian controls 
The sensitivity and specificity of the serological markers were calculated to determine 
their potential utility in differentiating South Asian IBD patients from healthy controls.  
The accuracy of ASCA (IgA or IgG isotypes) and anti-OmpC for differentiation of CD 
from healthy controls showed a sensitivity of 50% and 54% but a higher specificity 
(75% & 78%).  Using pANCA positivity, UC could be differentiated from controls with 
a sensitivity of 48% and a specificity of 97% respectively.   The combination of ASCA-
/pANCA+ did not show any higher sensitivity and specificity than pANCA alone for 
identifying UC patients from controls Table 6-3. 
 
Table 6-3: Accuracy of ASCA, anti-OmpC and atypical pANCA to distinguish patients with 
inflammatory bowel disease from healthy controls in a South Asian population 
 
 Sensitivity Specificity 
ASCA+ (Total) 50% (26/52)* 75% (27/36) 
OmpC 54% (28/52)* 78% (28/36) 
Atypical pANCA 48% (67/139)** 97% (35/36) 
ASCA+/pANCA- 42% (22/52)* 75% (27/36) 
ASCA-/pANCA+ 32% (45/139)** 97% (35/36) 
 
*Specificity for CD, **Specificity for UC 
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6.3.3 Diagnostic accuracy of ASCA and atypical pANCA in distinguishing CD 
from UC in South Asian patients with IBD compared to a white Northern 
European cohort 
When ASCA (IgG & IgA), anti-OmpC and atypical pANCA were used to distinguish 
between South Asian patients with UC and CD, pANCA demonstrated the highest 
specificity for patients with UC (85%) and ASCA was highly specific for CD (73%).  
The combination of ASCA-/pANCA+ was the most specific for a diagnosis of UC 
(92%). 
  
The sensitivity and specificity of the serological markers were analysed in a white 
Northern European IBD cohort using the same methodology (Table 6-4). There was no 
significant difference in the sensitivities of the serological markers between the South 
Asian and Northern European populations. However, anti-OmpC showed a significantly 
higher specificity in the Northern European CD population compared to the South Asian 
CD population (P=0.007).  
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Table 6-4:  Accuracy of serological markers to differentiate ulcerative colitis from Crohn’s disease in South Asian and white Northern European IBD 
patients 
 
 South Asian Northern European 
 Sensitivity % (n) Specificity % (n) Sensitivity % (n) ● Specificity % (n) P value ●P value 
ASCA+ (Total) for CD 50% (26/52) 73% (101/139) 54% (61/114) P=0.67 84% (69/82) P=0.051 
Anti-OmpC for CD 54% (28/52) 65% (90/139) 39% (45/114) P=0.13 82% (67/82) P=0.007 
Atypical pANCA for UC 48% (67/139) 85% (44/52) 37% (30/82) P=0.09 83% (95/114) P=0.83 
ASCA+/pANCA- for CD 42% (22/52) 89% (123/139) 46% (55/114) P=0.48 95% (78/82) P=0.09 
ASCA-/pANCA+ for UC 32% (45/139) 92% (48/52) 31% (25/82) P=0.77 86% (101/114)  P=0.46 
 
●When values compared to the South Asian IBD population using the Chi square test. Significance value set at P<0.02.  
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6.3.4 Clinical phenotype associated with serological markers in South Asian IBD 
patients 
South Asian CD patients were stratified for clinical phenotype associated with a positive 
ASCA or anti-OmpC result (Table 6-5). The presence of ASCA antibodies (either IgA 
or IgG) or anti-OmpC significantly correlated with small bowel CD with or without 
colonic involvement (P=0.01 & P=0.04 respectively).  When CD patients with 
nonstricturing, nonpenetrating (B1) behaviour were compared to patients with more 
aggressive behaviour (B2 or B3), the detection of positive ASCA antibodies was 
associated with a more aggressive disease behaviour (P=0.002).  ASCA and anti-OmpC 
positivity was significantly higher in South Asian CD patients with a history of surgery 
compared to CD patients without a history of surgery (P=0.009 for both). 
 
Table 6-5: Serology results for South Asian stratified by Crohn’s disease location and 
behaviour 
 ASCA+  (IgA or IgG) Anti-OmpC Atypical pANCA 
Disease location    
Ileal (L1)  60%   (3/5) 60% (3/5) 0%      (0/5) 
Colonic (L2)  23%   (5/22) 45% (10/22) 23%    (5/22) 
Ileocolonic (L3)  64%   (16/25) 60% (15/25) 12%    (3/25) 
Disease Behaviour    
Nonstricturing, 
nonpenetrating (B1)  
34% (11/32) 53% (17/32) 19%  (6/32) 
Stricturing (B2)  63% (10/16) 56% (9/16) 6%    (1/16) 
Penetrating (B3)  75% (3/4) 50% (2/4) 25%  (1/4) 
Required surgery  74% (14/19) 74% (14/19) 16%  (3/19) 
Disease location and behaviour as per the Montreal classification (Silverberg et al., 2005). 
ASCA+: Ileal involvement L1 + L3 [19/30] vs no ileal involvement L2 [5/22]; P=0.01. 
Anti-OmpC+: Ileal involvement L1 + L3 [18/30] vs no ileal involvement, L2 [10/22]; P=0.04. 
ASCA+: B1 [11/32] vs B2/B3 [13/20]; P=0.002. 
ASCA+: Required surgery [14/19] vs ASCA+ but didn’t require surgery [12/33]; P=0.009. 
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The presence of atypical pANCA was not significantly associated with disease extent in 
UC or with requirement for surgical (Table 6-6). 
 
 
Table 6-6: Atypical pANCA results stratified by ulcerative colitis phenotype 
 
 pANCA+ 
UC Phenotype* % (n)  
Proctitis (E1) 56% (9/16) 
Left sided (E2) 53% (18/34) 
Extensive (E3) 45% (40/89) 
Surgery (Colectomy) 43% (3/7) 
 
*No significant differences in pANCA positivity between disease phenotypes (P=0.58). 
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6.4 DISCUSSION 
IBD can be variable in its clinical presentation.  Therefore, biomarkers that could 
accurately distinguish IBD patients from patients suffering from diarrhoea or other non-
specific gastrointestinal symptoms would be very helpful in clinical practice.  In 
addition, it can be a challenge to classify some IBD patients into CD or UC using 
accepted clinical, endoscopic, histological, and radiological criteria.  This has particular 
relevance when initiating drug therapy or planning surgical intervention.  Non-invasive 
markers that could accurately help separate UC and CD patients would be of great 
value.  Serological markers associated with IBD have the potential to be a desirable 
clinical tool as they can be measured with little intervention and can be specific for CD 
and UC.  
 
The role of serological markers associated with IBD is rapidly developing and although 
not currently in routine clinical practice, they are likely to be a valuable tool in the 
future.  To date, the vast majority of studies in ASCA, anti-OmpC and atypical pANCA 
have been performed in white Northern European and North American populations but 
it is not clear if they have worldwide utility.  Information on the role of ASCA and 
pANCA is limited for the South Asian population and this is the first study to report the 
association of anti-OmpC with South Asian IBD patients and the association of ASCA 
and atypical pANCA with disease phenotype in this population. 
 
ASCA and anti-OmpC antibodies are known to be predominantly associated with CD, 
and have been shown to have a higher positivity in Caucasian CD patients compared to 
the background population.  This current study showed a significantly higher prevalence 
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of these antibodies in South Asian CD patients compared to healthy South Asian 
controls (total ASCA, P=0.018; anti-OmpC, P=0.003).  Although the markers had a 
high specificity for diagnosing CD (ASCA 75% and anti-OmpC 78%) their sensitivity 
was rather low (ASCA 54% and anti-OmpC 54%).  These findings are similar to the 
ASCA and anti-OmpC sensitivity identified in many Caucasian studies (Devlin et al., 
2007;Landers et al., 2002;Sandborn et al., 2001).  Atypical pANCA positivity was 
significantly higher in the South Asian UC cohort compared to controls (P<0.0001) 
giving a very high specificity of 97% but again sensitivity was limited to only 48%.   
 
Overall, the observed results would suggest that although the serological markers have 
good specificity, their lack of sensitivity limits their use as a screening tool in clinical 
practice.   
 
6.4.1 The role of serological markers for differentiating UC from CD 
Previous reports from Caucasian populations have suggested that ASCA and atypical 
pANCA may be of value in differentiating between UC and CD (Peeters et al., 
2001;Quinton et al., 1998).  Increased specificity has been obtained by assessing a 
combination of ASCA and pANCA, which has been shown to be helpful in 
differentiating UC from CD (specificity ranges from 95% to 99%).   In South Asian 
IBD patients, pANCA has a high specificity for separating UC and CD (85% for UC) 
and this was increased further to 92% specificity using a combination of 
pANCA+/ASCA-, although this was associated with a reduction in sensitivity (48% → 
32%).  There was no difference in the sensitivity or specificity of pANCA between the 
ethnic groups. ASCA antibodies also had similar sensitivities and specificities in South 
Chapter 6: The prevalence and diagnostic value of serological markers in South Asian IBD patients 
198 
 
Asian and white Northern European IBD cohorts. However, anti-OmpC was 
significantly more specific for differentiating CD from UC in the white Northern 
European population compared with the South Asian cohort.  As the specificity of this 
marker is significantly lower in the South Asian CD population, it may be a less 
valuable serological marker for differentiating CD from UC in this ethnic group.  Larger 
studies are required to confirm this finding.  
 
6.4.2 Stratifying IBD phenotype using serological markers 
The presence of ASCA and anti-OmpC could potentially be used for disease 
stratification in Caucasian populations as they were associated with a more aggressive 
disease phenotype  (Arnott et al., 2004) with a higher risk for surgery (Forcione et al., 
2004).  In this present study, a univariate analysis demonstrated that the presence of 
ASCA antibodies was associated with a more aggressive B2/B3 disease phenotype in 
CD (P=0.002), small bowel involvement (P=0.01) and an increased risk for surgery 
(P=0.009). Anti-OmpC was also associated with ileal disease (P=0.04) and an increased 
risk of surgery (P=0.009).   The knowledge of an IBD patient’s disease course could be 
extremely helpful in planning medical therapy.  There are no current markers available 
in clinical practice and although research has suggested that genetic markers may 
predict a disease course (eg. CARD15/NOD2 associated with more aggressive disease 
behaviour), these are non-specific and as allele frequencies vary between ethnic groups, 
they are therefore unhelpful in predicting disease course.  However, in view of the 
strong associations of ASCA and anti-OmpC with disease phenotype in both white 
Northern European and South Asian populations, these serological markers could be 
potentially helpful in the future.  It is clear from the literature that antibodies remain 
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relatively constant during the course of the disease and are independent of disease 
activity (Vasiliauskas et al., 1996;Vasiliauskas et al., 2000).  Therefore, antibodies are 
not suitable for monitoring disease activity. 
 
In this study, atypical pANCA was not associated with a particular UC phenotype.  This 
is in contrast to a pilot study by Sandborn et al. (1996) which demonstrated that 
pANCA+ UC patients have a higher probability of developing left sided UC, which has 
a more aggressive course requiring early surgery.  It is difficult to compare the studies, 
as Sandborn’s study was small and focused on patients with left-sided disease rather 
than all UC phenotypes.  The observed differences are unlikely to be related to ethnic 
differences as no such association with left-sided disease was noted for the white 
Northern European cohort examined in this study.  
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6.4.3 Conclusion 
Based on these results, it would suggest that ASCA, anti-OmpC and atypical pANCA 
antibodies have a limited clinical value for the primary diagnostic workup of IBD in the 
South Asian population. The determination of antibodies may be a more useful 
diagnostic tool in patients with IBD unclassified as it may help guide medical or 
surgical therapy.  At present, serology can only be recommended as an endoscopy 
adjunct to assist in the differential diagnosis and prognosis of IBD.  Both ASCA and 
atypical pANCA have similar sensitivities and specificities in South Asian and white 
Northern European cohorts.  However, anti-OmpC had increased specificity for 
distinction between individuals with CD and UC in the white Northern European cohort 
compared to South Asian IBD patients.  
 
In addition to playing a role in IBD diagnosis, there is a great opportunity for 
serological markers to help identify patients at the time of diagnosis who will or will not 
develop a disabling disease course. This study has shown the potential role of ASCA 
and anti-OmpC is determining CD phenotype and this would greatly enhance the ability 
to tailor therapy at the time of diagnosis based on the risk of complicating disease.  
 
As new serological markers are identified and additional studies examine the diagnostic 
performance of various combinations of markers, the utility of these markers in daily 
practice may improve. However, given the results from this study, it will be important 
to study any new markers in different ethnic groups to ascertain there worldwide 
application.   
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This thesis describes a number of studies to give insights into the question of whether 
inflammatory bowel disease in South Asians is clinically, genetically and 
immunologically distinct from IBD in white Northern Europeans.  This in turn may give 
insights into the pathogenesis of IBD overall. 
 
IBD phenotype in UK South Asians 
 
In Chapter 3, I have shown that the phenotype of IBD is different between South Asians 
and Northern Europeans living in the UK.  A significantly higher proportion of South 
Asian patients had extensive UC and a lower number had proctitis when compared with 
the Northern European UC cohort.  Disease behaviour was significantly different 
between the CD cohorts with less penetrating behaviour in the South Asian population 
and a lower requirement for surgery.  This is the largest phenotyping study performed in 
UK South Asians and lends weight to the argument that there is ethnic variation in the 
phenotype of IBD. 
 
Phenotyping studies such as this one may be prone to ascertainment basis and great care 
was taken to recruit the cohorts from the same hospitals in a defined geographic area 
therefore recruiting similar proportions of patients from secondary and tertiary care into 
each group.  A potential bias may be that the South Asian and European cohorts were 
not collected over the same time frame: 18 months for the South Asian group and 6 
months for the Northern European group.  We aimed to collect populations of similar 
sizes to study, as Northern Europeans are the predominant ethnic group attending IBD 
clinics in North West London, the collection of this population was faster than that of 
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the South Asian population.  A potential basis that could result from this would be that 
Northern European patients under annual review with less severe disease and on no 
regular medications may not have been included in the study.  This would have been a 
relatively small number of patients and would have been likely to include more patients 
with limited left-sided disease/proctitis than patients with extensive colitis, therefore 
unlikely to impact on the observed differences in UC phenotype. 
 
Future directions: IBD phenotyping in UK South Asians 
Although the number of UC patients collected was large in comparison to previous 
South Asian phenotyping studies in the UK, the study had only a limited number of CD 
patients.  Studies from Leicestershire have reported a significantly higher prevalence of 
UC in the UK South Asian population compared with Europeans, while the prevalence 
of CD in South Asian Hindus was significantly lower than Europeans (Probert et al., 
1993).  This study reflected these reported differences with 273 UC patients recruited 
over the study period compared with only 94 CD patients.  This limited the analysis of 
first and second-generation CD patients.  Future phenotyping studies in UK South 
Asians would benefit from a multi-centre approach for patient recruitment and should 
aim to have higher numbers of CD patients. 
 
The highly significant differences in clinical phenotype between the ethnic groups 
prompted further investigations into potential underlying differences in genetic 
susceptibility and environmental triggers that could account for the observations.   
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Genetic differences between South Asian and white Northern European IBD 
patients 
 
The potential influence of genetic susceptibility to IBD in South Asians was assessed by 
determining the frequency of single nucleotide polymorphisms and HLA alleles 
previously associated with IBD in Caucasians, in a South Asian IBD cohort  (IL23R,  
HLA-DRB1*1502 & DRB1*0101  in UC patients; CARD15/NOD2, ATG16L1, IRGM , 
IL23R, HLA-DRB1*1502 & DRB1*0101  in CD patients).  The results were compared 
with cohorts of South Asian healthy controls, and white Northern European IBD 
patients.  For UC, the carriage frequency of HLA-DRB1*1502 was significantly higher 
in South Asian UC cases compared with controls.  However, this allele did not correlate 
with clinical phenotype.  No differences were observed between South Asian UC cases 
and controls for the IL23R polymorphism.  This result is consistent with a very recent 
report from a GWAS in India that showed no association of IL23R with UC in Indian 
Asians (Juyal et al., 2011).  There was also no difference between South Asian CD 
cases and controls for IBD associated polymorphisms in CARD15/NOD2, ATG16L1, 
IRGM or IL23R.   
 
When South Asian IBD patients were compared to white Northern European patients, 
there were significant differences between the cohorts, with higher frequencies of the 
HLA-DRB1*1502 allele in South Asians compared to Northern Europeans and a 
significantly lower frequency of the HLA-DRB1*0103 allele in the South Asian UC 
population.  CARD15/NOD2 polymorphisms associated with CD in Northern Europeans 
were rare in the South Asian CD population.  These polymorphisms are known to be 
associated with terminal ileal disease (Lesage et al., 2002) but in view of the low 
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frequency of CARD15/NOD2 polymorphisms seen in South Asian CD patients, they are 
less likely to influence disease phenotype in this population.   As this study did not 
recruit a large number of South Asian patients with ileal CD, larger studies would be 
required to confirm this finding. 
 
This study was under-powered with regard to CD, so it is possible with higher numbers 
differences may be reported.  However, the findings from this thesis are consistent with 
a small study from India showing that IBD associated polymorphisms in 
CARD15/NOD2 are not associated with CD susceptibility in this ethnic group 
(Pugazhendhi et al., 2008) .  In addition, studies from other parts of Asia (Japan and 
Korea) have shown no association with ATG16L1 and IRGM (Yamazaki et al., 
2007;Yang et al., 2009).   
 
Future directions: Insights into genetic susceptibility in South Asian IBD patients 
As no significant differences were observed between CD cases and controls in the South 
Asian population, it would be informative to sequence the CARD15/NOD2, ATG16L1, 
IL23R and IRGM genes to determine if there are other loci that could confer 
susceptibility to CD for this population.  Larger patient numbers are required to validate 
the genetic results observed in this study.  The Wellcome Trust Consortium is 
conducting a UK wide GWA study of susceptibility genes in South Asian IBD patients 
living in the UK.  DNA from patients involved in this study will form an integral part of 
the study. 
 
It is widely accepted that the pathogenesis of IBD is likely to be due to a combination of 
variation in genetic susceptibility, environmental and immune factors.  If the failure to 
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show any differences in the frequency of CD associated polymorphisms between South 
Asian cases and controls is not simply a matter of power then it raises the possibility 
that either CD in this ethnic group is associated with new polymorphisms of known 
susceptibility genes, or other susceptibility loci that have yet to be discovered or there 
may be less of a genetic effect and a stronger environmental influence on CD 
pathogenesis in South Asians. 
 
 
Urinary metabolic profiling in UK South Asian IBD patients 
 
An important potential environmental stimulus associated with IBD is the variation in 
gut microbiota, which is essential in triggering mucosal inflammation (Bhan et 
al.,1999).  It was hypothesised that there would be differences in the microbiota 
between South Asian IBD cases and controls.  The microbiota is difficult to investigate, 
as culture techniques are time-consuming and unreliable.  Studies using fluorescent in 
situ hybridization on surgical resections have suggested alterations in the gut microbiota 
and this has been further supported by studies showing variation in the bacterial 
composition of faecal samples in UC and CD patients compared to controls (Sokol et 
al., 2006).   
 
In this thesis, urinary metabolic profiling was used to investigate potential variations in 
the microbiota.  Spectral resonances generated by Nuclear Magnetic Resonance (NMR) 
spectroscopy allow metabolites that are influenced by the gut microbiota to be 
quantified and therefore act as a surrogate marker of bacterial composition.  Significant 
differences were found between South Asian IBD patients and healthy controls in the 
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urinary excretion of the microbial-influenced metabolites; hippurate, formate and 
TMAO.  Dietary intake may influence the excretion of certain metabolites and therefore 
a careful dietary history was taken from each participant.  Variation in the intake of fish 
products may explain the differences seen in TMAO between the groups but there were 
no dietary differences to account for the lower levels of formate and hippurate seen in 
the IBD populations.   The highly significant difference in urinary hippurate observed 
between South Asian IBD patients and controls is consistent with what is reported in 
Northern European cohorts, suggesting that hippurate is a specific determinant of IBD 
that is consistent across ethnic groups.   When the metabolic profiles of South Asian 
IBD patients were directly compared with a Northern European cohort, no differences 
were reported for CD but significantly lower levels of hippurate and 4-cresol sulphate 
were seen in the South Asian cohort compared with Northern Europeans.  The 
metabolite differences observed between South Asian and Northern Europeans UC 
patients may reflect subtle differences in the gut flora between the ethnic groups, 
perhaps increasing susceptibility to UC in South Asians.   Although it is possible that 
the observed differences could simply reflect differences in diet or different/additional 
environmental factors between these populations, it is of great interest that there are 
very consistent changes in hippurate excretion in South Asian and Northern European 
IBD patients. 
 
Unfortunately, despite collecting a large number of samples for this study, the results 
were limited by the number of samples that could be processed due to the closure of the 
NMR facility at the Hammersmith Hospital.  Efforts were made to try and get the 
remaining samples analysed in another facility with a similar NMR spectrometer (JOEL 
500MHz Eclipse+).  No other 500Hz spectrometers were available in the UK and for 
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this reason a collaboration was set up with Dr. Kishore Bakoo’s research team at the 
Imperial NMR facility in Singapore. The remaining samples were couriered to 
Singapore for spectral acquisition, and the data sent back to the UK for analysis. After 
analysing 100 samples from Singapore it became apparent that the water suppression 
differed significantly in these samples, compared to those samples acquired in the UK 
(Appendix 9).  This made it impossible to analyse the data comparatively.  A new 
collaboration has been established, and all of the samples will be re-analysed at the new 
NMR facility at Imperial College in South Kensington London.  Using these data, it will 
be possible to further validate the results.  
 
Future directions: Learning more about the gut microbiota in South Asians 
Data from epidemiological studies would suggest that as individuals migrate from a 
developing to a developed country the incidence of IBD rises.  This underlines the 
relative importance of environmental factors and it would be informative to investigate 
if there are differences in the gut microbiota between first- and second-generation South 
Asians as this may give further insights into IBD pathogenesis.   
 
In this thesis, I used a univariate approach to study metabolites that are known to be 
associated with the gut microbiota.  The next stage would be to use multivariate 
statistical techniques to determine which metabolites differ between sample classes with 
a non-targeted approach.  This will be useful in terms of hypothesis-generation and 
investigating potential pathophysiological explanations for the aetiology of IBD.   
 
Molecular techniques have revolutionised the study of the microbiota and the recently 
described transgenomic methodology for exploring microbial host metabolic 
Chapter 7: Discussion and suggestions for future work 
209 
 
relationships have revealed exciting results, allowing researchers to make a direct link 
between urinary metabolites and particular species of gut bacteria (Li et al., 2008).  The 
lower levels of hippurate are likely to correspond with a reduced number of Clostridia 
species in the microflora of IBD patients.  Future studies combining NMRS with 
ribosomal RNA typing are likely to identify further microbial candidates that have 
strong host metabolic connectivity. 
 
As NMR techniques become more sophisticated, there is the potential that urinary 
metabolic profiling could provide a faster, less invasive, and cost-effective technique for 
diagnosing IBD. 
 
 
Other potential environmental factors affecting IBD pathogenesis in UK South 
Asians 
 
Smoking 
Smoking represents one of the most consistently observed environmental influences on 
CD.  It is hypothesised that smoking modulates outcomes in CD through effects either 
on vascular endothelium, on mucin production, or other toxic effects of smoking by-
products on gut mucosal homeostasis.  Chapter 3 reported significantly higher numbers 
of smokers in the Northern European CD cohort compared to South Asian CD patients.  
Previous studies have demonstrated that smoking is more frequently associated with the 
development of strictures or fistulae with an increased risk of surgery (Picco and 
Bayless, 2003;Reese et al., 2008), therefore smoking could represent an important 
contributory influence on established disease.  The low number of smokers in the South 
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Asian CD cohort may in part explain the differences in disease behaviour between the 
CD cohorts.   
 
Diet and Vitamin D 
This thesis did not specifically investigate detailed dietary differences between the 
ethnic cohorts but previous studies have reported that dietary influences may be 
important in IBD pathogenesis (de Silva et al., 2010); this would be an important area 
for future research. 
 
There is mounting evidence that Vitamin D possesses a wide range of 
immunomodulatory properties (Brennan et al., 1987) and epidemiological/experimental 
evidence implicates Vitamin D insufficiency as a risk factor for developing IBD 
(Raman et al., 2011;Wang et al., 2010).   As Vitamin D levels are related to sun 
exposure and skin colour, they are therefore likely to vary between ethnic groups.  To 
evaluate this further, we formed a collaboration with Dr Andrew Milestone and Dr Ailsa 
Hart at St. Mark’s Hospital, London.  A study was conducted of 215 CD patients (70 
South Asian and 145 Northern European), mean 25-hydroxyvitamin D levels (25-OHD) 
varied significantly with ethnic origin (Northern European 31.1ng/mL, South Asian 
21.4ng/mL; P<0.01). A greater proportion of South Asians (45.8%) than Northern 
Europeans (24%) had 25-OHD levels <20ng/mL. Further observational and therapeutic 
studies are needed to determine the exact role of Vitamin D in IBD pathogenesis as this 
may be important factor contributing to IBD pathogenesis in this ethnic group. 
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The role of serological markers in South Asian IBD patients 
 
The idea that in IBD the intestinal flora triggers and drives an aberrant immune response 
is further supported by the occurrence of antibodies directed at microbial antigens and 
enteric bacteria (Cohavy et al., 2000).   Chapter 6 examined the prevalence of 
serological markers in a South Asian population and the association of autoantibodies 
with clinical phenotype.  This study concentrated on the most studied serological 
markers (ASCA, anti-OmpC and atypical ANCA).  Significant differences in the 
positivity of antibodies for ASCA and anti-OmpC were observed when the South Asian 
CD patients were compared to controls. Significantly higher numbers of atypical 
pANCA+ patients were reported in the South Asian UC cohort compared to controls.  
The exact target of the atypical pANCA antibody is not known but ASCA reactive 
antigens have been reported in the granulomas of bowel resections and on infiltrating 
lymphocytes and neutrophils in inflamed tissue from CD patients (Oshitani et al., 2003).  
The results would therefore suggest that there are differences in enteric bacteria between 
South Asian IBD patients and controls.   
 
Serological markers have been previously investigated in the clinical setting, to aid in 
the diagnosis of IBD or to differentiate UC from CD.  The sensitivity of the serological 
markers did not vary between ethnic groups but the specificity of anti-OmpC was 
significantly lower in the South Asian population for differentiating CD from UC.   
 
Future directions: The role of serological markers in different ethnic groups 
This study only concentrated on well known serological markers.  Further studies are 
warranted to investigate if newer serological markers including anti-glycans antibodies 
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(ALCA, AMCA & ACCA) or anti-I2 are more sensitive and specific in determining the 
presence of disease and disease behaviour in the South Asian population.  
 
In both Caucasian and South Asian populations, currently available serological markers 
(ASCA, anti-OmpC and atypical pANCA) have only a limited use in clinical practice 
and are only modestly helpful in distinguishing between a diagnosis of CD or UC.  
However, the study demonstrates that if serological markers advance into routine 
clinical practice, it will be important to determine their utility in different ethnic 
populations.   
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7.1 SUMMARY 
This thesis has demonstrated differences between two distinct ethnic groups with regard 
to disease phenotype and provided insights into potential differences in genetic 
susceptibility and the gut microbiota between the cohorts.  The exact reason for the 
phenotypic differences between the cohorts remains unclear and it is likely that no 
single susceptibility gene or bacterial species is directly associated with a particular 
phenotype but rather it is a combination of genetic and environmental factors.  Studies 
in migrant populations such as this one can provide vital clues into underlying disease 
pathogenesis.  A better understanding of the mechanisms responsible for disease 
pathogenesis, as well as development of less invasive diagnostic techniques, will help 
improve the quality of life of the many individuals that suffer from IBD. 
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Appendix 1:  Reagents required for DNA extraction using Millers Salting out technique 
 
Red Cell Lysis Buffer  
 
Composition: 0.144 M NH4Cl, 1.00 mM NaHCO3
Preparation: 15.405 g NH
. 
4Cl and 1.68 g NaHCO3 were added to 2 L 
deionised water and mixed. 
Nuclear Lysis Buffer Composition: 10 mM Tris-HCl pH 8.2, 0.4 M NaCl, 2 mM Na2
Preparation: 23.37 g NaCl were dissolved in 900 mL deionised water. 10 mL 
1M Tris-HCl pH 8.2 and 10 mL 200 mM Na
EDTA pH 8.0. 
2EDTA pH 8.0 were added and 
made up to 1 L with deionised water. 
6 M NaCl 
 
Preparation: 350.64 g NaCl were dissolved in 800 mL deionised water, and 
then topped up to 1L with deionised water. 
 
Appendix 2:  Primers used for identification of the three common CD associated 
CARD15/NOD2 polymorphisms using sequence specific primers (courtesy of 
Dr Tariq Ahmad). 
 
NCBI 
reference 
SNP 
Position 
SNP id 
 
Sense/ 
Anti 
Sense 
Primers (5’-3’) 
rs2066844 2104C SNP 8 [as] CTG AGA AGG CCC TGC TCC 
  2104T   [as] CTG AGA AGG CCC TGC TCT 
  2104   [s] GTC ACC TCT GAT TTG GTG TTG 
rs2066845 2722G SNP 12 [s] GTC ACC CAC TCT GTT GCC 
  2722C   [s] GTC ACC CAC TCT GTT GCG 
  2722   [as] GTA TTG GGA TTA CAC AAG TGA GC 
rs2066847 3020- SNP 13 [as] GGT GTC ATT CCT TTC AAG GGC 
  3020Ci   [as] GGT GTC ATT CCT TTC AAG GGG 
  3020   [s] GGA GAA GAG GGC TTG TTC AG 
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Appendix 3: HLA class II medium resolution primer sequences (courtesy of Dr. Hiroe Sato, derived 
from Bunce et al. (1995)). 
 
No. 
 
Primer Sequence 
36 5
’ 
T T G T G G C A G C T T A A G T T T G A A T  
37 5
’ 
C T G C A C T G T G A A G C T C T C A C    
38 5
’ 
C T G C A C T G T G A A G C T C T C C A    
39 5
’ 
C C G C C T C T G C T C C A G G A G      
40 5
’ 
C C C G C T C G T C T T C C A G G A T     
41 5
’ 
T C C T G T G G C A G C C T A A G A G     
44 5
’ 
T A C T T C C A T A A C C A G G A G G A G A  
46 5
’ 
G A C G G A G C G G G T G C G G T A      
47 5
’ 
G T T T C T T G G A G C A G G T T A A A C A  
48 5
’ 
C C T G T G G C A G G G T A A G T A T A    
49 5
’ 
C C C G T A G T T G T G T C T G C A C A C   
50 5
’ 
A G T A C T C T A C G G G T G A G T G T T   
51 5
’ 
C T G C A G T A G G T G T C C A C C A G    
53 5 C G G T T G C T G G A A A G A C G C G     
54 5
’ 
C T G G C T G T T C C A G T A C T C C T    
58 5
’ 
T C T G C A A T A G G T G T C C A C C T    
61 5
’ 
G T T T C T T G C A G C A G G A T A A G T A  
68 5
’ 
G T T T C T T G G A G T A C T C T A C G T C  
69 5
’ 
T T T C T T G G A G C T G C G T A A G T C   
70 5
’ 
G T T T C T T G G A G C T G C T T A A G T C  
76 5
’ 
G G A G T A C C G G G C G G T G A G      
77 5
’ 
G C T A C T T C A C C A A C G G G A C C    
78 5
’ 
T G G T A G T T G T G T C T G C A T A C G   
79 5
’ 
A C G G A G C G C G T G C G G G G       
82 5
’ 
G T G C G T C T T G T G A G C A G A A G    
102 5
’ 
T G T T C C A G T A C T C G G C G C T     
104 5
’ 
C C C G C C T G T C T T C C A G G A A     
107 5
’ 
C T G T T C C A G T G C T C C G C A G     
111 5
’ 
C C G C G G A A C G C C A C C T C       
112 5
’ 
C G T G C G G A G C T C C A A C T G      
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    151 
 
5
’ 
C C G T A G T T G T G T C T G C A G T A A   
152 5
’ 
C C C G C G G T A C G C C A C C T C      
181 5
’ 
G A C G G A G C G C G T G C G T T A      
252 5
’ 
C C A C C G C G G C C C G C G C        
255 5
’ 
G T C C A C C C G G C C C C G C T       
256 5
’ 
C T G T T C C A G G A C T C G G C G A     
258 5
’ 
A C C G C G G C C C G C C T G T C       
259 5
’ 
T C C A C C G C G G C C C G C T C       
263 5
’ 
G T T C C T G G A C A G A T A C T T C C    
268 5
’ 
C T G C A G T A A T T G T C C A C C C G    
270 5
’ 
G A T C G T T C G T G T C C C C A C A A    
273 5
’ 
T T C T T G G A G T A C T C T A C G G G    
283 5
’ 
G A T C G T T C G T G T C C C C A C A G    
314 5
’ 
C T G G T A C T C C C C C A G G T C A     
347 5
’ 
T T T C G T G C T C C A G T T T A A G G C   
348 5
’ 
G A C G T G G G G G T G T A C C G C      
349 5
’ 
G G A G C G C G T G C G T C T T G T A     
350 5
’ 
T G C A C A C C G T G T C C A A C T C     
351 5
’ 
T G C A C A C C C T G T C C A C C G      
353 5
’ 
G T G C G T C T T G T G A C C A G A T A    
485 5
’ 
T C C A C C G C G G C C C G C T T       
491 5
’ 
C T C C G T C A C C G C C C G G T       
492 5
’ 
G C T G T T C C A G T A C T C A G C G     
495 5
’ 
C T C C G T C A C C G C C C G G A       
831 5
' 
T G G C T G T T C C A G T A C T C G G C G G  
866 5
' 
C G C C T G G T A C T C C C C C A G      
1465 5
' 
G G A C G G A G C G C G T G C G T C T     
1466 5
' 
G C T G T T C C A G T A C T C G G C G T    
2489 5
' 
A T A C T T C C A T A A C C A G G A G G A G A 
2510 5
' 
G G C T G T T C C A G T A C T C G G C A T C  
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Appendix 4:  HLA CLASS II medium resolution primer sequences and reaction combination   
Reaction 
No. HLA Allelic Specificity Primer 1 µg/mL Primer 2 µg/mL Control 
1 DRB1*0101/2/4 36 10 39 10 63/64 
2 DRB1*0102,0104 36 10 38 10 63/64 
3 DRB1*0103 36 10 40 10 63/64 
4 DRB1*1501-1505 41 10 252 2 63/64 
5 DRB1*1501,1503-5 (not 1502) 41 10 38 10 63/64 
6 DRB1*1601-6 41 15 491 15 63/64 
7 DRB1*0301-5;*1107 68 10 255 5 63/64 
8 DRB1*0301,0304 46 10 38 10 63/64 
9 DRB1*0302,0305;*1302,1305;*1109,1120;*1402,1403,1409,1413,1419 44 10 37 10 63/64 
10 DRB1*0401-0422;*1410;*1122 47 10 37, 38 10 63/64 
11 DRB1*1122;*0415 47 10 54 10 63/64 
12 DRB1*0701 48 10 49 10 63/64 
13 DRB1*0801-0811;*1415 50 10 51, 102 10 63/64 
14 DRB1*0901 46 10 49 10 63/64 
15 DRB1*1001 53 10 37 10 63/64 
16 DRB1*1101-1121(not 1122);*1411 68, 273 10 54 10 63/64 
17 DRB1*1109,1116,1120 44 5 54 5 63/64 
18 DRB1*1201-1203 50 16 256 16 63/64 
19 
DRB1*1101-16,1118-22;*1201-
3;*1301/2/4/5/6/9/10/11/14/15/16/17
/18/20/21/22 
68, 47, 
273 10 495 10 63/64 
20 DRB1*0302,0303;*1117;*1401/2/3/5/6/7/8/9/12/13/14/16/18/19/20 68 10 491 10 63/64 
21 DRB1*1301/2/4/8/15/16/17/19/20/22,*1102/3/11/14/16/20/21,*1416 68, 273 10 259 10 63/64 
22 DRB1*1301,1302;*1416 263 12 259, 252 
12 of 
259; 2.5 
of 252 
63/64 
23 
DRB1*1301,1302, 
(1306),1310,1315,1316;*1419,1421;
*1116,1121 
44 10 40, 485 10 63/64 
24 DRB1*1305,1306,1310;*1109;*1419,1421 44 8 258, 485 8 63/64 
25 DRB1*1303,1310;*1419,1421 68 10 485 10 63/64 
26 DRB1*1303,1304,1312,1321;*1413 68 5 102 5 63/64 
27 DRB1*1305,1307,1311,1314,1318,1321;*1101/4/6/9/10/(11)/12/15 68 10 104 10 63/64 
28 DRB1*03 68 10 2510 10 63/64 
29 DRB1*03,13,14 2489 20 38 20 63/64 
30 DRB1*1401/7/16 68 10 107 10 63/64 
31 DRB1*1117, 1401/5/7/8/14/18/23/26 68 20 58 20 63/64 
32 DRB1*03,1402 etc 2489 10 51, 39 10 63/64 
33 DRB5*0101,0102,0201,0202,0203 61 10 492 10 63/64 
34 DRB3*0101 69 20 268 20 63/64 
35 DRB3*0201,0202,0203 151 10 76 10 63/64 
36 DRB3*0201,0301 70 13.2 38 13.2 63/64 
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37 DRB4*0101101,0102,0103 283 4 314 5 63/64 
38 DRB4*0103102N 270 10 866 10 63/64 
39 DQB1*0305 77 10 350 10 63/64 
40 DQB1*02 82 10 112 10 63/64 
41 DQB1*04 77 10 78 10 63/64 
42 DQB1*05 79 3 152 3 63/64 
43 DQB1*0601/2/3  347, 348 10 111 10 63/64 
44 DQB1*0602/3/7/8 348 10 350 10 63/64 
45 DQB1*0603-9 349 10 350, 351 10 63/64 
46 DQB1*0301,0304 181 10 112 10 63/64 
47 DQB1*0302 353 10 831 10 63/64 
48 DQB1*03032 1465 6 1466 6 63/64 
 
 
 
 
Appendix 5:  Control Primers used for SSP-PCR 
Control primers Primer (5’ – 3’) 
210 ATG ATG TTG ACC TTT CCA GGG 
211 TTC ATC AGT TGC TGC CCC TC 
63 TGC CAA CTG GAG CAC CCA A 
64 GCA TCT TGC TCT GTG CAG AT 
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Appendix 6: Primer sequences for SNPs analysed using pyrosequencing 
 
Gene NCBI 
reference 
SNP id  Base Sequence 
ATG16L1 rs2241880 ATG F1 CCCCCAGGACAATGTGGAT 
   R1 CGAAGACACACAAGGCAGTAGCT 
   S1 ACCAGAACCAGGATGA 
IL23R rs11209026 IL23R F1 TGCTGTTATGTTGTCAATTCTTTC 
   S1 TGGGATATTTAACAGATCAT 
   R1 GTAAAATAGGCCAGGAAGCTTTTC 
IRGM rs13361189 IRGM189 F1 CGTGTCGTACCCAAGCAGAGT 
   R1 CCCTTTCTAAACTGTACCCGCTGA 
   S1 CAGAGTGTGCTTGAAAAT 
IRGM rs4958847 IRGM847 F1 ATGGGTGAGGTCATCTTAACAGTC 
   R1 AAATCTATTTTAGGGAGTAGTGCA 
   S1 ATTTCATTGCCCAATAT 
 
F1, Forward primer; R1, Reverse primer; S1, sequence primer 
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Appendix 7: Urinary metabonomic questionnaire for inflammatory bowel disease patients 
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Appendix 8:  The preparation of 0.2M phosphate buffer and TSP/D20 solution 
0.2M phosphate buffer 
 
1.  Add together;  
• 3.8mls of 0.2M monohydrate solution ([NaH2PO4] (1.39g 
NaH2PO4 mixed with 50mls distilled water) 
• 16.2mls 0.2M Dibasic Anhydrous solution (Na2HPO4) (1.42g 
Na2HPO4 mixed with 50mls distilled water) 
• 20mls dH2O 
2. Vortex for 10 seconds 
3. Check with pH meter solution @pH 7.35 
TSP / D2O solution 
 
1.  Add 20mg of Sodium Trimethylsilyl-Propionate to 20mls of Deuterated 
water (deuterium oxide D2O). 
2. Vortex for 10 seconds (the mixture is stored at room temperature in a 
falcon tube covered with foil). 
 
 
Appendix 9: A comparison of NMR spectra acquired using the NMR facility at Hammersmith 
Hospital, Imperial College with spectra acquired from Singapore 
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